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  Traumatic brain injury (TBI) affects multiple aspects of health and daily functioning.  
However, TBI researchers whose primary interest is in the acute care setting have often 
used single measures of global functional outcome, such as the Glasgow Outcome Scale 
(GOS), to provide an overall assessment of recovery at follow-up, and have not routinely 
incorporated measures that capture the multi-dimensional impact of TBI.  CENTER-TBI is 
part of an international initiative towards standardizing and refining outcome assessment in 
TBI.  The aim of this initiative is to promote the use of common measures to provide a multi-
dimensional description of TBI outcomes in a range of study contexts.  This thesis uses data 
collected for CENTER-TBI to examine two main issues of relevance to outcome assessment 
in adult TBI: (1) methods of collecting information about global functional outcome; and (2) 
implementation of multi-dimensional approaches to outcome assessment in TBI.  The 
systematic review in Chapter 2 examines the patterns of use and reporting quality of 
outcome measures in clinical trials in adult TBI.  The findings from the review demonstrate 
heterogeneity in the use of outcome measures, limited use of multi-dimensional outcomes, 
and highlight the issue of incomplete reporting of outcomes in these studies, providing the 
impetus for the studies in Chapters 4, 5 and 6.  Chapters 4 and 5 compare outcomes 
assigned using clinician ratings and patient reports on the extended GOS (GOSE).  The two 
GOSE approaches were found to be broadly equivalent indicating that, in this context, 
patient reports generally provide information that is comparable to that obtained via 
clinician-rated interviews.  Chapter 5 demonstrates that the GOSE has significant, but 
modest, associations with prognostic factors and other outcome measures.  The role of the 
GOSE in implementing multi-dimensional outcome assessment is considered in Chapter 6.  
Chapter 6 demonstrates that the applicability of individual outcome assessments is strongly 
driven by level of disability.  Thus, a tailored approach to outcome assessment is needed.  
The studies in this thesis indicate that mixed modes of GOSE data collection can be used to 
maximise follow-ups in studies with pragmatic constraints.  Furthermore, outcome 
measures need to be carefully selected to capture the multi-dimensional impact of TBI 
across the spectrum of recovery.  The findings have implications for further CENTER-TBI 
analyses, for selecting outcome measures in future prospective studies, and for pooling data 
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Rationale and aims of the thesis  
 
 
  The impetus for this thesis comes from developments in three broad areas of research: (1) The 
drive towards harmonizing data collection in TBI studies; (2) Advances in outcomes research; 
and (3) Recommendations for multi-dimensional approaches to outcome assessment in TBI.  
Current progress in these areas of research will be evaluated in this chapter.  The aims of the 


















1.1. Rationale for this research  
1.1.1. Harmonizing data collection in TBI research  
  In the last decade, there has been a global drive towards the harmonization of data collection 
in TBI research (Yue et al., 2013).  Current initiatives which aim to promote streamlined 
approaches to clinical data collection include the Clinical Data Interchange Standards 
Consortium (CDISC) (Clinical Data Interchange Standards Consortium, 2015); National Institute 
of Neurological Disorders and Stroke (NINDS) Common Data Elements (CDE) project (Hicks et 
al., 2013; Wilde et al., 2010); and International Initiative for TBI Research (InTBIR) (Tosetti et al., 
2013).  CDISC aims to harmonize data collection in a wide range of therapeutic areas, including 
TBI (Clinical Data Interchange Standards Consortium, 2015).  More specifically, the NINDS CDE 
project aims to develop common data standards in a range of neurological research contexts, 
including TBI (Thurmond et al., 2010).  Consistent with these two broad data standardization 
initiatives, InTBIR was set up in 2011 to tackle the global burden of TBI through international 
collaboration, data sharing, and adherence to CDE recommendations for data collection in TBI 
studies (Tosetti et al., 2013).   
 
  An overarching aspiration of InTBIR is to promote joint analyses of data where this yields 
advantages, for example, in comparative effectiveness research (CER), prognostic studies, or 
genomics, where large sample sizes are needed (Tosetti et al., 2013).  A number of CER studies 
have been initiated as part of InTBIR, the largest of which are Transforming Research and 
Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) in the US (Yue et al., 2013) and 
Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) in Europe 
(Maas, Menon, et al., 2015).  TRACK-TBI and CENTER-TBI were set up in parallel and both 
projects have the aim of validating the applicability of the CDEs for TBI.  CENTER-TBI was 
launched in 2013 and patients were recruited between December 2014 and December 2017 via 
65 sites across 18 countries in Europe.  It includes a core study of 4509 patients, as well as a 
registry providing basic observational data on 22,782 patients presenting to the sites involved.  
The project comprises a total of 22 work packages which cover a number of research strands, 
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including CER, neuro-informatics, biomarkers, magnetic resonance imaging, genetic 
associations, and outcomes.  This PhD is part of the outcomes strand of CENTER-TBI.   
 
1.1.2. Advances in outcomes research    
  Outcomes research is a broad field of investigation, which aims to improve the quality of 
health care by developing a better understanding of the end results of clinical practice (Jefford, 
Stockler, & Tattersall, 2003).  Current developments in outcomes research are underpinned by 
the patient-centred model of health care and place emphasis upon outcomes that are 
important to the patient, such as functional status, participation in major life roles, and quality 
of life (Sacristan, 2013).  In 2009, the US Food and Drug Administration (FDA) provided guidance 
for the use of patient-reported outcomes (PRO) in medical product labelling (U.S. Food & Drug 
Administration, 2009).  Furthermore, in 2015, the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Task Force for Emerging Good Practices in Outcomes Research 
published a report that is consistent with the FDA’s guidance, in which the conceptual 
foundations for Clinical Outcome Assessments (COAs), including PROs, are presented (Walton 
et al., 2015).  ISPOR definitions (Eremenco et al., 2014; Walton et al., 2015) for the concepts of 
relevance to this thesis are presented in Tables 1.1 and 1.2.   
 
1.1.3. Multi-dimensional outcome assessment in TBI  
  TBI is a heterogeneous condition, which has been defined as “an alteration in brain function, 
or other evidence of brain pathology, caused by an external force” (Menon et al., 2010).  It can 
affect multiple aspects of health and daily life.  Thus, a single outcome measure is insufficient to 
describe the overall burden of disability from TBI, and there is currently a drive towards the use 
of multi-dimensional approaches to the measurement of TBI outcomes (Maas et al., 2017; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  The aim 
of multi-dimensional outcome assessment is to capture changes in specific areas of health and 
daily life using measures that reflect the outcome domains of relevance to TBI, such as 
cognitive, physical, and psychosocial functioning (Maas et al., 2017; Nelson, Ranson, Ferguson, 
Giacino, Okonkwo, Valadka, Manley, & McCrea, 2017).  The concept of multi-dimensional 
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outcome assessment is poorly defined, and there is currently no consensus about which 
outcome domains are key.  Nevertheless, it is logical to consider outcomes to be multi-
dimensional if they include two or more assessments that capture two or more outcome 
domains.    
Table 1.1: ISPOR Task Force key concepts and definitions  





“A clinical assessment instrument that is used as the measure of patient outcome 
in a clinical trial.  There are four types:  patient-reported outcomes (PRO), 
clinician-reported outcomes (ClinRO), observer-reported outcomes (ObsRO), and 




“The concept that the outcome assessment is intended to measure.  The COI may 
be identical to the selected meaningful aspect of feeling or function.  Frequently, 
however, the COI is a simplified form or component of a feeling or function that 
is not an inherently meaningful feeling or function of a patient’s typical life, that 
is, not a complete meaningful health aspect, but thought to be indirectly well 
related to a meaningful health aspect.” 
Context of 
Use (COU) 
“A description of the specifics of the study design, how the COA is used within 
the study, and result interpretation….The COU can affect whether the outcome 
assessment measurement of the COI is adequately related to the intended 
meaningful health aspect, as well as the measurement properties of the outcome 
assessment such as reliability and ability to detect change.”  
Treatment 
Benefit 
“A favourable effect on a meaningful aspect of how patients feel or function in 
their life, or on survival.  It is an effect on an aspect of health affected by the 
disease that is an alteration in feeling or functioning, about which the patient 
cares that it is affected, and has a preference that it does not become worse, 
improves, or is prevented.  The aspect of feeling or functions affected by the 




“Outcome assessments can be designed for more than one mode or method of 
administration.  There are options for 1) who administers the outcome 
assessment, for example, self-administration, an otherwise untrained person, or 
a trained professional, and 2) how it is administered, for example, visual versus 
auditory, face-to-face versus by telephone, and electronic versus non-electronic.” 
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Table 1.2: ISPOR Task Force definitions for different types of COA  




“A COA in which the report comes directly from the patient.  The patients’ 
responses to questions about their health condition are recorded without 





“A type of COA in which a member of the investigator team is the rater.  
The investigator’s professional training is relied upon to judge what rating 






“A COA in which observations can be made, appraised, and recorded by a 
person other than the patient who does not require specialized professional 





“A COA in which the patient is assessed by performing a defined task that is 
quantified in a specified way.  Although a member of the investigator team 
may administer the PerfO task and monitor the patient’s performance, the 
investigator does not apply judgment to quantify the performance.” 
 
  In acute care settings, TBI outcomes were traditionally based on ClinROs, such as the 
interviews for the Glasgow Outcome Scale (GOS) as a 5-point scale or 8-point scale (Jennett & 
Bond, 1975; Jennett, Snoek, Bond, & Brooks, 1981).  However, other types of outcome 
measure, including PROs, are increasingly being incorporated in TBI studies (Maas et al., 2017; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  Current 
CDE recommendations for adult TBI are multi-dimensional and include one core measure, the 
GOSE, as well as a set of basic and supplemental measures, which can be used in specific study 
settings (Hicks et al., 2013).  Examples of different types of COAs included in the CDE outcome 
measures for TBI (Hicks et al., 2013; Wilde et al., 2010) are presented in Table 1.3.   
 
  The CDEs for TBI were first selected in 2010 (Wilde et al., 2010), and subsequently updated in 
2013 (Hicks et al., 2013) to broaden their clinical utility and incorporate outcomes which are 
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relevant in specific contexts of use (i.e., paediatric TBI, adult TBI, epidemiology, acute hospital, 
moderate-to-severe TBI rehabilitation, mild TBI/concussion) (National Institute of Neurological 
Disorders and Stroke, 2018b).  Selection of the CDEs is an evolving process (Grinnon et al., 
2012), and as the original proposals were derived from clinical practice and based on expert 
consensus alone, research is needed to inform future refinements (Maas et al., 2011).  In 
particular, the outcome measures used in TBI studies need to be validated and the applicability 
of multi-dimensional approaches to outcome assessment needs to be evaluated in different 
contexts of use.  Large-scale studies, such as CENTER-TBI (Maas, Menon, et al., 2015), provide 
an opportunity to do this.  However, implementation of the CDEs is not a straightforward 
process, and researchers may need to compromise on the outcome measures that are selected.   
 
  CENTER-TBI used a multi-dimensional set of outcome measures, based on the CDEs (Maas, 
Menon, et al., 2015; Maas et al., 2017).  However, certain CENTER-TBI measures are not 
included in the current CDE recommendations.  A number of challenges were encountered 
when selecting the CENTER-TBI outcome measures: some instruments could not be used due to 
copyright issues, while others were cost prohibitive, or could not be translated into the 
required languages for an international population (Burton, 2017; Maas et al., 2017).   
 
Table 1.3: Types of COA included in the NINDS CDEs for TBI 
Type of COA  Example NINDS CDE outcome measures  
PRO Short Form-36 Medical Outcome Study (SF-36) 
Rivermead Post-concussion Questionnaire (RPQ) 
ClinRO Glasgow Outcome Scale - Extended (GOSE) 
ObsRO Not included   
PerfO Trail Making Test (TMT) 




Figure 1.1 is a schematic diagram of multi-dimensional outcome assessment in TBI, adapted 
from (Maas et al., 2017), showing the outcome domains and individual measures used in 
CENTER-TBI.    
 
Figure 1.1: Multi-dimensional assessment of TBI outcome  
 Outcome Domain 




JFK Coma Recovery  
Scale - Revised (CRS-R) 
Galveston Orientation and 



















Glasgow Outcome Scale 






 of life (HRQoL)  
36-Item Short Form Survey 
-Version 2 (SF-36v2) 
 
Quality of Life after Brain 
Injury Scale (QOLIBRI) 





Psychological status  
Post-Traumatic Stress  












Rey Auditory Verbal 
Learning Test (RAVLT) 
Trail Making Test (TMT) 
Cambridge   
Neuropsychological Test   
Automated Battery 
(CANTAB) 
Physical functioning 10-meter walk 
Timed Up & Go (TUG) 
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1.2. Aims of thesis  
  A number of aims were outlined for CENTER-TBI during the project planning phase.  
Furthermore, a manual for data access, study plan proposals, and publication requests was 
created, and researchers were responsible for submitting study proposals for acceptance by the 
CENTER-TBI Management Committee.  The CENTER-TBI project aims were defined during the 
planning phase, however studies for particular work streams were not fully specified at this 
stage.  Thus, during project implementation there was scope to develop specific research 
questions and methods for the studies presented in this thesis.  The studies in this thesis were 
developed in the first year of the PhD and put forward to the CENTER-TBI Management 
Committee in three separate study proposals.  The approved proposals are listed on the 
CENTER-TBI website and are titled and numbered as follows: Agreement between approaches 
for rating the GOSE in CENTER-TBI (75); The GOSE as a clinician-reported or patient-reported 
outcome (76); and Relation of GOSE level of disability to data quality and validity of outcomes 
in adult TBI (77).      
 
  The CENTER-TBI work plan was ambitious with respect to the collection of outcomes.  Data 
collection for the CENTER-TBI follow-ups was therefore done in a pragmatic and flexible way 
(Maas et al., 2015).  The GOSE could be completed as a structured interview and/or 
respondent-completed questionnaire.  Furthermore, at follow-up, investigators considered 
whether specific outcome measures were appropriate for use with individual patients, and 
assessments were attempted if patients were judged to be capable of completing them.  The 
pragmatic way in which outcomes were collected for CENTER-TBI provided an opportunity to 
examine two main issues of relevance to observational TBI studies: (1) the comparability of 
different approaches to measuring global functional outcome on the GOSE; and (2) the usability 
of individual outcome measures across the spectrum of recovery after TBI.  These issues were 
selected for investigation in this thesis because they were consistent with the CENTER-TBI 
objectives, and because both issues can potentially result in biased study findings (e.g., 
information collected via the GOSE structured interview and GOSE questionnaire might not be 
equivalent, and TBI patients can be difficult to follow-up in longitudinal studies, potentially 
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resulting in selective attrition of patients with particular characteristics (Corrigan et al., 2003; 
Krellman et al., 2014)).   
 
  There is limited research concerning the comparability of clinician ratings and patient reports 
on the GOSE.  Furthermore, the usability of individual outcome measures across the spectrum 
of disability after TBI has not been examined in the context of TBI research.  In light of this, the 
studies presented in this thesis were designed to investigate the measurement of global 
functional outcome and consider the implementation of multi-dimensional outcome 
assessment in different contexts of use.  The ISPOR Task Force framework for COAs was used to 
investigate the usability of ClinROs (i.e., structured interviews), PROs (i.e., questionnaires), and 
PerfOs (i.e., cognitive and functional mobility assessments) in TBI, and assessments were 
considered to be multi-dimensional if they measured two or more outcome domains.  
 
This thesis has three broad aims: 
1. To assess how COAs, including the GOS/GOSE, have been used and reported in acute and 
post-acute clinical trials in TBI, and to consider the extent to which multi-dimensional 
outcome assessment has been implemented in these studies  
2. To compare clinician ratings and respondent reports of global functional outcome in TBI, by: 
 Exploring whether information obtained via the GOSE structured interview provides 
added value over the GOSE questionnaire 
 Examining how the GOSE structured interview and GOSE questionnaire relate to 
prognostic factors and other outcome measures 
3. To examine the usability of multi-dimensional outcome measures in relation to level of 
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  This chapter is a systematic review on the patterns of use and reporting quality of COAs in 
clinical trials in adult TBI.  The findings from this review demonstrate the need for increased 
consistency and improved reporting of outcome measures in TBI trials.  The findings also 
highlight the limited use of multi-dimensional outcome assessment in published RCTs, 










2.1. Abstract  
  As part of efforts to improve study design, the use of outcome measures in randomized 
controlled trials (RCTs) in traumatic brain injury (TBI) is receiving increasing attention.  This 
review aimed to assess how clinical outcome assessments (COAs) have been used and reported 
in RCTs in adult TBI.  Systematic literature searches were conducted to identify medium to large 
(n ≥ 100) acute and post-acute TBI trials published since 2000.  Data were extracted 
independently by two reviewers using a set of structured templates.  Items from the 
Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement and CONSORT patient-
reported outcomes (PRO) extension were used to evaluate reporting quality of COAs.  Glasgow 
Outcome Scale/Extended (GOS/GOSE) data were extracted using a checklist developed 
specifically for the review.  A total of 126 separate COAs were identified in 58 studies.  The 
findings demonstrate heterogeneity in the use of TBI outcomes, limiting comparisons and meta-
analyses of RCT findings.  The GOS/GOSE was included in 39 studies, but implemented in a 
variety of ways, which may not be equivalent.  Multi-dimensional outcomes were used in 30 
studies, and these were relatively more common in rehabilitation settings.  The use of PROs 
was limited, especially in acute study settings.  Quality of reporting was variable, and key 
information concerning COAs was often omitted, making it difficult to know how precisely 
outcomes were assessed.  Consistency across studies would be increased and future meta-
analyses facilitated by (a) using common data elements recommendations for TBI outcomes 













  There is increasing awareness of the importance of clinical outcome assessments (COAs) in 
evaluating health care interventions (Walton et al., 2015).   Furthermore, in clinical research, 
there is increasing emphasis both on standardizing data collection, and on multi-dimensional 
outcome assessment including the patient’s perspective (Sheehan et al., 2016).  In recognition 
of the central role of outcomes in clinical studies, the US Food and Drug Administration (FDA) 
has implemented a qualification program for COAs (U.S. Food & Drug Administration, 2014).  
The terminology developed to describe COAs is outlined in a Task Force report by the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (Walton et al., 
2015) and summarized in Chapter 1 of this thesis (see Tables 1.1 & 1.2).  The ISPOR report 
recommends that COAs should be targeted to clinical treatments; that is, in randomized 
controlled trials (RCTs), selected COAs should be specifically chosen to determine whether 
there is a treatment benefit on the intended aspect of patient functioning or feeling (i.e., the 
concept of interest).  The COAs selected should also be of clinical value to patients, in that they 
should measure meaningful aspects of health that affect daily living (Walton et al., 2015).  
 
  In traumatic brain injury (TBI) research, there is currently a drive towards standardizing data 
collection using a common set of measures which can be used to provide a multi-dimensional 
description of outcome (Clinical Data Interchange Standards Consortium, 2015; Hicks et al., 
2013; Maas et al., 2017; Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, 
McCrea, et al., 2017; Tosetti et al., 2013; Wilde et al., 2010).  At its simplest, multi-dimensional 
assessment means going beyond using a single endpoint to include two or more outcome 
domains.  Multiple outcome domains are relevant to TBI, including global functional outcome, 
health-related quality of life, psychological status, TBI symptoms, cognition, and physical 
functioning (Hicks et al., 2013; Maas et al., 2017; Nelson, Ranson, Ferguson, Giacino, Okonkwo, 
Valadka, Manley, McCrea, et al., 2017).  Current common data elements (CDEs) 
recommendations for TBI outcomes include clinician-reported outcomes (ClinROs), patient-
reported outcomes (PROs), and performance outcomes (PerfOs) (Hicks et al., 2013).  The CDE 
outcomes for TBI comprise one core measure of global functioning, the GOSE, as well as a 
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variety of basic and supplemental outcome measures, which can be used in specific TBI study 
types (Hicks et al., 2013).  Use of common outcomes promotes meta-analyses and provides a 
potential opportunity for pooling data for secondary analysis; it is particularly desirable in 
medium to large-scale studies where the information collected may form a valuable legacy for 
use in the future (Maas et al., 2011).  
 
  Measures of global functional outcome, such as the Glasgow Outcome Scale (GOS) and its 
extended version, the Glasgow Outcome Scale-Extended (GOSE), have often been used alone as 
the primary endpoint in trials of treatments for moderate to severe TBI (Alali et al., 2015; 
Bragge et al., 2016; McMillan et al., 2016; Nichol et al., 2011).  However, the GOS/GOSE has 
been criticized for being insensitive to subtle changes in functioning (Alali et al., 2015; Maas et 
al., 2017; McMillan et al., 2016; Menon & Maas, 2015; Nelson, Ranson, Ferguson, Giacino, 
Okonkwo, Valadka, Manley, McCrea, et al., 2017; Nichol et al., 2011; Weir et al., 2012; Wilson, 
Pettigrew, & Teasdale, 2000). In addition, the GOS/GOSE may be collected in a variety of 
different ways, potentially yielding results that are not comparable.  There is currently no 
systematic overview of how COAs have been used in clinical trials in TBI.  Furthermore, the 
extent to which previous TBI trials have used a multi-dimensional set of outcomes, or a single 
measure of global functional outcome such as the GOS/GOSE, is unclear, and warrants 
investigation.  
 
  Transparency and completeness in the reporting of RCTs is essential to inform clinical decision-
making.  However, the reporting quality of COAs in TBI trials has not specifically been 
evaluated.  A review by Lu et al (2015) used the CONsolidated Standards of Reporting Trials 
(CONSORT) statement (Schulz, Altman, Moher, & Group, 2010) to evaluate whether the 
reporting quality of methodological characteristics in adult TBI trials has improved over time (Lu 
et al., 2015).  Although reporting has improved over time in line with developments in the 
CONSORT reporting guidelines, Lu et al (2015) concluded that there remains a need for 
increased transparency in the reporting of clinical trial methodologies in adult TBI. Incomplete 
reporting makes it difficult to assess the methodological rigour of RCTs and hinders ‘risk of bias’ 
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assessments.  Sub-optimal reporting of outcomes in clinical trials is also problematic because it 
interferes with the interpretation of findings, and ultimately, limits their ability to inform clinical 
practice guidelines.  
 
  The current systematic review focuses on medium to large scale RCTs in adults with TBI 
published from 2000 onwards.  The review had two main objectives: (1) To document patterns 
of use of COAs; and (2) To evaluate quality of reporting of COAs using COA-specific items from 




2.3.1. Search Strategy 
 Systematic online literature searches were conducted between October 2015 and May 2017 to 
identify RCTs investigating the effectiveness of acute and post-acute treatments, interventions, 
and management strategies in adult TBI.  The following online databases were searched: 
PubMed, CINAHL Complete, and PsychInfo.  PubMed and CINAHL Complete were searched 
using the MeSH terms “brain injuries” (exact subject) AND “randomised controlled 
trial/randomized controlled trial" (title/abstract).  PsychInfo was searched using the terms 
"traumatic brain injury" (DE subjects [exact]) AND "randomized controlled trial/randomised 
controlled trial" (AB Abstract).  Two clinical trials registries, www.clinicaltrials.gov and the 
Cochrane Central Register of Controlled Trials (CENTRAL), were searched using the MeSH term 
"brain injuries" and condition "traumatic brain injury."  A hand search was conducted by 
searching the reference lists of two recent systematic reviews of RCTs in TBI (Bragge et al., 
2016; Lu et al., 2015).  If a single study had more than one publication, linked papers were 
included in the review and evaluated as one publication.  
 
  The references retrieved from the database search were imported to the Covidence system, 
(Covidence, 2017) where the titles and abstracts were screened independently by two 
reviewers according to the following inclusion and exclusion criteria:   
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Inclusion Criteria  
1. Clinical trials investigating acute or post-acute treatments, interventions, or 
management strategies for TBI   
2. Adult participants (normally aged 16 and over) 
3. Articles published from 2000 to the present 
4. Articles published in academic journals 
5. Articles published in English  
6. Medium-scale (n = 100-500) and large-scale studies (n>500)  
 
Exclusion Criteria  
1. Small scale studies (n< 100)  
2. Feasibility studies, pilot studies, study protocols, progress reports 
3. Retrospective analyses of previously published RCTs    
 
2.3.2. Data Extraction 
  Data extraction was carried out independently by two reviewers. Quality was ensured by 
randomly selecting 5 studies, piloting data extraction for these studies, and refining the process 
where necessary before proceeding.  Further quality control measures were implemented by 
completing data extraction in sets of 10, and by discussing and resolving any discrepancies that 
occurred, until data extraction was complete.    
 
2.3.3. Study characteristics  
  The following information relating to general study characteristics was extracted: sample size 
(i.e., number randomized); study size (medium/large); participant age (overall mean/median 
age, age range); TBI severity (mild/moderate/severe); setting (acute/post-acute); participation 
sites (single/multicentre); intervention characteristics/type of study; treatment benefit; 
treatment mechanism; hypothesis; primary COA(s); secondary COA(s); time point of primary 




2.3.4. Risk of Bias   
  Selection bias has been found to influence RCT outcomes and is a central measure of study 
quality.  Therefore, risk of selection bias was assessed using two key domains from the 
Cochrane Risk of Bias Tool: random sequence generation and allocation concealment.  Risk of 
bias was categorized as high, low, or unclear (if insufficient information was provided), in line 
with Cochrane Collaboration definitions (Higgins et al., 2011).  This approach is consistent with 
that used in a recent scoping review of RCTs in moderate-to-severe TBI (Bragge et al., 2016).  
 
2.3.5. Patterns of use of COAs 
  Frequency counts were made to identify: (1) How many COAs were used; (2) Which 
assessments were used most often; (3) How many studies used multi-dimensional outcomes 
(i.e., use of two or more measures covering different assessment domains as defined in the 
CDEs); and (4) Which type of COA was used most commonly in each setting (i.e., ClinRO, PRO, 
PerfO, ObsRO), both for primary outcomes and for outcomes that were used in any capacity 
(including primary outcomes, secondary outcomes, and combined outcomes).  Combined 
outcomes consist of two or more component outcome measures which are combined into a 
single endpoint (Freemantle, Calvert, Wood, Eastaugh, & Griffin, 2003; Temkin et al., 2007), or 
analyzed jointly using a global test (Bagiella et al., 2010a; Zafonte et al., 2012).   
 
2.3.6. Quality of reporting of COAs 
  A checklist was developed to assess the reporting quality of COAs.  The checklist was based on 
COA-relevant items from the CONSORT PRO extension, (Calvert et al., 2013) CONSORT 2010 
Statement, (Schulz et al., 2010) and other additional COA-relevant reporting criteria. The 
CONSORT PRO extension provides guidance on how to describe patient-reported outcomes 
(PRO).  However, as this review is concerned with COAs more generally, items from the 
CONSORT checklists were evaluated for all four types of COA (i.e., ClinRO, PRO, PerfO, ObsRO).  
Some additional COA-relevant items were added, and some of the CONSORT checklist items 




2.3.7. Glasgow Outcome Scale  
  Patterns of use and quality of reporting were evaluated for the GOS/GOSE using a checklist, 
which was developed specifically for this review.  The checklist was used to assess the following 
items: (1) Whether the GOS/GOSE was used as a primary outcome, secondary outcome, or not 
at all; (2) Method of assessment (i.e., clinician assessed, structured interview, or questionnaire); 
(3) Whether extracranial injuries were included in the rating; (4) Method of dealing with severe 
pre-existing disability; (5) Method of contact for assessment (i.e., face-to-face, telephone, or 
postal); (6) Source of information (i.e., patient, proxy respondent, or other sources); (7) Method 
of assigning final rating (i.e., researcher rating or central review); (8) Whether the assessor was 
trained; (9) Whether scores were dichotomized; and (10) Whether ordinal analysis methods 
were used (including analysis of ranked data, sliding dichotomy, and proportional odds ratio 
methods).   
 
2.3.8. Statistical analysis 
  The results were summarized descriptively using frequencies (i.e. number of studies) and 
percentages (i.e. proportion of studies) for each of the items of interest.  The data were 
analyzed using Microsoft Excel®.
  
 
2.4.  Results  
2.4.1. Study selection process 
  The online literature search yielded a total of 1861 references.  The hand search revealed an 
additional 6 articles which met the inclusion criteria for the review.  After removing duplicates, 
a total of 1137 separate references were left to be screened.  Of these references, 1025 were 
excluded.  The remaining 113 full-text articles were assessed for eligibility.  Fifty-five of the full-
text articles were excluded, leaving a total of 58 studies to be included in the review.  The study 






2.4.2. Study characteristics  
  The general characteristics of the studies are presented in Appendix 2.  Key study 
characteristics are summarised in Table 2.1.  Most of the studies were conducted in acute 
settings (n = 38), and most were medium sized (n = 51).  Almost half of the studies were 
conducted with patients with severe TBI (n = 27), most studies were multicentre (n = 38), and 
most had follow-up rates of 90% or better (n = 41).  Six months post-injury was the most 
popular time point of primary interest (n = 31).  
 
 




Table 2.1: Key study characteristics  







Sample size   
      100-500 (medium) 31 (81%) 20 (100%) 51 (88%) 
      >500 (large) 7 (19%) 0 (0%) 7 (12%) 
TBI Severity (GCS score)  
      13-15 (mild) 1 (2%) 6 (30%) 7 (12%) 
      9-12 (moderate) 0 (0%) 0 (0%) 0 (0%) 
      3-8 (severe) 25 (66%) 2 (10%) 27 (46%) 
      3-15 (all severities) 3 (8%) 4 (20%)  7 (12%) 
      9-15 (mild/moderate) 0 (0%) 1 (5%) 1 (2%) 
      3-12 (moderate/severe) 9 (24%) 7 (35%) 16 (28%) 
Participation Centres   
      Single Centre 14 (37%) 6 (30%) 20 (34%) 
      Multicentre 24 (63%) 14 (70%) 38 (66%) 
Time point of primary interest  
      <6-months post-injury 5 (13%) 3 (15%) 8 (14%) 
      6-months post-injury 29 (77%) 2 (10%) 31 (53%) 
      1-year post-injury 0 (0%) 4 (20%) 4 (7%) 
      >1-year post-injury 1 (2%) 8 (40%) 9 (16%) 
      Other 3 (8%) 3 (15%) 6 (10%) 
Follow-up rate  
      ≥90% 32 (84%) 9 (45%) 41 (71%) 
      80-89% 2 (6%) 7 (35%) 9 (16%) 
      70-79% 1 (2%) 2 (10%)  3 (5%) 
      <70% 1 (2%) 2 (10%) 3 (5%) 




2.4.3. Risk of Bias  
  Risk of selection bias for each study is presented in Appendix 2.  Figure 2.2 shows that random 
sequence generation (RSG) was rated as low risk of bias in 42 studies (27 acute; 15 post-acute), 
unclear risk of bias in 15 studies (11 acute; 4 post-acute), and high risk of bias in 1 post-acute 
study.  Allocation concealment (AC) was rated as low risk of bias in 39 studies (25 acute; 14 
post-acute), unclear risk of bias in 18 studies (12 acute; 6 post-acute), and high risk of bias in 1 
acute study.   
 




2.4.4. Patterns of use of COAs 
  A total of 126 separate COAs were identified within the 58 studies.  The full list of COAs by 
type, study setting, and frequency of use are listed in Appendix 3.  Twenty-six (21%) of the COAs 
were used exclusively in acute studies, 82 (65%) were used exclusively in post-acute studies, 
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RSG Overall (n = 58)
RSG Acute Studies (n = 38)
RSG Post-Acute Studies (n = 20)
AC Overall (n = 58)
AC Acute Studies (n = 38)
AC Post-Acute Studies (n = 20)
Low Risk of Bias
Unclear Risk of Bias
High Risk of Bias
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commonly used COAs were the GOS, GOSE, Disability Rating Scale (DSR), Trail Making Test Parts 
A & B (TMT A&B), SF-36, Controlled Oral Word Association Test (COWAT), Functional 
Independence Measure (FIM), Selective Reminding Test (SRT), Galveston Orientation and 
Amnesia Test (GOAT), and Rivermead Post-Concussion Questionnaire (RPQ).  Of these 10 COAs, 
the 3 most frequently used were the GOS (21 studies), GOSE (21 studies), and DRS (12 studies).  
The GOS was used exclusively in the acute studies, whereas the GOSE was used in 16 of the 
acute studies and 5 of the post-acute studies.  The DRS was used in 8 of the acute studies and 4 
of the post-acute studies. 
 
Figure 2.3: Most commonly used COAs 
  
 
  A total of 30 studies used multi-dimensional outcomes (12 acute studies, 18 post-acute 
studies).  Twenty-four of the studies with multi-dimensional outcomes reported individual 









































global test to create a multi-dimensional outcome, i.e., the TBI Clinical Trials Network Core 
Battery (Bagiella et al., 2010a; Zafonte et al., 2012).  
 
  The COAs were classified according to whether they were ClinROs, PROs, PerfOs, or ObsROs.  
Table 2.2 shows the number and proportion of studies that used each type of COA, both as a 
primary outcome, and in any capacity (i.e., as a primary outcome, secondary outcome, or as 
part of a composite outcome).  
   
Table 2.2: RCT findings for different types of COA and study setting 
 




n (%) of RCTsA 
 
All COAs  






























































More than one 



















AData are n (%) of the 55 studies using COAs as a primary outcome      
BData are n (%) of the 58 studies using COAs in any capacity (i.e., as a primary outcome, secondary 
outcome, or as part of a composite outcome)     
CIncludes all outcomes that comprised more than one type of COA (e.g., ClinRO and PRO)  
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  Overall, ClinROs were the most popular type of COA: they were used mostly in acute settings 
and accounted for 54% of acute study primary outcomes.  PROs were used rarely in acute 
settings, but they were used more commonly in post-acute settings.  Overall, 20 studies used 
more than one type of COA (9 acute studies; 11 post-acute studies).  For primary outcomes, 10 
studies used more than one type of COA (3 acute studies; 7 post-acute studies).   
 
 
2.4.5. Quality of reporting of COAs  
  Reporting quality of COAs was assessed across the 58 studies.  The number and percentage of 
studies that met each quality criterion is reported in Table 2.3.  Each article was assessed 
according to whether the individual quality criteria were met.  For cases where the information 
was unclear, or partially met, the criterion was rated as unmet.  Reporting of primary and 
secondary outcome measures was assessed separately for checklist item 4.  The numbers and 
percentages for each criterion are adjusted accordingly for sub-groups (see Table 2.3 Legend).  
 
  Table 2.3 shows that reporting of COAs was variable across the quality criteria.  The checklist 
items that were reported most completely include: (2a) Treatment benefit defined (95% of all 
studies); (4i) Timing of follow up for primary outcomes stated (98% of all studies); (7) Baseline 
COA data provided, if collected (100% of the 20 applicable studies); (8) Numbers analysed for 
COA results stated (98% of all studies); (10c) Implications for clinical practice discussed (100% of 
all studies); (11) COA data interpreted in relation to clinical outcomes, including survival data, 
where relevant (100% of all studies).  Reporting varied between acute and post-acute studies, 
and primary outcomes were generally reported more completely than secondary outcomes, 
especially in the post-acute studies.  Reporting quality varied across criteria for checklist item 4: 
Overall, the proportion of studies meeting the criteria ranged from 6% for ‘Number of assessors 
stated for secondary outcomes,’ to 98% for ‘Timing of follow-up for primary outcomes stated.’  
The following checklist items were least complete: (3) COA hypothesis stated and relevant 
domains defined, if applicable (57% of all studies); (9a) Effect size reported (53% of all studies); 
(9aii) For binary outcomes, absolute effect size stated (28% of applicable studies); (9b) 
Confidence intervals (or other measures of precision) reported (57% of all studies); (10a) COA-
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specific limitations discussed (36% of all studies); and (10b) Implications for generalizability 
discussed (41% of all studies).  
 
Table 2.3: Quality of reporting of COAs 
 
Quality Criterion 
Number (% of RCTs) meeting criterion 
Acute 




(n = 58) 
1. COA identified in abstract as a primary/ secondary 
outcome 
28 (74%) 17 (85%) 45 (78%) 
2. Background and rationale for COA provided 
a. Treatment benefit defined* 


















4. Completely defined pre-specified primary outcomesA  
a. Validity & reliability described or source citation 
given 
b. Who assessed outcomes stated 
c. Number of assessors stated* 
d. Whether assessors were blind is clear 
e. Native language with validated translation* 
f. Methods of contact stated, e.g., 
telephone/postal/face-to-face 
g. Respondent stated (e.g., patient/proxy, other 
sources) 
h. Whether respondent was blind stated* 








































4. Completely defined pre-specified secondary 
outcomesB 
a. Validity & reliability described or source citation 
given 
b. Who assessed outcomes stated 
c. Number of assessors stated* 
d. Whether assessors were blind is clear 
e. Native language with validated translation* 
f. Methods of contact stated, e.g., 
telephone/postal/face-to-face 
g. Respondent stated (e.g., patient/proxy, other 
sources) 
h. Whether respondent was blind stated* 



















































6. Number of participants at baseline and subsequent    
38 
 
time points given 30 (79%) 19 (95%) 49 (85%) 
7.  Baseline COA data provided, if collectedC 
 
3 (100%) 17 (100%) 20 (100%) 
8. Numbers analysed for COA results stated 38 (100%) 19 (95%) 57 (98%) 
 
9. For each primary and secondary outcome, results for 
each group provided 
a. Effect size reported 
i. For binary outcomes, Drelative effect size stated 
ii. For binary outcomes, Dabsolute effect size stated 
b. Confidence intervals (or other measures of     






















10a.   COA-specific limitations discussed 
10b.   Implications for generalizability discussed  










11. COA data interpreted in relation to clinical outcomes, 







*Expanded items marked with asterisks 
 A Applicable in 55 studies (35 acute studies; 20 post-acute studies)  
B Applicable in 33 studies (16 acute studies; 17 post-acute studies) 
C Applicable in 20 studies (3 acute studies; 17 post-acute studies) 
D Applicable in 25 studies (24 acute studies; 1 post-acute study)       
 
2.4.6. Glasgow Outcome Scale 
  The GOS/GOSE was the most commonly used COA overall.  The scale was used in 39 of the 58 
studies (67%).  Figure 2.4 shows how often the scale was used as a baseline measure, primary 
outcome, secondary outcome, or as part of a composite outcome.  The scale was used in its 
original format (GOS) in 21 studies (GOS guided interview = 20 studies; GOS questionnaire = 1 
study), and in its extended format (GOSE) in 21 studies (GOSE questionnaire = 3 studies; GOSE 
structured interview = 18 studies).  It was used as a primary outcome in 29 studies (GOS = 19 
studies, GOSE structured interview = 8 studies, GOSE questionnaire = 1 study).  It was used as a 
secondary outcome in 7 studies (GOS = 3 studies, GOSE structured interview = 3 studies, GOSE 
questionnaire = 1 study): 3 of these studies used the GOS as a primary outcome as well as the 
GOSE questionnaire as a secondary outcome.  The GOSE structured interview was used as part 




  Table 2.4 displays the patterns of use and completeness of reporting in the 39 studies that 
used the GOS or GOSE.  Clinician assessed/guided interviews were used in 46% of the studies 
(17 acute studies; 1 post-acute studies), while structured interviews were used in 44% of the 
studies (13 acute studies; 4 post-acute studies), and questionnaires were used in 10% of the 
studies (4 acute studies; no post-acute studies).  None of the articles stated whether 
extracranial injuries were included in the ratings, and 90% (35 studies) did not state the 
methods used to deal with pre-existing severe disability.  Around half of the articles did not 
state the primary method of contact (18 acute studies; 2 post-acute studies), and 64% (23 acute 
studies; 2 post-acute studies) did not report the source of information/respondent.  Final 
ratings were assigned by the researcher in 87% of the studies (29 acute studies; 5 post-acute 
studies), and by central review in 13% of the studies (all 5 were acute studies).  Most articles 
(69%) did not state whether the outcome assessor was trained (22 acute studies; 5 post-acute 
studies).  GOS/GOSE scores were dichotomized in 59% of the studies (all 23 were acute studies), 




Figure 2.4: GOS/GOSE patterns of use for the original 5-point rating, postal questionnaires for 









GOS GOS questionnaire GOSE structured
interview
GOSE questionnaire
Primary Outcome Secondary Outcome Composite Baseline
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Method of assessment 
a. Clinician assessed/guided interview 














 Extracranial injuries included in rating 







Method of dealing with pre-existing SD  
a. Patients with pre-existing SD excluded 










Primary method of contact 
a. Face-to-face interview 
b. Telephone interview 
c. Postal questionnaire 
d. Face-to-face clinical assessment 
e. Face-to-face or telephone interview 
f. Postal questionnaire, telephone 
interview, or face-to-face interview 




























Source of information/respondent  
a. Patient alone 
b. Proxy alone 
c. Patient and proxy 
d. Patient or proxy 



















Method of assigning final rating 
a. Researcher 










Outcome assessor is trained 
a. Yes 










Scores are dichotomized 
a. Yes 
b. No 






























2.5. Discussion  
  This review aimed to evaluate how clinical outcome assessments (COAs) have been used and 
reported in RCTs in adult TBI from 2000 onwards.  In total, 58 clinical trials were assessed 
according to key study characteristics, risk of selection bias, patterns of use of COAs, and 
reporting quality of COAs.  The included articles demonstrate that the majority of RCTs that fit 
criteria were medium in size (i.e., n=100-500), and most studies investigated acute hospital 
treatments for moderate and severe TBI.  
 
  A wide range of COAs were used across the included studies, and there were differences in the 
use of outcomes depending on the setting in which the RCT was conducted (i.e., context of 
use).  A greater range of COAs were used in the post-acute studies, and there was little 
commonality between acute and post-acute settings.  The most popular COAs were measures 
of global functional outcome, including the GOS, GOSE, and DRS.  However, most of the COAs 
were used infrequently (i.e., in 1 to 3 studies).  Considerable variability therefore exists in the 
use of outcome measures in TBI trials, especially in post-acute settings, making it challenging to 
link acute and post-acute studies (Tosetti et al., 2013).  The frequent use of the GOS/GOSE in 
the reviewed studies is not surprising and is consistent with the subsequent CDE 
recommendations for TBI (Hicks et al., 2013).  Nevertheless, the GOS/GOSE has not been used 
universally in TBI clinical trials.  The introduction of outcome CDEs for TBI should help to reduce 
variability in the assessments used in RCTs.  However, it is notable that since first proposed 
(Wilde et al., 2010), the number of outcome CDEs has grown, and compartmentalisation of 
different areas of TBI assessment remains. 
 
  As multi-dimensional outcome assessment is increasingly important in the field of TBI, the 
GOS/GOSE is now recognised to be insufficient on its own as an outcome measure (Maas et al., 
2017; Menon & Maas, 2015; Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, 
McCrea, et al., 2017).  Despite this, around half of the reviewed studies used a single outcome: 
most of these were acute studies, and the GOS/GOSE was the most frequently used endpoint.  
Around half of the studies used multi-dimensional outcomes: most of the post-acute studies 
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used multi-dimensional outcomes, whereas a minority of the acute studies used multi-
dimensional outcomes.  Most studies with multi-dimensional outcomes used separate COAs to 
measure multiple outcome domains, and composite multi-dimensional outcomes were 
relatively rare.  While ClinROs such as the GOS/GOSE were common in the acute studies, PROs 
were used rarely in these studies.  Regulators have encouraged the use of PROs (U.S. Food & 
Drug Administration, 2009), but these assessments have not proven popular in TBI, perhaps 
because they are not as closely linked to the neural substrate as functional outcome measures 
(Bagiella et al., 2010a).  The findings from the review demonstrate that multi-dimensional 
outcomes are not used universally in TBI trials.  Moreover, multi-dimensional outcomes are 
more commonly used in rehabilitation settings, perhaps due to treatments that are more 
clearly targeted to behavioural change and designed to tap into multiple outcome domains.    
   
  The overall reporting quality of COAs was variable across the reviewed studies, suggesting that 
reporting is sub-optimal in TBI trials.  Most articles provided a sufficient background and 
rationale for the outcomes.  Furthermore, the criteria relating to timing of follow-ups, 
participant numbers, baseline outcomes data, implications for clinical practice, and 
interpretation of clinical outcomes, were consistently well met across the studies.  Overall, the 
most incompletely reported aspects included COA hypotheses, effect sizes and confidence 
intervals, COA-specific limitations, and implications for generalizability.  Some key differences 
were identified between the acute and post-acute studies.  Although acute studies were 
relatively better at explaining treatment mechanisms, more attention was paid to outcomes in 
rehabilitation settings (i.e., hypotheses were stated more clearly, primary outcomes were 
defined more fully, and COA-specific limitations and implications for generalizability were more 
likely to be discussed).  In the acute studies, there was often a lack of rationale for the choice of 
endpoint, possibly because pharmaceutical trials in acute TBI tend to be motivated by animal 
studies and there is a substantial gap between the behavioural measures typically used in 
laboratory work and the COAs used in human studies (i.e., GOS/GOSE).  In future clinical trials, 
investigators should therefore ensure that outcomes are well defined and carefully selected to 
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capture treatment benefit on specific aspects of the patient’s functioning or feeling (Walton et 
al., 2015).  
 
  Despite the wide use of the GOS/GOSE, certain aspects were reported particularly poorly 
across the studies.  None of the included articles reported whether extracranial injuries were 
included in the GOS/GOSE ratings, and most studies provided no information about the method 
used to deal with pre-existing severe disability.  Around two thirds of the articles did not state 
who the respondent was (i.e., the TBI patient or a proxy informant), or whether the outcome 
assessor was trained.  Furthermore, around half of the articles did not provide sufficient 
information about the primary method of contact for GOS/GOSE assessments (i.e., face-to-face 
contact, telephone contact, postal questionnaire).  In contrast, reporting of GOS/GOSE scoring 
and analysis methods was relatively complete, the method of assigning final ratings was clear in 
all of the articles, and it was apparent in most studies if the GOS/GOSE scores were 
dichotomized or if ordinal analysis methods were used.   
 
  Transparent reporting of how the GOS/GOSE is used and analysed is important in RCTs 
because variability in methods of data collection and scoring may influence study findings.  
Important issues to consider when assigning outcome on the GOS/GOSE include the influence 
of extracranial injury, pre-existing disability, and source of information (i.e., TBI patient or proxy 
informant) (Wilson, Pettigrew, & Teasdale, 1998).  Inter-rater variability is another important 
issue when assigning outcome and interviewer training is required to achieve high levels of 
agreement between assessors (Wilson et al., 2007).  Extracranial concomitant injury can have 
an effect on functional outcome (Dacey et al., 1991; Leong, Mazlan, Abd Rahim, & Ganesan, 
2013).  However, the original description of the structured interview for the GOSE noted that 
the scale did not distinguish the effects of brain injury from the effects of concomitant injuries 
to other parts of the body:  investigators needed to decide whether to include or exclude 
extracranial injuries in the overall rating of disability (Wilson et al., 1998).  Both approaches 
have been used in RCTs, with some trials including extracranial injuries in the assessment (e.g. 
the Dexanabinol Trial) (Maas et al., 2006), and others excluding the influence of non-brain 
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injuries (e.g. PROTECT III) (Wright et al., 2014).  This represents a substantial difference in the 
way that outcome assessments have been conducted, and one that should be documented in 
future trial reports.  
 
  Previous studies suggest that the GOSE questionnaire and structured telephone interview can 
be used as a reliable means of assigning functional outcome in the absence of face-to-face 
contact (Pettigrew, Wilson, & Teasdale, 2003; Wilson, Edwards, Fiddes, Stewart, & Teasdale, 
2002).  Nevertheless, robust comparisons between these different methods of GOSE data 
collection have not been made.  The GOSE questionnaire is increasingly used in TBI trials 
(Andrews et al., 2015; Gregson et al., 2015; Hutchinson et al., 2017; Mendelow et al., 2015).  
However, as impaired self-awareness can affect TBI patients’ ability to provide an accurate self-
report (Prigatano, 2005b), the GOSE questionnaire may not be appropriate in all contexts.  
Disagreements between GOSE questionnaires and GOSE interviews may occur if questionnaires 
are self-completed by patients who lack insight into their own functional limitations (Wilson et 
al., 2002), and investigators should take this into consideration when deciding which method of 
GOSE data collection to use in future TBI studies.    
 
2.5.1. Limitations  
  This review provides information about the patterns of use and reporting quality of outcomes 
in adult TBI trials published from the year 2000 onwards.  However, it is important to note that 
the review has limitations.  As changes in the use and reporting of COAs were not examined 
over time, the impact of the CDE recommendations for common outcome measures in TBI 
(Hicks et al., 2013; Wilde et al., 2010), and the CONSORT guidelines for RCT reporting (Calvert et 
al., 2013; Schulz et al., 2010), on clinical trials in TBI is unknown.  Furthermore, as the review 
was restricted to medium and large scale RCTs (i.e., n≥100), the findings may have differed if 
smaller scale RCTs had been included.  The inclusion criteria may have been biased against 






  This review demonstrates shortcomings in the use of COAs in adult TBI trials to date and 
highlights the issue of incomplete reporting of outcomes in these studies.  Heterogeneity in the 
use of clinical trial endpoints is problematic because it interferes with meta-analyses of trial 
findings and makes it difficult to pool data for secondary analyses.  Incomplete reporting of 
outcomes is also problematic because it limits the transparency of RCT findings and 
compromises their clinical applicability.  To address the issues raised in this review, future 
studies in adult TBI should follow CDE outcomes recommendations to increase consistency in 
the use of COAs and facilitate future meta-analyses (Hicks et al., 2013).  Future RCTs in adult TBI 
should also adhere to CONSORT guidelines to ensure transparency in the reporting of outcomes 
and contribute to the development of clinical guidelines (Calvert et al., 2013; Schulz et al., 
2010).  As the GOSE is currently recommended as the core COA within multi-dimensional 
outcome assessments in TBI (Hicks et al., 2013; Maas et al., 2017; Nelson, Ranson, Ferguson, 
Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017), further research into how it is used 




















Multi-dimensional TBI outcomes: Research methodology 
 
 
  This chapter outlines the research methodology used in this thesis and provides an overview 






















3.1. CENTER-TBI recruitment 
  All patients described in this thesis were recruited to CENTER-TBI (Maas, Menon, et al., 2015).  
CENTER-TBI comprises a core study of 4509 TBI patients recruited between December 2014 and 
December 2017 via 65 sites across 18 countries in Europe, as well as a registry providing basic 
observational data on TBI patients presenting to sites involved in the CENTER-TBI study 
between December 2014 and December 2017 (n=22,782).  Patients recruited to the CENTER-TBI 
core study were differentiated by clinical pathway into three strata: (1) the emergency room 
(ER) stratum, comprising 848 patients who were seen in the ER and discharged without being 
admitted to hospital; (2) the admission stratum, comprising 1523 patients who were admitted 
to hospital, but not to the intensive care unit (ICU); and (3) the ICU stratum, comprising 2138 
patients who were admitted to ICU.  Inclusion and exclusion criteria for CENTER-TBI are 
presented in Table 3.1.   
 
Table 3.1: Inclusion and exclusion criteria of CENTER-TBI (Reproduced from Maas et al., 2015)   
 Inclusion criteria Exclusion criteria 
CENTER-TBI core 
study (n=4509) 
Clinical diagnosis of TBI Severe pre-existing 
neurological disorder that 
would confound outcome 
assessments 
Clinical indication for CT scan 
Presentation within 24 hours of injury 
Informed consent obtained according 
to local and national requirements 
CENTER-TBI registry  
(n=22, 782) 
Clinical diagnosis of TBI 





3.2. Measures used  
  The sections below provide an overview of the CENTER-TBI measures and describe how they 
were used in this thesis.  The acute measures are described in Section 3.2.1 and the outcome 
measures are described in Section 3.2.2.  
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3.2.1.  Acute measures  
  Acute measures used in this thesis included the American Society of Anaesthesiologists’ (ASA) 
classification of Physical Health (Dripps, 1963), Glasgow Coma Scale (GCS) (Teasdale & Jennett, 
1974), CT abnormality, and Abbreviated Injury Scale (AIS) and Injury Severity Score (ISS) (Baker, 
O'Neill, Haddon, & Long, 1974a).  These measures were collected by medical staff in the 65 
acute hospitals involved in patient recruitment for CENTER-TBI.  The measures are described 
below.  
 
American Society of Anaesthesiologists’ (ASA) classification of Physical Health 
  Pre-injury physical health status was assessed using the ASA classification of Physical Health, 
which categorises physical health according to severity of systemic disease (Dripps, 1963).  ASA 
Physical Health classifications are as follows: a normal healthy patient; a patient with mild 
systemic disease (mild disease with no substantive functional limitation, e.g., treated 
hypertension); a patient with severe systemic disease (substantive functional limitations a 
result of disease, e.g., poorly treated diabetes, morbid obesity); a patient with a severe 
systemic disease that is a constant threat to life (functional limitation from severe life-
threatening disease, e.g., ongoing cardiac ischemia) (American Society of Anesthesiologists, 
2014; Dripps, 1963).  
 
Glasgow Coma Scale (GCS) 
  TBI severity was classified using the GCS (Teasdale & Jennett, 1974).  The GCS has three 
components: eye opening, best verbal response, and best motor response.  Each component is 
assessed using a standardised approach and GCS total scores range from 3 to 15.  
Conventionally, GCS scores of 3-8 are classified as severe TBI, scores of 9-12 are classified as 
moderate TBI, and scores of 13-15 are classified as mild TBI (Teasdale et al., 2014; Teasdale, 
Murray, Parker, & Jennett, 1979).  This thesis used baseline GCS scores which were calculated 
centrally by a review panel for use by CENTER-TBI investigators.  The baseline GCS scores were 
derived using the International Mission for Prognosis And Clinical Trial (IMPACT) approach to 
combining scores at different time periods (Marmarou et al., 2007). 
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CT Abnormality  
  CT abnormality was analysed by Icometrix (Icometrix, 2019) and assessed by a central review 
panel according to the NINDS CDEs (Duhaime et al., 2010).  In this thesis, CT abnormality 
indicates whether any of the following CDEs were present: mass lesion, epidural hematoma, 
subdural hematoma (acute), subdural hematoma (sub-acute/chronic), subdural collection 
mixed density, contusion, traumatic axonal injury, subarachnoid haemorrhage, intraventricular 
haemorrhage, midline shift or cisternal compression.  
 
Abbreviated Injury Scale (AIS) and Injury Severity Score (ISS)  
  The AIS was used to quantify the overall severity of injury in multiple body areas, including the 
head/neck, face, chest, abdomen, extremities, and external regions, while the overall severity 
of anatomical injuries was measured using the ISS (Baker, O'Neill, Haddon, & Long, 1974).  AIS 
scores for each body region range from 0 (no injury); 1 (minor: no treatment needed); 2 
(moderate: requires only outpatient treatment); 3 (serious: requires non-ICU hospital 
admission); 4 (severe: requires ICU observation and/or basic treatment); 5 (critical: requires 
intubation, mechanical ventilation or vasopressors for blood pressure support); to 6 
(unsurvivable).  The ISS ranges from 0 to 75 and the total ISS is computed by taking the three 
most severely injured body regions, squaring their AIS scores, and adding them together.  Total 
ISS scores >7 are indicative of severe injury and total ISS scores >15 are indicative of major 
trauma (Palmer, 2007).  
 
  This thesis distinguished between injuries to the head/neck/cervical spine and injuries to other 
body regions.  Firstly, AIS scores were used to describe the severity of head injury (composite 
AIS scores were calculated by combining AIS scores for the head/neck, brain, and cervical spine 
regions).  Secondly, total ISS scores for extracranial injuries were calculated using the three 
worst AIS scores for peripheral body regions and excluding the head/neck/cervical spine 





3.2.2. Outcome measures  
  The CENTER-TBI outcome measures reflect the multi-dimensional impact of TBI and include 
measures of global functional outcome, generic and disease-specific HRQoL, psychological 
status, TBI symptoms, cognition, and physical functioning.  For practical purposes, the outcome 
measures were categorised into two types: questionnaires/interviews and neuropsychological 
assessments. The questionnaires/interviews and neuropsychological assessments were 
administered at several time points after injury, including 2-3 weeks (ER stratum only); 3 
months (ER, admissions & ICU strata); 6 months (ER, admissions & ICU strata); 12 months 
(admissions & ICU strata); and 24 months (admissions & ICU strata).  Magnetic Resonance 
Imaging (MRI) was also used in a sub-group of CENTER-TBI study sites to characterise TBI 
pathology.   
 
  Table 3.2 illustrates the schedule for the CENTER-TBI outcome assessments by stratum 
(ER/admission/ICU), type of assessment, time point, and type of study site (i.e. MRI sites/all 
sites).   
 
Table 3.2: CENTER-TBI core study outcome assessment schedule 










ER Neuropsychology MRI sites MRI sites All sites   
Questionnaires All sites All sites All sites   
Admission Neuropsychology   All sites MRI sites MRI sites 
Questionnaires  All sites All sites All sites MRI sites 
ICU Neuropsychology   All sites MRI sites MRI sites 





  Due to barriers such as copyright, cost, and language restrictions, it was not possible to adhere 
to NINDS CDE recommendations for all CENTER-TBI outcome measures (Hicks et al., 2013; 
Maas, Menon, et al., 2015; Maas et al., 2017; Wilde et al., 2010).  The CENTER-TBI outcome 
measures that are included in the CDEs for adult TBI are listed in Table 3.3.  
 
Table 3.3:  CENTER-TBI outcome measures included in NINDS CDEs for adult TBI 
Outcome measure NINDS CDE Outcome Domain  
Glasgow Outcome Scale – Extended (GOSE)   
Global outcome  
36-item Short Form Survey – Version 2  
(SF-36v2) 
Quality of Life After Brain Injury (QOLIBRI) Health-related quality of life 
Galveston Orientation and Amnesia Test 
(GOAT) 
Recovery of consciousness  




Trail Making Test (TMT) 




   
   CENTER-TBI is one of the largest observational studies ever to be conducted in TBI, and an 
international collaborative effort was required to obtain follow-ups in the 65 participating study 
sites.  The study plan called for a total of 12,350 follow-ups employing interviews and 
questionnaires, and a subset of 5,850 follow-ups that required neuropsychological assessment. 
With over 2500 clinical, treatment and outcome variables, data collection for CENTER-TBI was 
complex and challenging (Burton, 2017).  Outcomes were collected by trained study personnel.  
Methods of collecting outcomes were described in the Standard Operating Procedures manual 
for the project.  This manual was available to investigators when data collection commenced.  
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The author of this thesis was responsible for obtaining follow-ups for patients recruited via NHS 
Lothian.   
 
  The CENTER-TBI outcome measures included in this thesis are summarised below with 
descriptions of how they were scored and used.  The outcome measures are organised 
according to the CDE outcome domains (Wilde et al., 2010).  All CENTER-TBI outcome measures 
are validated for use in research, but not all of them have been validated in the context of adult 
TBI.   
 
Global outcome   
Glasgow Outcome Scale - Extended (GOSE) structured interview and questionnaire  
Description 
  The GOSE is used to measure of global functional outcome following TBI.  It can be completed 
as a structured interview (Wilson et al., 1998) or as a self-completion questionnaire (Wilson et 
al., 2002).   
 
  The GOSE structured interview uses a standardised interview format to enable the assessor to 
objectively assign patients to the outcome category that reflects their current functional status 
(Wilson et al., 1998).  Outcome is assigned according to: the individual's current level of 
independence in activities of daily living both inside and outside the home (i.e., cooking, 
dressing, shopping, travelling); their ability to participate in major life roles such as work, social 
and leisure activities, and relationships with family and friend; and whether they have returned 
to ‘normal’ life (i.e., their previous level of functioning).   The GOSE structured interview can be 
completed face-to-face or via telephone and can be completed with the patient and/or a proxy 
informant such as a relative or caregiver.  It is designed to be administered and scored by a 
researcher or clinician, and the interviewer can exercise their professional judgement, where 
appropriate (Wilson et al., 1998).  The inter-rater and test-retest reliability for the GOSE 
structured interview is high (Weighted Kappa (w) ranges from 0.72 to 0.92) (Pettigrew et al., 
2003; Wilson et al., 1998; Wilson et al., 2007).  Furthermore, the GOSE structured interview has 
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substantial correlations with measures of post-traumatic amnesia (rho = -0.52), disability (rho = 
-0.89), HRQoL (rho = 0.47 - 0.71), depression (rho = -0.64), general health (rho = -0.59), and 
reported head-injury symptoms and problems (rho = 0.37 to 0.69), and modest correlations 
with neurocognitive tests (rho = -0.19 to 0.42)  (Wilson et al., 2000).   
 
  The GOSE postal questionnaire is an alternative method of collecting information about global 
functional outcome, which can be used on its own, or in conjunction with telephone or face-to-
face contact (Wilson et al., 2002).  It can be completed by the TBI patient and/or a proxy 
informant.  It can also be completed via post or on-line, providing a means of easily and 
inexpensively obtaining information about outcome instead of, or in addition to, telephone or 
face-to-face contact.  The GOSE questionnaire comprises 14 questions about the patient's 
independence inside and outside the home, as well as their participation in major life roles, and 
their return to ‘normal’ life.  The test-retest reliability of the GOSE postal questionnaire is high 
(w = 0.98) and it has high levels of agreement with the GOSE structured interview (w = 0.92) 
(Wilson et al., 2002).   
 
Scoring   
The GOSE has eight outcome categories, ranging from worst (i.e., death) to best (i.e., upper 
good recovery) (see Figure 3.1).  Scores are determined by identifying the area of greatest 
limitation, and by discounting pre-injury limitations.  Scores can be assigned on the GOSE if 
information is missing, although some judgement may be required and confidence in the rating 
may decrease if items are not completed.  The GOSE structured interview is usually rated by the 
interviewer, but it can also be scored centrally using an algorithm (Wilson et al., 1998; Wilson et 
al., 2007).  The GOSE questionnaire can be rated using the criteria from the GOSE structured 
interview as a guideline, or it can be scored electronically using an algorithm (Wilson et al., 
2002).  The categories ‘vegetative state’ and ‘lower severe disability’ are collapsed when the 
GOSE questionnaire is scored, because the self-completion form does not distinguish between 




  For CENTER-TBI, it was possible to complete the GOSE as a structured interview or 
questionnaire, although priority was given to the GOSE structured interview (Maas, Menon, et 
al., 2015).  A pragmatic approach to data collection was used and the GOSE could be completed 
face-to-face, via telephone, or via post, either with the patient alone, with a proxy informant 
alone, or with the patient and a proxy together (Maas, Menon, et al., 2015).  Decisions about 
mode of data collection were made locally on a patient-by-patient basis and were influenced by 
factors such as TBI severity, the patient’s ability to self-report, the patient’s availability for face-
to-face follow-up visits, and logistic considerations (e.g., travel time).  CENTER-TBI investigators 
were encouraged to complete both versions of the GOSE, if possible.  The flexible approach to 
data collection was employed as a means of ensuring good follow-up rates for the study and to 
allow comparisons to be made between different GOSE approaches.   
 
  Composite GOSE scores were calculated centrally for the CENTER-TBI study as part of the data 
curation process (Wilson & Horton, 2018).  The composite GOSE scores were created using the 
information available to maximise follow up rates.  The categories of ‘vegetative state’ and 
‘lower severe disability’ were collapsed when creating composite ratings and available 
information was used in the following order of precedence:  
1. Central scoring of GOSE structured interview completed by investigators 
2. Central scoring of respondent-completed GOSE questionnaires  
3. Interviewer ratings for survivors when neither the GOSE structured interview or GOSE 
questionnaire was completed 
 
Use in this thesis 
  Study 1 used the GOSE interview and GOSE questionnaire.  Possible outcomes for this study 
ranged from ‘vegetative state’ to ‘upper good recovery.’  GOSE interviews were rated locally by 
trained interviewers in accordance with published guidelines (Wilson et al., 1998).  The GOSE 
questionnaire was scored in two ways.  Firstly, it was scored using the standard algorithm 
developed by Wilson and colleagues (Wilson et al., 2002).  Secondly, it was scored using a 
revised algorithm (described in Chapter 4).  Study 2 also used the GOSE structured interview 
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(rated locally by trained interviewers in accordance with published guidelines (Wilson et al., 
1998)) and GOSE questionnaire (scored centrally using the standard algorithm (Wilson et al., 
2002)).  Possible outcomes for Study 2 ranged from ‘lower severe disability’ to ‘upper good 
recovery.’  Study 3 used the composite GOSE score described above.  Possible outcomes for this 
study ranged from ‘lower severe disability’ to ‘upper good recovery.’     
 
  Figure 3.1: GOSE:  Schematic diagram of the decisions involved in assigning an outcome  
 
   
36-Item Short Form Survey - Version 2 (SF-36v2)  
Description 
  The SF-36v2 is a generic measure of health-related quality of life, which has been used across 
many types of health conditions (Ware & Sherbourne, 1992).  It is categorised as a measure of 
global outcome in the NINDS CDEs.  The SF-36v2 is self-completed by the patient and provides 
an assessment of their perceived health and wellbeing.  It is the most frequently used patient-
reported outcome across registered clinical trials (Scoggins & Patrick, 2009), and in TBI studies, 
it is the most frequently used measure of health-related quality of life (Polinder, Haagsma, van 
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Klaveren, Steyerberg, & van Beeck, 2015).  The SF-36 has a 4-week reference period.  It 
comprises eight domains, including Physical Functioning, Role Limitations-Physical, Bodily Pain, 
General Health, Vitality, Social Functioning, Role Limitations-Emotional, and Mental Health.  
HRQoL can be summarised by computing a physical component summary (PCS) score and 
mental component summary (MCS) score.  The SF-36v2 has high levels of internal consistency 
in TBI (Cronbach’s alpha (α) = 0.79 to 0.93) (Findler, Cantor, Haddad, Gordon, & Ashman, 2001; 
MacKenzie et al., 2002; von Steinbüchel et al., 2016).  Furthermore, the physical health sub-
scales have been found to correlate highly with the PCS score (r = 0.55 to 0.83) while the 
mental health sub-scales correlate highly with the MCS score (r = 0.68 to 0.89)  (MacKenzie et 
al., 2002).   
 
Scoring 
  The SF-36v2 was scored using Optum Software and norm-based scoring algorithms.  Each 
health domain and summary component measure has a mean score of 50 and a standard 
deviation of 10.  The minimum score for the PCS and MCS is 2 and the maximum score is 74.  
Higher scores indicate better health-related quality of life. The Full Missing Score Estimation 
(MSE) method was used to deal with missing data. 
 
 Use in this thesis 
  The SF-36v2 was used in Studies 2 and 3 to measure patient-reported HRQoL. 
 
Health-related quality of life (HRQoL) 
Quality of Life after Brain Injury Scale (QOLIBRI) and QOLIBRI Overall Scale (QOLIBRI-OS) 
Description 
  The QOLIBRI is a TBI-specific measure of HRQoL (von Steinbüchel, Wilson, Gibbons, 
Hawthorne, Hofer, Schmidt, Bullinger, Maas, Neugebauer, Powell, von Wild, Zitnay, Bakx, 
Christensen, Koskinen, Sarajuuri, et al., 2010).  It was developed to tap into the quality of life 
domains important to TBI patients, as existing generic HRQoL measures, such as the SF-36, are 
not designed to address condition-specific issues.  The QOLIBRI is completed by the patient via 
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self-rating. It comprises 37 items and has 6 domains, including four 'satisfaction' scales (i.e., 
cognition, self, daily life and autonomy, and social relationships), and two 'bothered' scales (i.e., 
emotions and physical problems).  The QOLIBRI has a 1-week reference period.  Thus, 
respondents must be able to recall how they have been feeling over the week preceding 
assessment.  The internal consistency of the QOLIBRI ranges from 0.75 ('physical problems') to 
0.89 ('cognition' and 'self') (total score = 0.95) and the test-retest reliability ranges from 0.78 
('emotions') to 0.85 (‘physical problems’) (total score = 0.91).   All sub-scales correlate with the 
GOSE (0.19 – 0.42), Hospital Anxiety and Depression Scale (HADS) anxiety sub-scale (-0.59), 
HADS Depression Scale  -0.67), SF-36 PCS (0.63), and SF-36 MCS (0.61), and the QOLIBRI total 
score is associated more strongly with the SF-36 MCS (0.61) than the SF-36 PCS (0.49) (von 
Steinbüchel, Wilson, Gibbons, Hawthorne, Hofer, Schmidt, Bullinger, Maas, Neugebauer, 
Powell, von Wild, Zitnay, Bakx, Christensen, Koskinen, Formisano, et al., 2010).   
 
  The QOLIBRI-OS (von Steinbüchel et al., 2012) is the short version of the QOLIBRI comprising 6 
items that cover the following domains: physical condition, cognition, emotions, daily life and 
autonomy, personal and social life, and current situation and future prospects.  It also has a 1-
week reference period.  The QOLIBRI-OS has high levels of internal consistency (α = 0.86) and 
test-retest reliability (0.81).  Furthermore, it correlates strongly with the QOLIBRI total score (r = 
0.87), and with the GOSE, SF-36 and HADS (r=0.54 to -0.76) (von Steinbüchel et al., 2012).   
 
Scoring 
  Responses for the QOLIBRI and QOLIBRI-OS are recorded on a 5-point Likert-type scale ranging 
from ‘not at all’ to ‘very’ and then summed and converted to total scores that range from 0 to 
100.  Higher scores on the ‘satisfaction’ scale indicate better HRQoL, while higher scores on the 
‘bothered’ scale are indicative of poorer HRQoL.  The QOLIBRI has recently been mapped 
against the normative scoring criteria for the SF-36 to aid in the interpretation of QOLIBRI 
scores: QOLIBRI total scores below 60 are considered to be representative of impaired HRQoL 
(Wilson et al., 2017).  In CENTER-TBI, prorating was used if up to one third of items were 
missing on the QOLIBRI and QOLIBRI-OS.  
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Use in this thesis 
 The QOLIBRI and QOLIBRI-OS were used in Studies 2 and 3 to measure TBI-specific, patient-
reported HRQoL.  
 
Psychological status 
Post-Traumatic Stress Disorder Checklist-5 (PCL-5) 
Description 
  The PCL-5 is a self-report inventory for measuring the severity of post-traumatic stress 
disorder (PTSD) symptoms (Weathers et al., 2013).  The earlier version of the inventory, the PCL 
(Weathers, Litz, Herman, Huska, & Keane, 1993), is one of the most widely used instruments for 
measuring self-reported PTSD symptoms.  The PCL-5 was developed in 2013 to reflect the 
revised diagnostic criteria for PTSD in the Diagnostic and Statistical Manual of Mental Disorders 
Fifth Edition (DSM-5).  It comprises 20 items and 4 sub-scales which relate to clusters B-E in the 
DSM-5: intrusion (5 items), avoidance (2 items), negative alterations in cognition and mood (7 
items), and alterations in arousal and reactivity (6 items).  The PCL-5 has a 1-month reference 
period and responses relate to a specific stressful event (i.e., the event which caused the TBI).  
The PCL-5 has been shown to have high levels of test-retest reliability (r = 0.82) and internal 
consistency (α = 0.94), and is strongly associated with other measures of PTSD symptoms (r = 
0.84 to 0.85) and measures of anxiety and depression (r = 0.40 to 0.60), when used with 
trauma-exposed college students  (Blevins, Weathers, Davis, Witte, & Domino, 2015).   
 
Scoring 
  Responses for each item are recorded on a 5-point Likert-type scale and include: ‘not at all,’ ‘a 
little bit,’ ‘moderately,’ ‘quite a bit,’ and ‘extremely.’  Total symptom severity scores range from 
0 to 80, and higher scores reflect greater severity.  Severity scores can also be calculated for 
each symptom cluster.  Items rated as ‘moderately’ or higher are used to make provisional 
PTSD diagnoses.  Cut-off scores have been generated for the PCL-5 relative to the DSM-5 
diagnostic criteria for PTSD: a score of 33 has been found to be optimally efficient for detecting 
PTSD (Wortmann et al., 2016).  In CENTER-TBI, PCL-5 scores were valid if up to 5 items were 
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missing.  Consistent with the four DSM-5 symptom clusters for PTSD, no more than 1 missing 
item was permitted in items 1-5; zero missing items were permitted in items 6-7; no more than 
2 missing items were permitted in items 8-14; and no more than 2 missing items were 
permitted in items 15-20.  
 
Use in this thesis 
  The PCL-5 was used in Studies 2 and 3 as a self-reported measure of the severity of PTSD 
symptoms in TBI patients.  
 
Patient Health Questionnaire-9 (PHQ-9) 
Description 
  The PHQ-9 is a self-report instrument for measuring depression severity in clinical settings 
(Kroenke, Spitzer, & Williams, 2001).  It is unidimensional and comprises 9 items which relate to 
each of the DSM-5 diagnostic criteria for clinical depression.  It has a 2-week reference period 
and responses are recorded on a 4-point Likert-type scale.  Respondents are required to 
indicate how often they have been bothered by each of the 9 listed problems.  If any item is 
endorsed, respondents are also required to indicate how difficult the problem(s) have made it 
for them to work, perform activities of daily living, and get on with others.  Scores for each item 
range from 0 (not at all), 1 (several days), 2 (more than half the days), to 3 (nearly every day). 
The internal consistency of the PHQ-9 has been found to be high in primary care settings 
(α=0.86) (Kroenke et al., 2001).  Furthermore, when used with TBI patients, the PHQ-9 has good 
test-retest reliability (r = 0.76 & =0.46) and correlates strongly with other measures of 
depression (r = 0.78-0.90), functional limitation (r = 0.59), and perceived general health (r = 
0.40) (Fann et al., 2005).  
 
Scoring 
  Total scores range from 0 to 27 and higher scores are indicative of greater depression severity.  
Scores on the PHQ-9 can be interpreted in a variety of ways.  Cut-off points have been 
recommended for mild (5-9), moderate (10-14), moderately severe (15-19), and severe 
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depression (20-27) (Kroenke & Spitzer, 2002).  In CENTER-TBI, the PHQ-9 was scored if up to 
one third of items were missing.  Missing values were substituted with the mean score of non-
missing items and total scores were rounded to an integer.  
 
Use in this thesis 
  The PHQ-9 was used in Studies 2 and 3 as a self-reported measure of the severity of 
depression symptoms in TBI patients. 
 
Generalized Anxiety Disorder-7 (GAD-7) 
Description 
  The GAD-7 is a self-report instrument for measuring the severity of generalized anxiety 
symptoms in clinical settings (Spitzer, Kroenke, Williams, & Lowe, 2006).  It is unidimensional 
and comprises 7-items which relate to the DSM-5 diagnostic criteria for generalised anxiety 
disorder.  Respondents indicate how often they have been bothered by each symptom during 
the last 2-weeks and responses are recorded on a 4-point Likert-type scale ranging from 0 (not 
at all), 1 (several days), 2 (more than half the days), to 3 (nearly every day).  If any item is 
endorsed, respondents are also required to indicate on a 4-point scale how difficult the 
problem(s) have made their work, activities of daily living, and relationships with others. The 
GAD-7 has high test-retest reliability (intraclass correlation = 0.83) and internal consistency (α= 
0.92), and increasing anxiety scores are strongly associated with functional limitations and 
reduced HRQoL (Spitzer et al., 2006).  
 
Scoring 
Total scores range from 0 to 21, with higher scores indicating greater symptom severity.  The 
cut-off for diagnosing generalized anxiety disorder in clinical populations is 10, and cut-off 
points of 5, 10 and 15 can be interpreted as indicative of mild, moderate, and severe levels of 
anxiety in clinical and general populations (Lowe et al., 2008; Spitzer et al., 2006).  In CENTER-
TBI, the GAD-7 was scored if up to one third of items were missing.  Missing values were 
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substituted with the mean score of non-missing items and total scores were rounded to an 
integer.  
 
Use in this thesis 
  The GAD-7 was used in Studies 2 and 3 as a self-reported measure of the severity of anxiety 
symptoms in TBI patients. 
 
TBI symptoms  
Rivermead Post-concussion Questionnaire (RPQ) 
Description 
  The RPQ is a self-report instrument which was originally developed for measuring the severity 
of 16 post-concussion symptoms following mild or moderate TBI, including headaches, 
dizziness, nausea/vomiting, noise sensitivity, sleep disturbance, fatigue, irritability, feeling 
depressed/tearful, feeling frustrated/impatient, forgetfulness, poor concentration, taking 
longer to think, blurred vision, light sensitivity, double vision, and restlessness (King, Crawford, 
Wenden, Moss, & Wade, 1995).  Respondents are required to indicate the extent to which each 
of the 16 symptoms has been experienced in the last 7 days, and to consider whether each 
symptom is more of a problem since their head injury.  The RPQ also includes 2 blank spaces for 
respondents to report any other difficulties they are currently experiencing.  The inter-rater and 
test re-test reliability of the RPQ is high (r= 0.72 to 0.91) and total scores correlate strongly with 
measures of social and functional outcome (0.62 to 0.83) (Eyres, Carey, Gilworth, Neumann, & 
Tennant, 2005; King et al., 1995).     
 
Scoring 
  Responses are recorded using a 5-point Likert-type scale ranging from 0 (not experienced at 
all), 1 (no more of a problem), 2 (a mild problem), 3 (a moderate problem), to 4 (a severe 
problem).  There is no established cut-off point for differentiating favourable and unfavourable 
outcomes on the RPQ.  However, a threshold of at least 3 symptoms rated as a moderate or 
severe problem has previously been defined as being indicative of the presence of post-
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concussion symptoms (Sterr, Herron, Hayward, & Montaldi, 2006).  In the CENTER-TBI study, 
the RPQ total scores were calculated using prorating if up to one third of items were missing.   
 
Use in this thesis 
  The RPQ was used in Studies 2 and 3 as a self-reported measure of the severity of post-
concussion symptoms following TBI. 
 
Recovery of consciousness  
Galveston Orientation and Amnesia Test (GOAT)  
Description  
  The GOAT (Levin, O'Donnell, & Grossman, 1979) is used to assess the extent to which a patient 
is in post-traumatic amnesia (PTA) following brain injury.  PTA is a state of altered 
consciousness following TBI, characterised by confusion and amnesia (Marshman, Jakabek, 
Hennessy, Quirk, & Guazzo, 2013).  The GOAT comprises 10 questions and assesses orientation 
for time, place, and person, as well as anterograde amnesia (the inability to recall events 
occurring after the injury), and retrograde amnesia (the inability to recall events occurring 
before the injury).  The GOAT can be used as a screening test during the sub-acute phase after 
TBI to determine whether the patient is sufficiently oriented to undergo formal cognitive 
testing. The inter-rater reliability is high (0.99) and GOAT scores relate to measures of injury 
severity such as GCS scores and CT scans (Levin et al., 1979).   
 
Scoring 
  GOAT scores are calculated by awarding error points for each incorrect response and 
subtracting the number of error points from 100.  The total error score ranges from 0 to 108: 
therefore, total GOAT scores can range from -8 to 100.  Higher scores indicate the absence of 
PTA, whereas lower scores reflect disorientation and amnesia.  Scores between 66 and 75 are 
considered to be 'borderline abnormal', while scores of 75 of more indicate that the patient is 
no longer in PTA (Levin et al., 1979; Lezak, 2012).  If items were missing from the GOAT in the 
CENTER-TBI study database, total scores were not calculated.  
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Use in this thesis 
  The GOAT was used in the CENTER-TBI study to screen for PTA and to assess whether cognitive 
testing was appropriate.  It was included in Study 2 as a measure of PTA.  
 
Neuropsychological impairment  
Rey Auditory Verbal Learning Test (RAVLT) 
Description 
  The RAVLT is used to measure verbal memory and learning (Schmidt, 1996).  It comprises a 
total of seven trials, during which participants are asked to recall concrete nouns from two 15-
word lists (List A and List B), which are spoken aloud by the assessor.  During the acquisition 
phase, participants are presented with the words from List A five times.  Immediately after each 
trial, the participant is instructed to repeat as many words as they can, in any order, whether or 
not they have said the same words in previous trials.  The fifth trial is immediately followed by a 
sixth trial comprising a single auditory presentation of a 15-word interference list (List B).  The 
participant is required to repeat as many words as they can from the interference list, in any 
order, before being asked to recall as many words as they can remember from List A, without 
hearing it again.  The seventh and final trial is presented after a 20-minute delay and requires 
the participant to recall as many words as they can from the list they heard several times.  The 
RAVLT has adequate test-retest reliability (r ~ 0.60 to 0.70), high levels of internal consistency 
(α = 0.90), and it correlates moderately with other measures of learning and memory (Strauss, 
Sherman, & Spreen, 2006).  It has also been found to be sensitive to neuropsychological 
impairment in a range of conditions, including closed head injury in adults (Strauss et al., 2006).    
 
Scoring 
Performance on the RAVLT is scored by recording the number of words the participant correctly 
recalls for each trial.  Two RAVLT summary scores were used in this thesis: (1) Total score (sum 
of words recalled across 5 trials), (2) 20-minute delay (number of words recalled after 20-
minute delay).  Normative data exist to aid the interpretation of RAVLT scores for individuals 
aged 16 to 89 years old (Schmidt, 1996).  It is Important to note that performance on the RAVLT 
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declines with advancing age.  However, norms for adults ages 16 to 89 range from 53.9 (6.7) to 
37.1 (7.5) for the RAVLT total score, and 11.7 (2.2) to 7.0 (2.4) for the RAVLT 20-minute delay.  
 
Use in this thesis 
The RAVLT was used in Studies 2 and 3 as a measure of verbal memory and learning.  
 
Trail Making Test (TMT) Parts A & B 
Description 
  The TMT measures scanning and visuo-motor tracking, divided attention, and cognitive 
flexibility (Strauss et al., 2006).  Part A comprises 25 consecutively numbered circles distributed 
randomly on a page: the participant is required to connect the numbers sequentially with lines 
without lifting the pencil from the paper.  Part B is more demanding and comprises 
consecutively numbered (1-13) and lettered (A-L) circles distributed randomly on a page: the 
participant is required to draw lines between alternate numbers and letters in sequential order.  
The participant is instructed to draw the lines as quickly and accurately as possible and their 
performance on both parts of the test is timed.  The TMT has been shown to have adequate 
test-retest reliability (r = 0.66 to 0.94) when used with neurological groups and correlates 
moderately with other neuropsychological measures.  The TMT is sensitive to cognitive 
impairment in TBI and completion times have been found to increase with greater injury 
severity (Strauss et al., 2006).    
 
Scoring  
  Scoring is based on the time taken to complete each part of the test.  If the participant makes 
an error, the assessor draws their attention to it and instructs them to correct the error as 
quickly as possible without stopping the timer.  Performance is usually slower during Part B 
because it requires greater executive control and demands upon working memory.  Part A is 





Use in this thesis 
  The TMT was used in Studies 2 and 3 as a measure of scanning and visuo-motor tracking, 
divided attention, and cognitive flexibility.   
 
Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Description 
  CANTAB was developed in 1986 by neuroscientists at Cambridge University and comprises a 
set of 25 computer-automated assessments of memory, attention and executive function 
(Cambridge Cognition Ltd, 2014).  The tests are administered by a clinician or researcher using 
an automated touchscreen computer.  Computer-based neuropsychological tests, such as the 
CANTAB, provide a number of advantages over traditional pencil-and-paper based cognitive 
assessments: CANTAB is user-friendly, requires little training, and is relatively quick and easy to 
administer. Standardized instruction scripts are used to ensure consistency between 
assessments.  Data is collected automatically, resulting in increased scoring accuracy and 
efficiency.  The difficulty of the tests is graded to permit the assessment of a broad range of 
cognitive abilities, and normative data is available for many of the tests to aid interpretation of 
the scores.  The tests also use non-verbal and culture-free stimuli, making CANTAB a good 
choice for multicentre studies where more than one language is spoken (Levaux et al., 2007; 
Parsons, 2016).   
 
Use in this thesis 
  The CANTAB tests used in this thesis include 5-choice Reaction Time (RTI), Paired Associates 
Learning (PAL), Attention Switching Task (AST), Spatial Working Memory (SWM), Rapid Visual 
Information Processing (RVP), and Stockings of Cambridge (SOC) (outcome measures for the 
tests are provided in Table 3.4).  Normative data is available for all of the tests, apart from the 
AST.  The CANTAB has been used previously in the context of TBI.  For example, in moderate-to-
severe TBI, changes in reaction time and performance on the PAL are associated with changes 
in diffusion tensor imaging (Newcombe et al., 2016).  Furthermore, measures of reaction time, 
sustained attention, and episodic memory/ new learning have been found to be sensitive to 
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abnormalities in the cholinergic system (e.g., basal forebrain, bilateral hippocampal formation) 
in patients with moderate-to-severe TBI (Salmond, Chatfield, Menon, Pickard, & Sahakian, 
2005).   
 
5-choice Reaction Time (RTI) 
  This test measures reaction and movement time.  Five white circles are displayed on the 
screen.  The participant must press down the button on the press pad until they see a yellow 
spot appearing inside one of the circles on the screen.  When they see the yellow spot, they 
must let go of the button and touch the screen where they saw the yellow spot as quickly as 
they can.  The button on the press pad must be pressed down at all times apart from when the 
participant touches the screen where the yellow spot appeared. 
 
Paired Associates Learning (PAL) 
  This test measures visual episodic memory and new learning.  A set of boxes are displayed on 
the screen: these boxes open and close in a random order to display one or more hidden 
patterns.  During each trial, once all of the boxes have opened, the patterns are displayed one 
by one in the middle of the screen.  The participant must then touch the box where they 
originally saw each pattern.  If they make an error, the boxes will re-open in a random order to 
remind them where the patterns are located.  The test is relatively easy at the start (one hidden 
pattern) and gets progressively more difficult until there is a total of eight hidden patterns to 
remember.  Participants are given up to ten attempts at any stage of the test.  
 
Attention Switching Task (AST) 
  This test measures cognitive flexibility and attention switching in accordance with changing 
task goals.  A series of arrows are displayed on the screen.  Each arrow either points to the left 
or the right or is located on the left or right side of the screen.  Throughout the task, the arrows 
may point in either direction and they may appear on either side of the screen.  The participant 
uses the left and right buttons on the press pad to respond to the direction or location of the 
arrows.  During the first stage, the instruction “which direction” is presented on the screen: the 
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participant is required to press the left button if the arrow points to the left and the right 
button if the arrow points to the right (Rule 1).  During the second stage, the instruction “which 
side” appears on the screen: the participant is required to press the left button if the arrow is 
located on the left side of the screen and the right button if it appears on the right side of the 
screen (Rule 2).  During the third stage, both instructions are presented on the screen in a 
random order: here, the participant must pay attention to which rule is presented on-screen 
before pressing the appropriate button on the press pad.  Participants are instructed to 
respond as quickly as possible while avoiding mistakes.   
 
Spatial Working Memory (SWM) 
  This test measures the ability to retain and manipulate visuospatial information in working 
memory.  A series of coloured boxes are displayed on the screen.  The participant is instructed 
to search the box for hidden blue tokens.  Using a process of elimination, the participant must 
search the boxes one by one and enter the tokens in an empty ‘home’ space at the side of the 
screen as they are retrieved.  The test is relatively easy at the start with three boxes to search 
and gets progressively more difficult until there are eight boxes to search.  The likelihood of 
search strategies becoming stereotyped is reduced by changing the colour and positioning of 
the boxes throughout the test. 
 
Rapid Visual Information Processing (RVP) 
  This test measures sustained visual attention.  A series of numbers are presented in a white 
box in the middle of the screen.  The numbers are presented in a pseudo-random order, for 
four minutes, at a rate of 100 numbers per minute.  Participants are instructed to use the press 
pad button to respond to three target sequences of numbers (i.e., 3-5-7, 2-4-6, and 4-6-8).  
Participants must press the button after the third number in the target sequence has been 






Stockings of Cambridge (SOC) 
  This test measures spatial planning.  The screen is divided vertically into two displays of 
coloured balls hanging in pockets.  The participant must move the balls in the bottom display to 
match the arrangement in the top display.  The test starts relatively easy and gets progressively 
more difficult until a minimum of 5 moves are required to solve each problem.  The participant 
is instructed to plan their moves in advance with the aim of solving each problem in the 
minimum number of moves.   
 
Physical function  
10-Meter Walk Test and Timed Up & Go (TUG) 
Description 
  The 10-meter walk is a test of mobility, in which the patient is required to walk between two 
clearly marked points spaced 10-meters apart.  The patient is timed walking 10-meters and the 
procedure is repeated 3 times.  The TUG is another test of mobility, in which the patient is 
timed while they stand up from a seated position, walk to a marker on the floor 3 meters away, 
turn around, and walk back to the chair and sit down (Podsiadlo & Richardson, 1991). 
 
Scoring 
  For the 10-meter walk test, the time is recorded for the quickest trial of three.  For the TUG, 
the time taken to complete the test is recorded, and results are interpreted as follows; <10 = 
normal mobility; <20 seconds = good mobility, can go out alone, mobile without a gait aid; <30 
seconds problems with mobility, cannot go outside alone, requires a gait aid.   
 
Use in this thesis 
  The 10-meter walk and TUG were used in Studies 2 and 3 as measures of physical mobility. 
 
  The key characteristics of the CANTAB sub-tests are outlined below and the sub-test outcome 




Table 3.4: Outcome measures used for CANTAB sub-tests 
Test  Outcome Measures Descriptions* 




The median duration between the onset of the stimulus and 
the release of the button. Calculated for correct, assessed 
trials where the stimulus could appear in any one of five 
locations. 
PAL Total errors 
(adjusted) 
 
The number of times the subject chose the incorrect box for a 
stimulus on assessment problems (PALTE), plus an adjustment 
for the estimated number of errors they would have made on 
any problems, attempts and recalls they did not reach. 
AST Median reaction 
latency 
The median latency of response (from stimulus appearance to 
button press), calculated across all correct, assessed trials. 
SWM Between errors 
 
The total number of times the subject revisits a box in which a 
token has previously been found in the same problem 
(calculated for assessed problems only). 
RVP A’ (A prime) 
 
A’ (A prime) is a signal detection measure of sensitivity to the 
target, regardless of response tendency (on this measure 0.50 
is chance while 1.00 is perfect performance).  In essence, this 
metric is a measure of how good the subject is at detecting 
target sequences. 
SOC Problems solved in 
minimum moves 
The number of times the subject has successfully completed a 
problem in the minimum possible number of moves. 
*Descriptions taken from CENTER-TBI outcomes scoring manual  
 
 
3.3. Design of the studies in this thesis  
  All studies presented in this thesis were cross-sectional analyses of observational data 
collected for CENTER-TBI.  Study 1 used outcomes data collected at 3 months and 6 months 
after injury, while Studies 2 and 3 used outcomes data collected at 6 months after injury. 
 
3.4. Ethical approval  
  Ethical approval was obtained for CENTER-TBI prior to the commencement of this PhD 
project.  Informed consent was obtained according to local and national requirements, and in 
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cases where the patient was unable to provide informed consent upon enrolment to the study, 
a legally acceptable representative was identified (Maas, Menon, et al., 2015).   
 
3.5. Data management 
  All local data for the CENTER-TBI core study were de-identified using Global Unique Personal 
Identification (GUPI) labels before being entered on electronic case report forms (eCRFs) 
managed by the QuesGen data management platform (QuesGen Systems Inc, 2016).  INCF 
(International Neuroinformatics Coordinating Facility, 2019) was responsible for data hosting 
and created an informatics platform, Neurobot, to allow cleaned data to be stored and 
downloaded for analysis.  All CENTER-TBI core study data used in this thesis were downloaded 
from the INCF Neurobot database (Version 1) on 8 November 2018 and saved in SPSS files.  
 
3.6. Selection of study participants  
3.6.1. Characteristics of the CENTER-TBI study sample 
  The demographic and clinical characteristics of the 4509 patients enrolled in the CENTER-TBI 
















Table 3.5: Demographic characteristics of the total CENTER-TBI core study sample 
 n (%) 
Age band 
  0-15 
  16-25 
  26-35 
  36-45 
  46-55 
  56-65 
  66-75 
  76-86 
  >86  













  Male 





  Caucasian  
  Other  






  Primary school or less 
  High school  
  Post-high school training  
  College/University  








  Working  
  Not working   
  Retired 
  Student/homemaker 








  Partnered 
  Previously partnered 
  Single/unspecified 












Table 3.6: Clinical characteristics of the total CENTER-TBI core study sample 
 n (%) 
ASA Physical Health  
  Healthy patient 
  Mild systemic disease  
  Severe/life threatening 
  systemic disease 







Cause of injury  
  Road traffic accident 
  Incidental fall 
  Violence/assault 
  Other 







Clinical Care Pathway  
  Emergency Room 
  Admitted to hospital 






  Mild TBI 
  Moderate TBI  
  Severe TBI  






CT abnormality  
  Present 
  Absent 





Injury Severity  
  Median (IQR) total ISS  
 
16 (9-29) 
Head & neck injury1 
  No injury/minor injury  
  Moderate injury  
  Serious injury  
  Severe injury  
  Critical injury 








Non-head & neck injury2 
  No injury/mild injury 
  Severe injury  





IQR = Inter-quartile range; 1Head & neck injury = combined Abbreviated Injury Severity (AIS) score for 
head, neck & cervical regions; 2Non-head & neck injury (severe injury=total Injury Severity Score (ISS) >7)  
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  The median (IQR) age of the CENTER-TBI sample was 50 (30-66).  Two-thirds of the patients 
were male, and most patients were Caucasian.  Information about educational level was 
missing for one-fifth of the patients.  However, around two-thirds of the sample was educated 
to high school level (28%) or better (37%).  Information about previous employment and 
marital status was missing for around one-tenth of the sample.  However, 43% of patients were 
in employment prior to injury, around one-quarter were retired, and around one-quarter were 
students, homemakers or not working.  Almost half of the patients were partnered prior to 
injury, and the rest were previously partnered (14%), single/unspecified (31%), or unknown 
(10%).   
 
  Over half of the patients were healthy prior to injury and 31% had mild systemic disease (i.e., 
conditions with no functional limitations).  Incidental falls were the most common cause of 
injury, accounting for 45% of all TBIs, while road traffic accidents accounted for 37% of TBIs.  
Almost half of the patients were admitted to ICU, while 34% were admitted to the hospital 
ward, and 19% were recruited via the ER.  Two-thirds of the patients scored in the GCS 13-15 
range, and CT abnormalities were present in around half of the sample.  The median (IQR) total 
ISS score for the sample was 16 (9-29), which is above the threshold (>15) for major trauma.  
Almost 70% of the sample had head and neck injuries in the ‘serious’ or worse categories. 
Moreover, 38% of patients had severe injuries to non-head and neck regions. 
 
  CENTER-TBI provides up-to-date information about the demographic and clinical 
characteristics of TBI in Europe, and the registry data helps to improve the generalizability of 
the core study.  The core study sample reflects the changing epidemiology of TBI in Europe, in 
that TBI is becoming increasingly common in elderly individuals and falls have surpassed road 
traffic accidents as the most common cause of injury, especially in older adults (Brazinova et 








3.6.2. Participant selection process  
  The studies reported in this thesis included sub-samples of CENTER-TBI patients selected from 
the adults who were eligible for 3-month and 6-month follow-up (i.e., surviving patients aged 
16 and over, who were still enrolled in the study at 6-months after injury).  Study 1 (reported in 
Chapter 4) included a 3-month sub-sample and a 6-month sub-sample.  Patients were selected 
for inclusion in Study 1 if GOSE scores were in the ‘vegetative state’ category or better, and if 
the GOSE structured interview and GOSE questionnaire were completed within a 3-week 
interval at each time-point.  Study 2 (reported in Chapter 5) included patients who were 
selected from the 6-month sub-sample described in Chapter 4.  Patients were selected for 
inclusion in Study 2 if GOSE scores were in the ‘lower severe disability’ category or better, and if 
they were assessed alone, or with help from another person.  Study 3 (reported in Chapter 6) 
included patients who were assessed using the GOSE (as a structured interview and/or 
questionnaire), alone or with help, at 6 months post-injury, and patients were included if GOSE 
scores were in the ‘lower severe disability’ category or better.  The participant selection process 
for the studies reported in Chapters 4, 5, and 6 is presented in Figure 3.2. 
 
3.7. Statistical analysis  
Demographics and clinical characteristics  
  The demographic and clinical characteristics of the patient sub-groups selected for the studies 
in Chapters 4, 5 and 6 were described using frequencies and percentages for categorical 
variables and medians and inter-quartile ranges (IQR) for continuous variables.  In Chapter 6, 
the study sample was compared to patients without a 6-month GOSE using independent 
samples t-tests for continuous variables and Chi-square (2) tests for categorical variables.    
 
Study specific analyses 
  In Study 1 (reported in Chapter 4), strength of agreement between clinician rated GOSE 
structured interviews and respondent completed GOSE questionnaires was evaluated using the 
weighted kappa statistic (w) for overall GOSE ratings and kappa statistic () for ratings on 
individual GOSE sections.  The Wilcoxon signed-rank test was used to test for bias on overall 
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GOSE scores.  McNemar’s test was used to compare ratings for patients assigned to ‘better’ 
(i.e., ‘moderate disability’ and ‘good recovery’ categories) and ‘worse’ (i.e., ‘vegetative state’ 
and ‘severe disability’ categories) outcome groups.  The symptoms section of the GOSE 
questionnaire was re-scored and agreement with the GOSE structured interview was evaluated 
using the Kappa statistic.  Weighted Kappa was also used to explore whether clinical factors and 
type of respondent affected levels of agreement between overall GOSE scores.  In Study 2 
(reported in Chapter 5), Spearman correlations were used to examine how clinician ratings on 
the GOSE structured interview and patient reports on the GOSE questionnaire related to 
prognostic factors and other outcome domains.  Steiger’s tests were used to examine whether 
correlations for the two GOSE approaches were significantly different from each other.        
  
 In Study 3 (reported in Chapter 6), means and standard deviations (SD) were calculated for 
scores on the CENTER-TBI outcome measures.  Patients were divided into sub-groups based on 
GOSE category and one-way analysis of variance (ANOVA) was used to test for differences on 
the outcome measures.  Frequencies and percentages were used to examine outcome measure 
completion rates and reasons for non-completion of the RAVLT, TMT, and 10-meter walk/TUG.  
Floor and ceiling effects were examined for each outcome measure.  Floor and ceiling ranges 
were generally defined as the top and bottom 10% of the range of possible scores for each 
outcome measure.  For the CANTAB sub-tests, empirical minimum and maximum scores were 
defined using Tukey’s rule to exclude outliers and floor and ceiling ranges were calculated as 
1.5 times the interquartile range below the 25th percentile and above the 75th percentile.  The 
internal consistency of the PROs was assessed using Cronbach’s alpha (α).   
 
  Multiple testing is an issue in clinical research as it increases the risk of finding spurious effects 
(i.e., type 1 error).  There is no universally accepted method for dealing with multiple testing 
and several methods for adjusting p values have been advocated, including the Bonferroni 
approach, which adjusts the significance level by the number of tests being performed (Bender 
& Lange, 2001; Feise, 2002; Sainani, 2009; Walters, 2016).  To reduce the risk of type 1 errors, 
statistical tests were considered significant only if p<0.01.  Bonferroni adjustment for multiple 
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testing was carried out where type 1 errors were considered relevant.  All statistical analyses 
were conducted using IBM SPSS Statistics 23 using data downloaded from the INCF Neurobot 
database (Version 1) on 8 November 2018.   
 
  Figure 3.2: Participant selection process for the studies reported in this thesis 
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(Total no. patients who 
completed 6-month GOSE 
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Approaches to GOSE assignment: Comparison of clinician-rated 
structured interviews and respondent-completed questionnaires 
 
  The systematic review in Chapter 2 demonstrated that information for the Glasgow Outcome 
Scale has been collected in various ways in previous clinical trials in TBI.  As different 
approaches to data collection may not be equivalent, the use of mixed modes of data collection 
in clinical studies may affect study outcomes.  The study presented in this chapter compares 
outcomes obtained via the clinician-rated GOSE structured interview and the respondent-
completed GOSE questionnaire.  This study provides information about the comparability of the 
two GOSE approaches and explores whether information obtained via the GOSE structured 












  Information for the GOSE can be collected via clinician-rated interviews or by respondent-
completed questionnaires.  However, there is limited evidence concerning the value that can be 
added when assigning global functional outcomes via clinician ratings on the GOSE structured 
interview.  This chapter compared outcomes obtained using the GOSE structured interview and 
GOSE questionnaire and explored whether agreement between ratings were affected by the 
patient’s functional level and clinical factors, such as the presence of pre-existing functional 
limitations, extracranial injury, and greater injury severity.  The study used cross-sectional data 
collected for CENTER-TBI and compared GOSE assessments completed at 3 months (n=992) and 
6 months (n=626) after injury.  Overall GOSE scores were found to be similar at 3 months 
(w=0.77) and 6 months (w=0.82).  Furthermore, at the item-level, agreement was good for 
sections dealing with independence in everyday activities (=0.70-0.79) and moderate for 
sections dealing with subjective aspects of functioning, such as relationships and symptoms 
(=0.43-0.51).  The greatest levels of disagreement between the two approaches were found in 
the ‘good recovery’ categories, suggesting that there is some subjectivity and lower reliability in 
ratings of whether significant symptoms are present.  Exploratory analyses revealed that ratings 
on the GOSE questionnaire were systematically less favourable for patients with poorer 
outcomes at 3 months, but not at 6 months; thus, patients with greater functional limitations 
may underestimate their capabilities in the first few months after TBI.  Extracranial concomitant 
injury/illness, in combination with TBI, was found to be associated with lower levels of 
agreement between GOSE scores at 3 months after injury (w=0.55), but not at 6 months after 
injury (w=0.79).  Taken together, these findings indicate that the two GOSE approaches are 
broadly comparable and suggest that respondent reports and clinician ratings on the GOSE 
provide similar information about level of functioning after TBI.  Supplementing responses on 
the GOSE questionnaire with information obtained via structured interview may be useful in 
certain circumstances, and in CENTER-TBI the GOSE structured interview appears to offer 






  The GOS/E is commonly used in clinical studies in TBI and is associated with high follow-up 
rates due to its ease of use and flexibility in administration (Horton, Rhodes, & Wilson, 2018; 
McMillan et al., 2016).  It has undergone considerable refinement since an expanded 8-point 
scale was originally proposed in 1981 (Jennett et al., 1981), including the publication of 
structured interview guidelines for the GOSE in 1998 (Wilson et al., 1998), and the subsequent 
introduction of the GOSE postal questionnaire in 2002 (Wilson et al., 2002).  The original open-
ended approach to assigning functional outcome was criticised for its potential to result in 
idiosyncratic use of the scale and a lack of consistency between assessors, particularly when the 
expanded version was used (Anderson, Housley, Jones, Slattery, & Miller, 1993; Maas, 
Braakman, Schouten, Minderhoud, & van Zomeren, 1983; Teasdale, Pettigrew, Wilson, Murray, 
& Jennett, 1998; Wilson et al., 1998).  Thus, structured interview guidelines were introduced to 
improve the objectivity and reliability of the instrument (Teasdale et al., 1998; Wilson et al., 
1998), while the respondent-completed questionnaire was originally developed to assess 
outcomes more easily while avoiding investigator bias (Wilson et al., 2002).  The two versions of 
the GOSE appear to be broadly equivalent, although existing comparisons between clinician 
ratings and respondent reports of global functional outcome are limited.    
 
 The GOSE questionnaire offers pragmatic advantages over the structured interview as it 
provides a means of collecting outcomes inexpensively and with minimal effort, especially in 
studies with geographically dispersed populations.  The GOSE questionnaire has also been 
favoured in studies where blinding is not feasible and interviewer bias may be an issue, for 
example, in surgical TBI trials (Mendelow et al., 2005).  The structured interview is nevertheless 
considered the optimal mode of data collection for the GOSE, as the interviewer can use their 
clinical judgement when assigning outcomes, and there is scope to clarify any issues or 
inconsistencies that may arise through discussion with the respondent (Wilson et al., 2002).  
The structured interview should therefore, in theory, provide considerable added value over 
simply using the respondent-completed questionnaire.   
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  Previous clinical trials in TBI have collected information for the GOSE in a variety of ways, 
including in-person interviews, telephone interviews, and postal questionnaires (Horton et al., 
2018).  The GOSE has also been completed with the patient alone and/or with a proxy 
informant, such as a relative or caregiver (Horton et al., 2018).  Studies may specify a preferred 
way of administering the GOSE, but employ additional data collection strategies as a means of 
improving follow up rates.  For example, multicentre trials such as Corticosteroid 
Randomization After Significant Head Injury (CRASH) (Edwards et al., 2005) and Eurotherm 
3235 (Andrews et al., 2015) used postal questionnaires as the primary method of assessing 
outcomes, and also followed up non-responders by telephone interviews, thereby combining 
clinician ratings with patient reports of daily functioning.    
 
  Combining data collection modes is advantageous as it can facilitate follow-ups in studies with 
hard-to-reach populations.  However, it is important to note that measurement error can be 
introduced if different data collection methods lack sufficient comparability (Eremenco et al., 
2014).  Measurement  equivalence  between  modes  cannot  always  be  assumed  because  the  
GOSE, like other instruments, relies on the interpretations and reports  of  patients,  clinicians,  
or  other  observers,  all  of  which  can  be  influenced  by  human judgement or motivation 
(Powers et al., 2017; Walton et al., 2015).  Scores on the respondent-completed GOSE 
questionnaire may be affected by bias as patients may have a skewed understanding of their 
capabilities or a lack of self-awareness, making it difficult for them to provide an accurate self 
report (Prigatano, 2005a, 2005b).  Clinician ratings on the GOSE structured interview may also 
be affected by bias (Sherer, Roebuck-Spencer, & Davis, 2010), as study management processes 
and predictors of outcome are often not masked in observational and prognostic studies.   
 
  The CENTER-TBI study employed a non-experimental design and a flexible, pragmatic data 
collection approach was taken to maximise follow-ups (Maas, Menon, et al., 2015).  The study 
plan called for a total of 12,350 follow-ups after allowing for attrition:  this included 5,850 
follow-ups that involved neuropsychological assessment and, therefore, face-to-face contact, 
and 6,500 follow-ups that required questionnaire assessments.  Investigators were not masked 
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at follow-up.  Thus, there was potential for structured interview ratings to be affected by the 
interviewer’s prior knowledge of the patient.   
 
  Despite concerns about the equivalence of different modes of GOSE data collection, there is 
evidence to suggest that different approaches yield comparable information about global 
functional outcome after TBI.  For example, in the original reliability study for the GOSE 
questionnaire (Wilson et al., 2002), high levels of agreement were found between the 
structured interview (completed via telephone) and the postal questionnaire (n=35, w=0.92).  
High levels of test-retest reliability have also been found between in-person and telephone 
structured interviews for the GOSE (n=30, w=0.92) (Pettigrew et al., 2003).  Together, these 
studies indicate that information can reliably be collected about global functional outcome in 
the absence of face-to-face contact, and indicate that respondent-completed questionnaires 
are comparable to outcomes assigned by investigators via structured interviews.   
 
  To date, no study has explored differences between clinician ratings and respondent reports 
on individual sections of the GOSE.  Furthermore, no study has explored whether factors known 
to have a confounding effect on GOSE assignment affect levels of agreement between clinician 
ratings and respondent reports.  CENTER-TBI provides an opportunity to examine these issues.  
Patients may rate themselves as more, or less, capable than clinicians.  Furthermore, as patient 
reports of subjective cognitive complaints after TBI can be unreliable (Ngwenya et al., 2018), 
inconsistencies may particularly occur between clinician ratings and patient reports of TBI-
related symptoms.  As factors such as pre-injury functional limitations, extracranial concomitant 
injury, epilepsy, injury severity, and source of information (i.e., patient or proxy respondent) 
can have an effect on the assessment of global functional outcome following TBI (Wilson et al., 
2002; Wilson et al., 1998), it is also important to examine whether these factors affect levels of 






4.2.1. Study aim  
  The primary aim of this study was to investigate whether the GOSE structured interview 
provides additional information about global functional outcome after TBI by comparing 
clinician-ratings on the GOSE structured interview and respondent reports on the GOSE 
questionnaire.    
 
4.2.2. Exploratory analyses 
  Exploratory analyses were conducted to: 
 Examine whether GOSE ratings differed for patients with ‘better’ outcomes (i.e., patients 
assigned to the ‘moderate disability’ and ‘good recovery’ categories) and ‘worse’ outcomes 
(i.e., patients assigned to the ‘vegetative state’ and ‘severe disability’ categories) and to 
explore potential ways of improving agreement between GOSE assessments 
 Investigate whether factors known to have an effect on the assessment of global functional 





  Potentially eligible patients were enrolled in the CENTER-TBI core study (see CENTER-TBI 
inclusion criteria in Chapter 3).   
 
Additional inclusion criteria for the current study were as follows: 
 Adults aged 16 years and over (no upper age limit) 
 All injury severities  
 GOSE score ≥2 (i.e., vegetative state (VS) or better)  
 The GOSE structured interview and GOSE questionnaire must be complete and scorable for 
each participant at 3 months and 6 months after injury 
 GOSE assessments must be completed within a 3-week time interval at each time-point to 




  The study used cross-sectional data collected for CENTER-TBI, which included pairs of GOSE 
assessments completed 3 months and 6 months after injury.  
 
4.3.3. Measures and procedure 
The following acute measures were used (described in detail in Chapter 3): 
 American Society of Anaesthesiologists’ (ASA) classification of Physical Health (Dripps, 1963) 
 Glasgow Coma Scale (GCS) (Teasdale & Jennett, 1974) 
 CT abnormality 
 Abbreviated Injury Scale (AIS) and Injury Severity Score (ISS) (Baker et al., 1974) 
 Injury severity was also categorised according to clinical care pathway (i.e., emergency 
room (ER), admission to hospital ward (Admission), intensive care unit (ICU)).  
 
GOSE administration and scoring 
  The study compared two main GOSE approaches used in CENTER-TBI: the clinician-rated 
structured interview (Wilson et al., 1998) and the respondent-reported questionnaire (Wilson 
et al., 2002).  The GOSE is described in detail in Chapter 3.  For CENTER-TBI, the GOSE was 
collected together with a range of other outcome measures.  The overall aim was to maximize 
completeness of all outcome measures mandated at each follow-up.  In order to maximise 
follow-up rates, CENTER-TBI employed a flexible and pragmatic approach to outcome 
assessment, i.e., GOSE interviews could be completed face-to-face or via telephone, and the 
GOSE could be completed with the patient and/or a proxy informant such as a relative or 
caregiver (Maas, Menon, et al., 2015).  Individual sites therefore administered the assessment 
in different ways and the way in which the GOSE was used was not uniform across the study.   
 
  As data collection for the GOSE structured interview and GOSE questionnaire was not 
managed by independent assessors, interviewers potentially had access to information 
collected via the GOSE questionnaire and other assessments.  Nevertheless, as the 
questionnaires were scored electronically by algorithm, investigators were not provided with 
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GOSE questionnaire ratings.  As described in the CENTER-TBI study manual, investigators were 
expected to interview patients (or their carers/relatives), ask additional questions as needed, 
form a judgement about the person’s ability to perform activities, resolve any ambiguities or 
inconsistencies, and finally assign an overall rating when completing the GOSE structured 
interview.  Therefore, in comparison to the respondent-completed questionnaire, the 
structured interview had the potential to provide additional relevant information that could be 
used to assign outcomes.        
 
  GOSE structured interviews were rated locally by trained interviewers in accordance with 
published guidelines (Wilson et al., 1998).  GOSE questionnaires were scored centrally by 
machine using the standard scoring algorithm developed by Wilson and colleagues (Wilson et 
al., 2002).  A revised scoring algorithm, developed for this study, was also used in exploratory 
analyses to improve levels of agreement on the ‘symptoms’ section of the GOSE structured 
interview and GOSE questionnaire. 
 
4.3.4. Statistical analysis   
Demographics and clinical characteristics 
  The demographic and clinical characteristics of the 3-month sub-sample, 6-month sub-sample, 
and ‘eligible sample’ (i.e., all adult patients who were alive and eligible for follow-up 
assessments at 6 months post-injury) were described using frequencies and percentages and 
medians and interquartile ratios (IQR) were used for continuous data (i.e., age and total ISS 
score).     
 
Agreement between GOSE scores 
  Strength of agreement between the GOSE structured interview and GOSE questionnaire was 
evaluated in two ways:  
1. Agreement between overall ratings for the two approaches was evaluated using the 
weighted kappa statistic (w), which uses quadratic weights to penalise extreme 
disagreements between ratings more heavily than slight disagreements (Fleiss & Cohen, 
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1973), and in line with conventions for interpreting kappa: 0.01-0.20 = poor agreement; 
0.21-0.40 = fair agreement; 0.41-0.60 = moderate agreement; 0.61-0.80 = good agreement; 
and 0.81-1.00 = very good agreement (Landis & Koch, 1977).  The overall percentage 
agreement between scores was assessed for overall GOSE ratings and the magnitude of 
disagreement (i.e., number of GOSE categories) between overall GOSE scores was 
evaluated.  The Wilcoxon signed-rank test was used to test for bias on overall GOSE scores.  
2. Agreement between ratings for individual sections of the structured interview and 
questionnaire was evaluated using the kappa statistic () (Cohen, 1960), and a kappa 
threshold of 0.40 was used to indicate acceptable levels of agreement (Yip, Wilber, Myrtle, 
& Grazman, 2001).   
 
Exploratory analyses 
  For some analyses and in line with conventions (McMillan et al., 2016), overall GOSE scores 
were dichotomised into two groups, i,e., ‘better’ outcomes (‘moderate disability’ and ‘good 
recovery’) versus ‘worse’ outcomes (‘vegetative state’ and ‘severe disability’), and McNemar’s 
test was used to compare outcomes on the GOSE structured interview and GOSE questionnaire 
at 3 and 6-months post-injury.  Potential ways of improving agreement between clinician-
ratings and respondent reports were then explored by examining individual sections of the 
GOSE, and the ‘symptoms’ section of the respondent-completed questionnaire was re-scored 
using a revised algorithm (Wilson & Horton, 2018).  
 
  Exploratory analyses also examined whether clinical factors (i.e., pre-existing disability, 
extracranial injury, epilepsy, and injury severity) and type of respondent, had an impact on 
levels of agreement between GOSE scores at 3 and 6-months post-injury. 
 
  All statistical analyses were conducted using IBM SPSS Statistics 23.  The data were 






4.4.1. Demographics and clinical characteristics  
  A total of 3692 adults were eligible for follow-up 6 months after injury.  At 3 months, 1096 
patients completed both versions of the GOSE:  9.5% (n=104) were excluded as they did so 
outside of the 3-week time interval.  Thus, 992 patients met the inclusion criteria at the 3-
month follow-up.  At 6 months, 678 patients completed both versions of the GOSE:  7.7% 
(n=52) were excluded as they did so outside of the 3-week time interval.  Thus, 626 patients 
met the inclusion criteria at the 6-month follow-up.  The participant selection process for the 
study is detailed in Figure 4.1.  Tables 4.1 and 4.2 summarise the demographic and clinical 
characteristics of the 3-month sub-sample, 6-month-sub-sample, and eligible sample.   
 
  The median (IQR) age was 53 years (33-66) for the 3-month sample; 51 years (31-64) for the 6-
month sample; and 49 years (31-64) for the eligible sample.  Around two-thirds of the patients 
were male and most of them were Caucasian.  Most patients had high school, post-high school, 
or college/university education.  Around half of the patients were in employment prior to 
injury.  Furthermore, around half of the patients were partnered prior to injury.  Most of the 
patients were healthy or had mild systemic disease (i.e., conditions with no functional 
limitations) prior to injury.  Road traffic accidents and incidental falls were the most common 
causes of injury, each accounting for around 40% of the samples.  Most patients were either 
admitted to the hospital ward or intensive care unit, and emergency room admissions 
accounted for around one-fifth of the samples.  Around two-thirds of the patients had GCS 
scores of 13-15 and CT abnormalities were present in around half of the patients.  Total ISS 
scores of 15 or more are indicative of major trauma: the median (IQR) total ISS was 16 (9-26) 
for the 3-month sample; 16 (8-29) for the 6-month sample; and 16 (9-26) for the eligible 
sample.  A total of 514 (51.8%) of the 3-month sub-sample, 336 (53.7%) of the 6-month sub-
sample, and 1876 (50.8%) of the eligible sample met criteria for major trauma.  Around one-










core study sample (n=4509) 
 
Total no. patients aged 
< 16 years (n=149) 
 
Total no. patients with 
date of death within 6 months  
of injury (n=471) 
 
Total no. patients 
withdrawn from study 
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(surviving adult patients eligible  
for follow-up at 3 months  



















Total no. patients assessed 
using the GOSE structured 
interview and/or GOSE 
questionnaire at 3 months 
(n=2673) 
Total no. patients assessed 
using the GOSE structured 
interview and/or GOSE 














Total no. GOSE assessments 
completed at 3 months: 
 Interview (n=1986) 
 Questionnaire (n=1750) 
Total no. GOSE assessments 
completed at 6 months: 
 Interview (n=2165) 
 Questionnaire (n=977) 




Total no. patients assessed 
using the GOSE structured 
interview and questionnaire 
at 3 months: 1096 
 
Total no. patients assessed 
using the GOSE structured 
interview and questionnaire 
at 6 months: 678 




3-month sub-sample (n=992) 
(total no. patients assessed at 3 months using the 
GOSE structured interview and questionnaire 
within a 3-week interval) 
6-month sub-sample (n=626) 
(total no. patients assessed at 6 months using the 
GOSE structured interview and GOSE 
questionnaire within a 3-week interval) 
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  16-25 
  26-35 
  36-45 
  46-55 
  56-65 
  66-75 
  76-86 





























  Male 











  Caucasian  
  Other  














  Primary school or less 
  High school  
  Post-high school 
  training  
  College/University  























  Working  
  Not working   
  Retired 
  Student/homemaker 




















  Partnered 
  Previously partnered 
  Single/unspecified 






















Table 4.2: Clinical characteristics of the 3 and 6-month sub-samples and eligible sample 






ASA Physical Health  
  Healthy patient 
  Mild systemic disease  
  Severe/life threatening 
  systemic disease 



















Cause of injury  
  Road traffic accident 
  Incidental fall 
  Violence/assault 
  Other 
















 208 (5.6%) 
361 (9.8%) 
94 (2.6%) 
Clinical Care Pathway  
  Emergency Room 
  Admitted to hospital 














  13-15 
  8-12  
  3-8  

















  Present 
  Absent 













Head & neck injury1 
  No injury/minor injury  
  Moderate injury  
  Serious injury  
  Severe injury  
  Critical injury 






















Non-head & neck injury2 
  No injury/mild injury 
  Severe injury  













Data are n (%); 1Head & neck injury = combined AIS score for head, neck and cervical regions  




  Figure 4.2 shows that most GOSE assessments were completed by the patient alone (i.e., at 3-
months, 77% of interviews and 74.2% of questionnaires; and at 6-months, 78.6% of interviews 
and 80.2% of questionnaires).  A minority of assessments were completed by the patient and a 
proxy together (i.e., at 3-months, 8.6% of interviews and 15.8% of questionnaires; and at 6-
months, 8.5% of interviews and 10.2% of questionnaires), or by a relative/caregiver alone (i.e., 
at 3-months, 13.5% of interviews and 9.8% of questionnaires; and at 6-months, 9.7% of 
interviews and 9.4% of questionnaires).  Information about who responded was missing in a 
small number of cases.  
 
































Patient alone Patient & proxy together Proxy alone Respondent Missing
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  At 3 months, 76.7% (n=761) of the GOSE assessments were completed within a 1-week time 
window; 14.6% (n=145) were completed between 1 and 2-weeks apart; and 8.7% (n=86) were 
completed between 2 and 3-weeks apart.  The GOSE questionnaire was completed first for 
29.9% of patients (n=297), while the structured interview was completed first for 15.2% of 
patients (n=150).  A total of 54.9% (n=545) of the 3-month assessments were completed on the 
same day. 
 
  At 6 months, 90.7% (n=568) of the GOSE assessments were completed within a 1-week time 
window; 5.6% (n=35) were completed within a 2-week time window; and 3.7% (n=23) were 
completed within a 3-week time window.  The GOSE questionnaire was completed first for 
10.8% of patients (n=68), while the structured interview was completed first for 12.5% of 
patients (n=78).  A total of 76.7% (n=480) of the 6-month assessments were completed on the 
same day.  
 
4.4.2. Agreement between GOSE scores 
Overall GOSE ratings 
  Cross-tabulations of overall GOSE ratings are displayed in Tables 4.3 (3-month follow-up) and 
4.4 (6-month follow-up).  w was 0.77 (CI: 0.73-0.80) for the 3-month comparison and 0.82 (CI: 
0.78-0.86) for the 6-month comparison.  There was perfect agreement for 52.5% of the 3-
month sample (n=521) and 60.1% of the 6-month sample (n=376).  Most discrepancies were 
within 1 GOSE category (i.e., 67.7% of disagreements in the 3-month sample, and 75.2% of 
disagreements in the 6-month sample).  Extreme discrepancies (i.e., ≥3 GOSE categories) were 
uncommon, comprising 12.3% of disagreements in the 3-month sample, and 10% of 
disagreements in the 6-month sample.  Wilcoxon signed-ranks tests indicated that GOSE scores 
were comparable at the 3-month follow-up (interview mean rank=219.55, questionnaire mean 
rank=259.29, Z= -1.77 p=0.08), but not at the 6-month follow-up (interview mean rank=123.34, 





Table 4.3: Cross tabulation of overall ratings from GOSE structured interview  























11 2 0 2 2 90 
(9.1%) 
Upper SD 16 
 
35 8 2 6 8 75 
(7.6%) 
Lower MD 9 
 
22 44 8 11 10 104 
(10.5%) 
Upper MD 2 
 
21 21 45 30 26 145 
(14.6%) 
Lower GR 3 
 
17 14 21 67 137 259 
(26.1%) 
Upper GR 3 
 
2 3 9 32 270 319 
(32.2%) 














w= 0.77; 95% Confidence Intervals = 0.73-0.80; Overall level of agreement = 52.5% 
 
Table 4.4: Cross tabulation of overall ratings from GOSE structured interview 





















54 3 0 0 1 1 59 
(9.4%) 
Upper SD 3 15 
 
1 3 3 5 30 
(4.8%) 
Lower MD 0 11 51 
 
4 4 6 76 
(12.1%) 
Upper MD 1 7 15 34 
 
17 15 89 
(14.2%) 






















w= 0.82; 95% Confidence Intervals = 0.78-0.86; Overall level of agreement = 60.1%  
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Ratings for individual sections of the GOSE  
  Levels of agreement between individual sections of the structured interview and 
questionnaire are displayed in Tables 4.5 (3-month sub-sample) and 4.6 (6-month sub-sample).  
The responses for each section of the GOSE are coded according to whether a limitation was 
recorded.  Sections dealing with independence at home and during shopping and travel had 
good levels of agreement (=0.70-0.79), and levels of agreement for sections dealing with work 
and participation in social and leisure activities were generally good (=0.60-0.74).  Subjective 
aspects of functioning (i.e., relationships and symptoms) had moderate levels of agreement 
(=0.43-0.51), with the symptoms section of the GOSE having the lowest levels of agreement 
(=0.43 at both time-points).  Figures 4.3 and 4.4 show the percentages of patients who 
endorsed limitations on each section of the GOSE structured interview and GOSE questionnaire: 
limitations were most common in the domains of TBI-related symptoms, social and leisure 
activities, and work, and least common for domains pertaining to independence inside and 
outside the home, and relationships.   
 
Table 4.5: Levels of agreement between individual sections of the GOSE structured interview 
and GOSE questionnaire completed 3 months after injury  
 I-/Q- I-/Q+ I+/Q- I+/Q+ % 
Agreement 




























377 34 258 307 70.1% 0.43 0.03 0.41-
0.51  
I- = no limitation recorded on interview; I+ = limitation recorded on interview 
Q- = no limitation recorded on questionnaire; Q+ = limitation recorded on questionnaire 
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Table 4.6: Levels of agreement between individual sections of the GOSE structured interview 
and GOSE questionnaire completed 6 months after injury  
 I-/Q- I-/Q+ I+/Q- I+/Q+ % 
Agreement 

































I- = no limitation recorded on interview; I+ = limitation recorded on interview 
Q- = no limitation recorded on questionnaire; Q+ = limitation recorded on questionnaire  
 
Figure 4.3: Percentage of patients endorsing limitations in individual sections of the GOSE 
structured interview and GOSE questionnaire at 3 months post-injury 
 





















GOSE structured interview GOSE questionnaire
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Figure 4.4: Percentage of patients endorsing limitations in individual sections of the GOSE 




4.4.3. Exploratory analyses 
Dichotomised GOSE ratings 
  Comparisons were made for patients assigned to ‘better’ (i.e., ‘moderate disability’ and ‘good 
recovery’ categories) and ‘worse’ (i.e., ‘vegetative state’ and ‘severe disability’ categories) 
outcome groups using McNemar’s test.  At 3 months, there was a significant difference in the 
proportion of patients assigned to ‘better’ and ‘worse’ outcome groups (p<0.001).  However, at 
6 months, these groups were comparable (p=0.08).  Figures 4.5 and 4.6 show the proportions of 
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Figure 4.5:  Dichotomised GOSE ratings at 3 months post-injury  
 
 
Figure 4.6:  Dichotomised GOSE ratings at 6 months post-injury  
 
 
Re-scoring the GOSE questionnaire  
  Limitations were endorsed most frequently on the symptoms section of the GOSE.  
Furthermore, the symptoms section of the scale had the lowest levels of agreement (=0.43 at 
both time-points), and symptoms were less likely to be endorsed when the GOSE questionnaire 
Worse outcome Better outcome
GOSE structured interview 165 827











GOSE structured interview GOSE questionnaire
Worse outcome Better outcome
GOSE structured interview 89 537
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was completed.  The symptoms section of the GOSE questionnaire was therefore re-scored 
using a revised algorithm in which all symptoms were counted as relevant to outcome even if 
respondents indicated that they did not have an impact on daily functioning (Wilson & Horton, 
2018).  Table 4.7, and Figures 4.7 and 4.8, show that levels of agreement between the 
structured interview and questionnaire improved when the revised algorithm was used.  
 
Table 4.7: Levels of agreement between GOSE structured interview and GOSE questionnaire 
when the symptoms section is re-scored using a revised scoring algorithm 
 
Symptoms 
I-/Q- I-/Q+ I+/Q- I+/Q+ % 
Agreement 








199 85 51 264 77.3% 0.54 0.03 0.48-
0.60  
I- = no limitation recorded on interview; I+ = limitation recorded on interview 
Q- = no limitation recorded on questionnaire; Q+ = limitation recorded on questionnaire  
 
 
Figure 4.7: Number of patients assigned to ‘good recovery’ categories at 3-months post-injury 
for the GOSE questionnaire (scored using the standard algorithm and revised algorithm), and 
the GOSE structured interview  
 





















Figure 4.8: Number of patients assigned to ‘good recovery’ categories at 6-months post-injury 
for the GOSE questionnaire (scored using the standard algorithm and revised algorithm), and 





  Comparisons were made for sub-groups of patients to examine whether pre-existing 
functional limitations, extracranial concomitant injury, epilepsy, injury severity, CT abnormality, 
and type of respondent affected levels of agreement between overall scores on the GOSE 
structured interview and GOSE questionnaire.  
 
  Table 4.8 shows that there was at least good agreement (i.e., w>0.60) between GOSE 
assessments for the sub-group comparisons. However, the 3-month comparison for patients 
with functional limitations due to the combined effects of head injury and extracranial 






















Table 4.8: Levels of concordance between overall scores for GOSE structured 
 interview and GOSE questionnaire for sub-groups at 3 and 6-months post-injury  
 3-month GOSE 
assessments 
(w, 95% CIs) 
6-month GOSE 
assessments 
(w, 95% CIs) 
Pre-existing functional limitations 
  Healthy patients/patients with mild systemic 
  disease (no pre-existing functional limitations)  
  Patients with severe/life threatening systemic 











Extracranial concomitant injury 
  No extracranial injury (outcome is the  
  result of head injury alone) 
  Outcome is the result of head injury & 
  extracranial injury/illness  
  Outcome is the result of extracranial   




0.55 (0.41-0.69)  
(n=152) 










  Patients without epilepsy 
 












  Mild TBI (i.e., GCS=13-15) 
 
  Moderate TBI (i.e., GCS 9-12) 
 
















  Present 
 











Type of respondent 
  Patient alone or with proxy 
 












4.5. Discussion  
  This study compared two main approaches to collecting information about global functional 
outcome after TBI to determine whether clinician ratings on the GOSE structured interview 
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provide added value over respondent reports on the GOSE questionnaire.  Overall GOSE scores 
were found to be similar:  there was perfect agreement for more than half of the patients, and 
where discrepancies occurred, most were slight (i.e., within 1 category).  Levels of agreement 
for ratings on individual sections of the GOSE were also acceptable: concordance was strongest 
for objective aspects of functioning such as independence in activities of daily living, and 
weakest for subjective aspects of functioning such as TBI-symptoms and relationships.  The 
findings indicate that outcomes obtained using the two GOSE approaches are broadly 
comparable and suggest that respondent reports on the GOSE questionnaire provide adequate 
information about global functioning after TBI.  Nevertheless, exploratory analyses revealed 
that there are certain circumstances in which it may be preferable to supplement questionnaire 
assessments with the GOSE structured interview.  In particular, information obtained via the 
structured interview may be particularly useful in the first 3 months after injury when assessing 
patients with greater levels of disability or extracranial concomitant injuries/illness.  The 
structured interview may also be useful to distinguish between patients in the upper and lower 
‘good recovery’ categories, as ratings for TBI symptoms were found to be inconsistent between 
the two GOSE approaches.  
 
  At 3 months post-injury, dichotomized GOSE scores revealed that questionnaire responses 
were systematically less favourable than structured interview ratings for patients with greater 
levels of disability (i.e., those assigned to the ‘vegetative state’ and ‘severe disability’ outcome 
groups).  A possible explanation for this finding is that at 3-month follow-up, patients with 
poorer outcomes may not have returned to previous daily activities, despite being capable of 
doing so.  They may therefore not have considered whether they would theoretically be 
capable of activities such as looking after themselves at home, going shopping, or using public 
transport.  In contrast to self-reports on the GOSE questionnaire, when completing the GOSE 
structured interview, investigators are encouraged to assess whether patients would 
theoretically be capable of performing activities (Wilson et al., 1998).  This may result in more 
optimistic clinician ratings at the lower end of the scale.  Small discrepancies between ratings 
on the GOSE structured interview and GOSE questionnaire are not particularly important, but 
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may be problematic in study analyses, particularly if GOSE scores are dichotomized.  As the 
GOSE is often dichotomized in acute clinical trials, conventionally at the division between 
‘moderate’ and ‘severe’ disability (Horton et al., 2018; McMillan et al., 2016), particular care 
should be taken when assessing patients who may be unable to participate independently in 
life roles outside the home.     
 
  A significant number of patients in the current study had characteristics that are associated 
with poorer prognosis (Roozenbeek et al., 2012).  For example, they were older than samples in 
previous TBI studies, reflecting the increasing incidence of TBI in older adults (Brazinova et al., 
2016; Peeters, Majdan, Brazinova, Nieboer, & Maas, 2017; Peeters et al., 2015).  Most of the 
patients were admitted to the hospital ward or intensive care unit upon injury and around half 
of them met criteria for ‘major trauma.’  Half of the patients had CT abnormalities, and more 
than one-third also had severe extracranial injuries.  Despite the potential for investigator 
ratings to be influenced by knowledge of prognostic factors, outcomes were found to be similar 
for the sub-group comparisons.  Furthermore, despite the potential for respondent reports to 
be influenced by lack of insight (Prigatano, 2005a, 2005b), outcomes on the two GOSE 
approaches were not affected by injury severity.  These results suggest that both GOSE 
approaches can be used with patients with pre-existing functional limitations, epilepsy, and 
moderate-to-severe TBI.  Nevertheless, inconsistencies were found between the two GOSE 
approaches for patients with functional limitations as a result of extracranial injury/illness in 
combination with TBI.  Agreement was in the moderate range at the 3-month follow-up for 
patients in this sub-group, but improved at the 6-month follow-up.  This finding may be due to 
differences in the way in which extracranial injuries were rated on the GOSE structured 
interview and GOSE questionnaire.  However, the finding suggests that peripheral injury has a 
substantial effect on the assessment of global functional outcome, but only in the first few 
months after TBI.  As severe extracranial injuries often occur alongside mild TBI and are 
associated with poorer long-term functional outcomes (Leong et al., 2013), it is important to 
pay attention when assessing daily functioning in patients with polytrauma, especially in the 
first few months after injury.   
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  The GOSE is quick and easy to administer and is associated with better follow-up rates than 
other types of outcome assessment, such as neuropsychological tests (McMillan et al., 2016). 
Consistent with guidance from the FDA (U.S. Food & Drug Administration, 2009), the GOSE 
questionnaire is particularly useful in studies where interviewer bias may be an issue (i.e., 
surgical trials).  The current study indicates that respondent reports on the GOSE questionnaire 
are broadly equivalent to clinician ratings on the GOSE structured interview and can be used to 
obtain information about daily functioning after TBI.  The clinician-rated interview provided 
modest added value over the respondent-completed questionnaire in CENTER-TBI.  However, 
the specific choice of outcomes will depend on the purposes of the research.  For high stakes 
situations in which the GOSE is the primary endpoint of the study, it is advisable to use a single 
approach, and generally that will be the structured interview administered by trained assessors.  
In circumstances where the GOSE is being collected together with other outcomes and there 
are logistic constraints, studies may exploit the flexibility of the GOSE, and mixed data 
collection modes can be utilised to facilitate participant retention at follow-up.  
 
  A key benefit of the current study is that the large sample sizes made it possible to explore 
differences in that way symptoms were rated on the GOSE.  Levels of agreement were weakest 
for the symptoms section of the GOSE and symptoms were less likely to be endorsed by 
patients if the GOSE questionnaire was completed.  This finding is not surprising, as it can be 
difficult to judge the impact of TBI-related symptoms on daily functioning:  symptoms are the 
most subjective aspect of daily functioning; they can be attributed to other causes; and they 
may fluctuate over time.  Different methods of eliciting information about symptoms have been 
shown to result in inconsistent responses about TBI-related symptoms.  For example, when 
interviewed using a standardized checklist made-up of common post-mild TBI symptoms, 
patients were found to report significantly more symptoms than if they are asked to freely 
identify their symptoms (Villemure, Nolin, & Le Sage, 2011).  With this in mind, investigators 
should be aware of the potential influence different interviewing styles may have on patient 
disclosures about TBI-related symptoms, and GOSE structured interview guidelines should be 
followed to ensure that sufficient information is collected about whether symptoms are having 
103 
 
an impact on daily functioning (Wilson et al., 1998).  For patients assigned to the ‘good 
recovery’ categories, it may be necessary to include a supplementary assessment of TBI-
symptoms, such as the Rivermead Post-concussion Questionnaire (RPQ) (King et al., 1995), to 
gather additional information about the impact of symptoms on daily activities.     
 
4.5.1. Limitations  
  This study involved analysing CENTER-TBI data. Thus, it was not possible to employ an 
experimental design.  Investigators were not masked to information about prognostic factors or 
scores on other outcome assessments and patient self-awareness was not measured directly.  
Furthermore, as the GOSE was not collected in a uniform way across study sites, systematic 
comparisons between different modes of data collection (i.e., telephone versus face-to-face 
interviews; patient versus proxy informant) were not possible.  Given these limitations, it would 
be useful to conduct further research in which formal comparisons were made between 
different data collection modes, using investigators who were masked to all other study 
measures.  However, conducting such a study may not be feasible, as multiple modes of GOSE 
data collection would increase the burden of assessment and may prove difficult to obtain.  
 
4.5.2. Conclusion  
  This study indicates that clinician-rated interviews and respondent-completed questionnaires 
yield broadly comparable information concerning global functional outcome, even when used 
with patients with pre-existing functional limitations, epilepsy, CT abnormalities, moderate-to-
severe TBI, and significant extracranial injuries.  The study also suggests that in large-scale 
studies with pragmatic constraints, information collected via interviews makes little overall 
difference to GOSE ratings.  However, there are certain circumstances in which the GOSE 
structured interview may provide additional detail that is not captured by the GOSE 
questionnaire, e.g., when assessing patients with greater functional limitations or significant 
extracranial injury at 3-month follow-up, and when rating the impact of TBI-related symptoms 






The GOSE as a clinician-reported or patient-reported outcome 
 
 
  The study described in Chapter 4 provides evidence for the comparability of the clinican-rated 
GOSE structured interview and respondent-reported GOSE questionnaire.  However, it did not 
examine the relationship between the two GOSE approaches and other variables.  This chapter 
will investigate whether there are systematic differences in the constructs being assessed using 
the GOSE structured interview and GOSE questionnaire by examining how the two GOSE 


















  The GOSE is conventionally classified as a clinician-reported outcome (ClinRO).  However, 
when administered as a self-completion questionnaire and scored mechanically, it can 
essentially be considered a patient-reported outcome (PRO).  The current study aimed to 
examine the associations between the GOSE structured interview and GOSE questionnaire with 
prognostic variables from the IMPACT and CRASH models, as well as with other types of 
outcome measure, including PROs (measures of HRQoL, psychological status, and TBI 
symptoms) and PerfOs (measures of cognition and physical functioning).  The study used cross-
sectional data collected for CENTER-TBI at the 6-month follow-up and examined GOSE 
assessments which were completed by TBI patients alone or with assistance from a proxy 
respondent.  A total of 537 patients were included in the study.  On an ‘investigator bias’ 
hypothesis, the GOSE structured interview was predicted to have stronger associations with 
prognostic variables and measures of cognition and physical functioning than the GOSE 
questionnaire. On a ‘patient perspective’ hypothesis, the GOSE questionnaire was predicted to 
have stronger associations with patient-reported questionnaires than the GOSE structured 
interview.  Most of the examined variables were found to have significant correlations with the 
two GOSE approaches (-0.13 to 0.42 for prognostic factors; 0.29 to 0.65 for PROs; -0.14 to -0.32 
for PerfOs), and consistent with previous research, the associations between the GOSE and 
other outcome measures were modest.  The correlations for the two GOSE approaches were 
comparable, indicating that clinician-ratings and patient-reports of functional outcome were 
equivalent in terms of how they related to prognostic factors and other outcome measures.  
The findings therefore suggest that GOSE assignment is not affected by investigator bias or the 
patient’s perspective. The current study also supports recommendations for the GOSE to be 









  The GOSE provides a global index of function after TBI, in that it addresses what the patient is 
able to do, and categorises outcome by identifying the area of greatest limitation in daily 
activities (Jennett et al., 1981).  It has most commonly been administered as a clinician-rated 
interview in RCTs in adult TBI (Horton et al., 2018).  However, for pragmatic reasons, and to 
avoid investigator bias in studies where blinding is not possible, the respondent-completed 
questionnaire is increasingly being used as a primary mode of GOSE data collection in 
multicentre clinical trials (Andrews et al., 2015; Gregson et al., 2015; Horton et al., 2018; 
Hutchinson et al., 2017; Mendelow et al., 2015).  The GOSE is conventionally classified as a 
ClinRO, because when it is administered as a structured interview and rated by the interviewer, 
outcomes are assigned using the professional judgement of the investigator (McMillan et al., 
2016; Powers et al., 2017).  Nevertheless, when administered via questionnaire and scored 
mechanically by algorithm, the GOSE can essentially be considered a PRO, as it offers an insight 
into the perspective of the respondent without their ratings being interpreted by the 
investigator (Walton et al., 2015; Wilson et al., 2002).   
 
  Evidence concerning the construct validity of the GOSE comes from the wide variety of studies 
that have used it and from relationships described with clinical characteristics and other 
outcome measures (McMillan et al., 2016).  Recent analyses of the TRACK-TBI pilot study 
sample indicate that the GOSE has small-to-medium correlations with acute measures of injury 
severity (-0.18 to 0.39), psychological status (-0.40 to -0.52), TBI symptoms (-0.44 to -0.64), 
satisfaction with life and HRQoL (0.38-0.42), and cognition (0.17 to 0.30) (Kreitzer et al., 2018; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  
Additionally, a recent meta-analysis of the neuropsychological predictors of functional outcome 
demonstrates that the GOSE has significant correlations with assessments of immediate and 
delayed verbal memory (0.43), visuo-spatial construction (0.29), set-shifting (response speed) ( 
-0.31), and generativity (0.44) (Allanson, Pestell, Gignac, Yeo, & Weinborn, 2017).  Poorer 
outcomes on the GOSE are associated with greater injury severity and longer PTA duration, 
whereas better functional recovery is associated with lower levels of emotional distress, milder 
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TBI symptoms, better satisfaction with life, and better performance on cognitive tests (Allanson 
et al., 2017; Kreitzer et al., 2018; Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, 
Manley, McCrea, et al., 2017).  The effect that GOSE modality of asssessment has on its 
associations with clinical characteristics and other outcome measures has not specifically been 
examined.  It is therefore unclear whether clinician ratings and patient reports of functional 
ability are comparable in terms of how they relate to prognostic variables and other outcome 
domains.  
 
  In CENTER-TBI, unmasked outcome assessors may have been aware of acute prognostic 
factors known to influence outcomes.  The associations between the two GOSE approaches and 
prognostic variables warrant exploration because ‘unmasked’ interviewers may be 
unintentionally biased by their knowledge of the patient’s clinical status (Sherer et al., 2010).  
Various prognostic models have been reported in TBI research (Lingsma, Roozenbeek, 
Steyerberg, Murray, & Maas, 2010).  However, the IMPACT (Steyerberg et al., 2008) and CRASH 
(Collaborators et al., 2008) models are recommended over other prognostic models because 
they were developed using large datasets and have also been externally validated (Maas, 
Lingsma, & Roozenbeek, 2015; Roozenbeek et al., 2012).  The IMPACT model was developed 
using data from patients with moderate and severe TBI, whereas the CRASH model also 
included patients with mild TBI.  Both models include three core predictor variables: age, 
Glasgow Coma Scale (GCS) full score or motor score, and pupillary reactivity to light.  The basic 
CRASH model also includes major extracranial injury as a predictor.  The IMPACT and CRASH 
predictions were derived using different methods of assessing functional outcome: the IMPACT 
model was developed using guided interviews on the 5-point GOS (Steyerberg et al., 2008); 
while the CRASH model was developed from a short questionnaire version of the 5-point GOS 
which was completed primarily via mail (Roberts et al., 2004).  It is therefore unclear whether 
the way in which information was collected about functional outcome affected the final 




  The associations between the two GOSE approaches and other outcome measures warrant 
investigation because unmasked outcome assessors’ ratings on the GOSE structured interview 
may be influenced by knowledge of the patients’ performance on PerfOs (i.e., cognitive 
assessments and tests of physical functioning), while patient reports on the GOSE questionnaire 
may be biased by the patient’s perspective.  The GOSE self-report questionnaire essentially 
assesses the perspective of the patient, and one might therefore expect it to have a stronger 
relationship with PROs than the GOSE structured interview.  In clinical studies, it is important to 
include outcome measures that capture both how the patient functions and how they feel 
(Walton et al., 2015).  In the context of TBI, this involves incorporating tools that measure the 
patient’s perspective within a multi-dimensional outcomes framework (Maas et al., 2017; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  ClinROs 
and PerfOs measure the patient’s level of functioning.  In contrast, PROs measure how the 
patient feels.  Like PROs, the GOSE questionnaire reflects the perspective of the respondent.  
However, unlike other PROs, it does not tap into the subjective meaning the patient ascribes to 
their functional limitations (Koskinen et al., 2011; Nichol et al., 2011; Polinder et al., 2015).  The 
GOSE questionnaire therefore differs from other PROs, in that it is a self-reported index of the 
patient’s level of functioning, rather than how they feel.  Table 5.1 illustrates the distinctions 
between these different types of COA.   
 
Table 5.1: Distinctions between different types of COA and whether they measure  
how the person functions or how the person feels   
 “how the person functions” 
 
“how the person feels” 
ClinRO 
 
GOSE structured interview  
PRO 
 
GOSE questionnaire  Measures of HRQoL, psychological 
status, TBI symptoms   
PerfO 
 
Cognitive tests, assessmnents 





5.2.1. Study aims 
  CENTER-TBI provides an opportunity to investigate how clinician-ratings and patient-reports of 
functional outcome may differ in their associations with other factors.  Thus, the current study 
aimed to investigate the associations between the GOSE structured interview and GOSE 
questionnaire with other CENTER-TBI measures, including:  
 Prognostic variables from the basic CRASH and core IMPACT models (i.e., age, GCS score, 
pupil reactivity, and extracranial injury) 
 Other types of outcome measure, including PROs (i.e., measures of HRQoL, psychological 




  As the GOSE structured interview is based on investigator ratings, which can be influenced by 
the interviewer’s knowledge of the patient, it will have stronger associations with acute stage 
prognostic variables and PerfOs (i.e., measures of cognition and physical functioning) than the 
patient-reported GOSE questionnaire. 
 
Effect of the patient’s perspective 
  As the GOSE questionnaire is based on the patient’s self-report and not influenced by the 
perspective of the investigator, it will have stronger associations with other PROs than the 




  Potentially eligible participants were selected from the 6-month CENTER-TBI sub-sample 
described in Chapter 4, which comprised all surviving adult patients who were assessed using 
the GOSE structured interview and GOSE questionnaire within a 3-week time interval at 6-
month follow-up.  Patients were selected for the current study only if the GOSE assessments 
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were completed alone or with assistance, and not if they were completed by a proxy informant 
alone.   
 
5.3.2. Design 
  This study used cross-sectional data collected for the CENTER-TBI 6-month follow-up, which 
included the GOSE, as well as the other outcome measures listed below.    
 
5.3.3. Measures (all measures are described in detail in Chapter 3) 
The following acute measures were used: 
 American Society of Anaesthesiologists’ (ASA) classification of Physical Health (Dripps, 1963) 
 Glasgow Coma Scale (GCS) (Teasdale & Jennett, 1974)   
 CT abnormality  
 Abbreviated Injury Scale (AIS) and Injury Severity Score (ISS) (Baker et al., 1974) 
 Injury severity was also categorised according to clinical care pathway (i.e., emergency 
room (ER), admission to hospital ward (Admission), intensive care unit (ICU)).  
 
  The outcome measures used in this study are organised below according to the CDE outcome 
domains (Wilde et al., 2010): 
 
Global outcome 
 GOSE structured interview (Wilson et al., 1998)  
 GOSE questionnaire (Wilson et al., 2002)  
 36-Item Short Form Survey - Version 2 (SF-36v2) (Ware & Sherbourne, 1992)  
 
Health-related quality of life 
 Quality of Life after Brain Injury Scale (QOLIBRI) (von Steinbüchel, Wilson, Gibbons, 
Hawthorne, Hofer, Schmidt, Bullinger, Maas, Neugebauer, Powell, von Wild, Zitnay, Bakx, 
Christensen, Koskinen, Sarajuuri, et al., 2010) 




 Post-Traumatic Stress Disorder Checklist-5 (PCL-5) (Weathers et al., 2013) 
 Patient Health Questionnaire-9 (PHQ-9) (Kroenke, Spitzer, Williams, & Lowe, 2010) 
 Generalized Anxiety Disorder-7 (GAD-7) (Spitzer et al., 2006)  
 
TBI symptoms 
 Rivermead Post-concussion Questionnaire (RPQ) (King et al., 1995) 
 
Neuropsychological impairment  
 Rey Auditory Verbal Learning Test (RAVLT) (Schmidt, 1996)   
 Trail Making Test (TMT) Parts A & B (Strauss et al., 2006)  
 Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI), 
Paired Associate Learning (PAL), Visual Attention Switching Task (AST), Spatial Working 
Memory (SWM), Rapid Visual Information Processing (RVP), and Stockings of Cambridge 
(SOC) (Cambridge Cognition Ltd, 2014)  
 
Physical functioning  
 10-meter walk and Timed Up and Go (TUG) (Podsiadlo & Richardson, 1991)  
 
Recovery of consciousness   
 Galveston Orientation and Amnesia Test (GOAT) (Levin et al., 1979)  
 
  The GOAT was used to describe the clinical characteristics of the patients and to screen for 








5.3.4. Statistical analysis  
Demographic and clinical characteristics  
  The demographic and clinical characteristics of the current study sample were described using 
frequencies and percentages, and medians and inter-quartile ratios (IQR) were used for 
continuous data (i.e., age and total ISS score).    
 
Associations between the GOSE and other variables 
  Associations between the GOSE and other variables were assessed using Spearman 
correlations.  Non-parametric correlations were used because the GOSE is an ordinal scale and 
because scores on several of the other measures were skewed.  The two modes of GOSE data 
collection were correlated separately with prognostic factors (i.e., age, GCS score, pupil 
reactivity, and extracranial injury), and with other outcome measures (i.e., measures of HRQoL, 
psychological status, TBI symptoms, cognition, and physical functioning).  The significance level 
was set at p<0.01 (two-tailed) for correlations, given the relatively large sample size. No formal 
adjustments were made for multiple testing because both type 1 errors (i.e., finding spurious 
relationships/differences) and type 2 errors (i.e., failing to detect relationships/differences) are 
relevant to the study aims and hypotheses.  Steiger’s test (Lee & Preacher, 2013; Steiger, 1980) 
was used to examine whether the correlations for the GOSE structured interview and GOSE 
questionnaire were significantly different from each other.  All Steiger’s tests were two-tailed 
and they were not performed if the correlations were identical, or if both correlations were 
non-significant at the p<0.01 level.  All statistical analyses were conducted using IBM SPSS 
Statistics 23.  The data were downloaded from the INCF Neurobot database (Version 1) on 8 
November 2018.   
 
5.4. Results  
5.4.1. Demographic and clinical characteristics  
  A total of 537 patients met the inclusion criteria for this study (i.e., they were eligible for the 6-
month follow-up, scored in the ‘lower severe disability’ category or better, and completed both 
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types of GOSE assessment alone or with help from a proxy informant, within a 3-week time 
interval).  Tables 5.2 and 5.3 describe the current study sample.   
 
Table 5.2: Demographic characteristics of the current study sample  
 n (%) 
Age band 
   16-25 
   26-35 
   36-45 
   46-55 
   56-65 
   66-75 
   76-86 











  Male 





  Caucasian  
  Other  






  Primary school or less 
  High school  
  Post-high school training  
  College/University  








  Working  
  Not working   
  Retired 
  Student/homemaker 








  Partnered 
  Previously partnered 
  Single/unspecified 










Table 5.3: Clinical characteristics of the current study sample  
 n (%) 
ASA Physical Health  
  Healthy patient 
  Mild systemic disease  
  Severe/life threatening systemic disease 






Cause of injury  
  Road traffic accident 
  Incidental fall 
  Violence/assault 
  Other 







Clinical Care Pathway  
  Emergency Room 
  Admitted to hospital 






  13-15 
  9-12 
  3-8  







  Present 
  Absent 





Head & neck injury1 
  No injury/minor injury  
  Moderate injury  
  Serious injury  
  Severe injury  
  Critical injury 








Non-head & neck injury2 
  No injury/mild injury 
  Severe injury  






  GOAT total score <75 
  GOAT total score >75 





1Head & neck injury = combined AIS score for head, neck and cervical regions; 
 2Non-head & neck injury (severe injury= Total ISS >7) 
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  The median (IQR) age for the current study sample was 50 years (30-63).  Around two-thirds of 
the patients were male, and the majority were Caucasian.  Most patients had high school, post-
high school, or college-university education.  Around half of the patients were in employment 
prior to injury, and around half of them were partnered.    Most of the patients were healthy or 
had mild systemic disease (i.e., conditions with no functional limitation) prior to injury.  Road 
traffic accidents and incidental falls were the most common causes of injury, accounting for 
around 80% of the sample.  Most of the patients were either admitted to the hospital ward or 
intensive care unit.  Around two-thirds of the sample had GCS scores of 13-15, while almost half 
had CT abnormalities.  The median (IQR) total ISS for the sample was 16 (8-27), which is above 
the threshold for major trauma (i.e., ≥15).  A total of 50.3% (n=270) of the patients met criteria 
for major trauma, and around one-third had severe non-head and neck injuries.  Most of 
patients who were tested (i.e., 72.6% of the study sample) scored above 75 on the GOAT and 
were therefore no longer in post-traumatic amnesia. 
 
5.4.2. Associations between the GOSE and other variables  
  The correlation between the structured interview and questionnaire was significant at the 
0.01 level (2-tailed, rho = 0.72), indicating a strong positive association between GOSE scores.  
Spearman correlations for the GOSE structured interview and GOSE questionnaire against other 
variables are displayed in Tables 5.4 - 5.6.  Prognostic variables are displayed in Table 5.4, PROs 
are displayed in Table 5.5, and PerfOs are displayed in Table 5.6.     
 
   Table 5.4 shows that most prognostic variables had significant correlations at the p<0.01 level, 
apart from the correlation between age and the GOSE questionnaire, which was non-
significant.  The correlations were strongest for GCS Score and total ISS (correlations ranged 
from 0.37 to 0.42), and weakest for pupil reactivity and age (ranging from -0.04 to -0.19). 
Steiger’s test was significant for age only (Z = -2.80, p<0.01), indicating that age correlated more 
strongly with scores on the GOSE structured interview than it did with scores on the GOSE 
questionnaire.  Nevertheless, the strength of the relationship between age and scores on the 
GOSE was very weak and accounted for only 2% of the variance.  Thus, there was little support 
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for the hypothesis that the GOSE structured interview would systematically correlate more 
strongly than the GOSE questionnaire with prognostic factors. 
 
Table 5.4: Spearman correlations between the GOSE and prognostic factors  






Age (n=537) -0.13* -0.04 Z=-2.80, p<0.01* 
GCS score (n=502) 0.37* 0.39* Z=-0.63, p=0.51 
Pupil reactivity (n=491) -0.19* -0.17* Z=-0.61, p=0.54 
Total ISS (n=528) -0.37* -0.42* Z=1.69, p=0.09 
*Correlation is significant at the 0.01 level (2-tailed) 
 
 
  Table 5.5 shows that most PROs had significant correlations with the GOSE at the p < 0.01 
level.  Correlations ranged from rho = 0.26-0.65, and the correlations between the GOSE and 
PROs were generally stronger than those for prognostic factors and PerfOs.   The strongest 
correlation was found between the GOSE and the SF-36v2 ‘role - physical’ sub-scale (GOSE 
structured interview = 0.63; GOSE questionnaire = 0.65).  Correlations were 0.50 or above for 
the SF-36v2 ‘physical functioning’ (GOSE structured interview only), and ‘social functioning’ 
sub-scales, SF-36v2 PCS Score, QOLIBRI ‘daily life & autonomy’ and ‘physical problems’ sub-
scales, QOLIBRI total score, and QOLIBRI-OS (GOSE structured interview only).  Correlations 
were 0.40 or above for the SF-36v2 ‘general health’ (GOSE structured interview only), ‘role - 
emotional,’ and ‘energy and fatigue’ sub-scales, QOLIBRI ‘cognition’ and ‘self’ sub-scales (GOSE 
interview only), QOLIBRI-OS (GOSE questionnaire only), and PHQ-9.  Correlations were 0.30 or 
above for the SF-36v2 ‘pain’ and ‘mental health’ sub-scales, SF-36v2 MCS Score, QOLIBRI ‘self’ 
‘and ‘emotions’ (GOSE questionnaire only) sub-scales, PCL-5, and GAD-7.  The lowest 
correlations were found for the QOLIBRI ‘social relationships’ and ‘emotions’ sub-scales (rho = 
0.29).  Steiger’s tests were non-significant for all comparisons, indicating that the GOSE 
structured interview and GOSE questionnaire were equivalent in terms of strength of 
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relationships with the PROs.  The hypothesis that the GOSE questionnaire would correlate more 
strongly with PROs than the GOSE structured interview was therefore not supported. 
 
Table 5.5: Spearman correlations between the GOSE and PROs  







  Physical functioning (n=468) 
  Role – physical (n=467) 
  Pain (n=467) 
  General health (n=468) 
  Social functioning (n=467) 
  Role – emotional (n=467) 
  Energy and fatigue (n=463) 
  Mental health (n=463) 
  MCS Score (n=463) 



































  Cognition  
  Self  
  Daily life & autonomy  
  Social relationships  
  Emotions  
  Physical problems  

























QOLIBRI-OS (n=482) 0.50* 0.45* Z=1.70, p=0.09 
PCL-5 (n=464) -0.39* -0.37* Z=-0.63, p=0.53 
PHQ-9 (n=464) -0.47* -0.47* n/a 
GAD-7 (n=465) -0.34* -0.34* n/a 
RPQ (total) (n=470) -0.51* -0.49* Z=-0.68, p=0.49 
*Correlation is significant at the 0.01 level (2-tailed) 
 
 
  Table 5.6 shows that most PerfOs had significant correlations with the GOSE at the p<0.01 
level.  Significant correlations ranged from -0.14 to -0.32.  Steiger’s tests were non-significant 
118 
 
for all comparisons.  Thus, the hypothesis that the GOSE structured interview would correlate 
more strongly with measures of cognition and physical functioning than the GOSE 
questionnaire was not supported. 
 
Table 5.6: Spearman correlations between the GOSE and PerfOs  







  Principal list 
  total score (n=361) 
  Principal list  













Trail Making Test  
  TMT A (n=375) 











  RTI (n=239) 
  PAL (n=276) 
  AST (n=265) 
  SWM (n=263) 
  RVP (n=238) 






















Timed up & go (n=238)  -0.24* -0.25* Z=0.21, p=0.83 
10-metre walk (n=206) -0.30* -0.30* n/a 
*Correlation is significant at the 0.01 level (2-tailed) 
 
 
5.5. Discussion  
  Due to the pragmatic way in which outcomes were collected for CENTER-TBI (Maas, Menon, et 
al., 2015), the data provide a novel opportunity to examine whether clinician ratings and 
patient reports of global functional outcome are equivalent in terms of how they relate to other 
factors. The current study examined how the GOSE structured interview and GOSE 
questionnaire relate to prognostic variables and other outcome measures.  Scores on the GOSE 
were strongly positively correlated.  Furthermore, most of the variables examined showed 
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significant associations, albeit small-to-medium in magnitude, in the expected directions with 
the GOSE.  On an ‘investigator bias’ hypothesis, the structured interview was predicted to have 
stronger associations with prognostic variables and measures of cognition and physical 
functioning than the questionnaire; whereas on a ‘patient perspective’ hypothesis, the 
questionnaire was predicted to have stronger associations with other patient-reported 
questionnaires than the structured interview.  The two GOSE approaches were comparable in 
terms of the strength of their relationships with the other variables, suggesting that neither 
investigator’s knowledge about patients, nor the patient’s perspective, affected GOSE ratings.   
 
  Blinding of outcome assessors is a particularly important methodological aspect of design in 
clinical trials because investigator bias can give rise to misleading results which are aligned with 
expected treatment benefits or predictor variables  (Schulz et al., 2010; Sherer et al., 2010).  A 
similar problem arises with prognostic studies and observational studies in comparative 
effectiveness research.  As the CENTER-TBI outcome assessors were not masked to information 
concerning the patient’s clinical status and GOSE interviewers potentially had knowledge about 
the patient’s performance on tests of cognition and physical functioning, there was the 
possibility for clinician ratings on the GOSE structured interview to be biased.  Despite this, the 
prognostic variables and PerfOs examined in the current study were found to have equivalent 
relations with two GOSE approaches.  These findings suggest that ratings on the GOSE 
structured interview were largely unaffected by the investigators’ knowledge of the patient.  
These findings also have implications for prognostic studies in TBI, as the IMPACT (Steyerberg et 
al., 2008) and CRASH (Collaborators et al., 2008) predictions were derived using different 
methods of data collection for the GOS (i.e., guided interviews and postal questionnaires).  The 
similarity between clinician ratings and patient reports with predictor variables suggests that 
the IMPACT and CRASH models were unlikely to have been affected by the way in which 
information was collected about global outcome.     
 
  Regulators have encouraged the use of PROs in TBI studies because they capture the patient’s 
perspective and provide information about how they are feeling (U.S. Food & Drug 
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Administration, 2009).  The GOSE and SF-36v2 are both categorised as measures of global 
outcome in the NINDS CDEs (Wilde et al., 2010).  Thus, in CENTER-TBI, the GOSE self-report 
questionnaire and the SF-36v2 both provided information about the patient’s perspective 
about their level of global functioning after TBI.  In the current study, both GOSE approaches 
were found to have the strongest associations with domains relating to physical functioning on 
the SF-36v2 (i.e., correlations for the ‘physical functioning,’ ‘role-physical,’ and PCS score 
ranged from 0.49 to 0.65).  The strength of these associations indicates that the SF-36v2 
captures the construct of global functional outcome in TBI, and suggests that it could be used as 
a substitute for the GOSE.  It is important to note, however, that unlike the GOSE, the SF-36v2 
does not take prior functional limitations or changes in functional status since TBI into 
consideration.  The language used in the SF-36v2 may also be challenging for patients with 
cognitive impairment.  The SF-36v2 might therefore have limitations when used with TBI 
patients with pre-existing functional limitations, cognitive impairment, or communication 
difficulties, whereas the GOSE is appropriate for use with these individuals.       
 
  Concerns have been raised about the use of PROs in TBI studies, as patients with more severe 
injuries may be unaware of their own limitations, and may therefore paint an overly optimistic 
picture of their recovery (Prigatano, 2005a, 2005b).  It may not always be advisable to use 
PROs, including the GOSE questionnaire, in TBI studies.  Nevertheless, in the current study, the 
two GOSE approaches were found to be equivelant in terms of their associations with PROs, 
suggesting that patient reports of global functioning can be used in situations where clinician-
ratings are not possible due to pragmatic constraints.  These findings suggest that patients were 
able to provide an accurate self-report about global functioning and a realistic appraisal of their 
HRQoL, psychological status, and TBI symptoms.  It would, however, be useful to conduct 
further research in which self-awareness was examined directly.  The use of a direct measure of 
self-awareness, such as the Patient Competency Rating Scale (Prigatano & Fordyce, 1986), 
along with the use of proxy only reports on the GOSE questionnaire, would enable a more 




  The associations between the GOSE and other factors were in the expected directions in the 
current study.  Greater disability was associated with older age, greater injury severity, and 
greater severity of patient-reported PTSD symptoms, depression, anxiety, and post-concussion 
symptoms.  In contrast, better functional recovery was associated with better patient-reported 
HRQoL and better performance on cognitive assessments and tests of physical functioning.  
These findings are consistent with previous research (Allanson et al., 2017; Kreitzer et al., 2018; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017), and 
demonstrate that the variables examined in this study tap into the construct of global 
functional outcome.  Nevertheless, as the associations between the GOSE and other outcome 
measures were modest, it is clear that the GOSE may miss important details about specific 
aspects of functioning after TBI, especially in the cognitive domain.  A multi-dimensional 
approach has been recommended by TRACK-TBI and CENTER-TBI investigators to adequately 
characterise outcome after TBI (Maas et al., 2017; Nelson, Ranson, Ferguson, Giacino, 
Okonkwo, Valadka, Manley, McCrea, et al., 2017).  It should be noted, however, that TBI 
patients can be a hard to reach population and comprehensive follow-up assessments can be 
challenging to obtain.  Consideration should therefore be given to how feasible it is to include 
multiple outcome measures in TBI studies.   
 
5.5.1. Limitations  
  This study builds upon the findings reported in Chapter 4, as it provides further evidence for 
the comparability of the GOSE structured interview and GOSE questionnaire and suggests that 
the two approaches have shared underlying constructs.  Nevertheless, some key limitations 
should be mentioned.  Firstly, the observational nature of the CENTER-TBI study meant that it 
was not possible to employ an experimental design and systematic comparisons between GOSE 
approaches, including proxy informant reports on the GOSE questionnaire, were not possible.  
Secondly, as no direct measure of self-awareness was used in CENTER-TBI, the study lacks 
verification about the accuracy of patients’ self-reported difficulties on the GOSE and other 
PROs.  Thirdly, the current study did not consider the effect of baseline predictors of outcome, 
such as age and injury severity, on the strength of the correlations between the two GOSE 
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approaches and other outcome measures.  The causal relationship between prognostic factors 
and TBI outcomes was not examined in this thesis, but is a potential area for investigation in 
future CENTER-TBI analyses.       
 
5.5.2. Conclusion  
  This study provides further evidence for the comparability of the GOSE structured interview 
and GOSE questionnaire and demonstrates that the variables examined tap into the underlying 
construct of global functional outcome.  GOSE assignment was largely unaffected by 
investigator bias or by the patient’s perspective.  Therefore, where appropriate, future 
observational TBI studies can exploit the flexibility of the GOSE and employ a pragmatic 
approach to GOSE administration, to facilitate data collection and maximise study follow-up 
rates.  As the associations between the GOSE and other outcome measures were modest, the 
findings from this study also indicate that the GOSE is insufficient on its own for describing the 
sequelae of TBI.  TBI studies should therefore incorporate multiple assessments across outcome 
domains to capture how the patient feels and functions.  However, as the use of multiple 
outcome measures might not always be feasible, further research is needed to explore how a 


















CENTER-TBI outcome measures 
 in relation to post-TBI functional level  
 
 
  This chapter examines the CENTER-TBI outcome measures with patients at different levels of 
functional recovery and considers the practicality of tailoring multi-dimensional outcome 


















  There is increasing awareness of the importance of multi-dimensional outcome assessment in 
TBI studies in acute care settings, but currently no consensus about how it might be 
implemented.  The current study examined the completeness, sensitivity, and internal 
consistency of the CENTER-TBI outcome measures in relation to GOSE assignment and 
considered how multi-dimensional outcome assessment could be tailored for patients with 
different post-TBI functional levels.  The study used cross-sectional data collected from 2573 
survivors who were followed up 6 months after injury using the GOSE.  Patients with better 
levels of functional recovery were found to have better outcome completion rates than those 
with poorer functional recovery, indicating that multi-dimensional outcome assessment is 
particularly challenging to implement with patients with severe disabilities.  Furthermore, PRO 
completion rates were better than those for cognitive assessments and tests of physical 
functioning; highlighting the logistic challenge posed by PerfOs in large-scale TBI studies.  Most 
of the PROs and some CANTAB sub-tests had ceiling effects, particularly when completed with 
patients with better functional recovery.  Certain measures therefore lacked sensitivity across 
the spectrum of recovery.  Ceiling effects were most common for patients with better levels of 
recovery and were most notable on measures of emotional adjustment, TBI symptoms and the 
CANTAB Paired Associates Learning test.  Floor effects were minimal, but present for patients in 
the ‘lower severe disability’ group on some of the SF-36v2 sub-scales, and on measures of 
physical functioning.  The PROs had high levels of internal consistency across the GOSE 
categories, indicating that when questionnaires were completed, they were reliable across the 
spectrum of recovery.  The findings from this study demonstrate that the applicability of TBI 
outcome measures is strongly driven by level of functional outcome.  Thus, a tailored approach 
to multi-dimensional outcome assessment allows investigators to capture the multi-
dimensional impact of TBI across different levels of functional recovery: this approach to 
outcome assessment has not commonly been implemented in research in acute care settings.  
The findings from this study have implications for selecting outcomes for retrospective analyses 
of data collected for CENTER-TBI, for future prospective TBI studies, and for future refinement 




  Multi-dimensional outcome assessment is important in TBI, because, in contrast to using a 
measure of global functioning such as the GOSE, it enables investigators to characterise 
outcomes in a comprehensive and granular way by capturing changes in domains of specific 
interest.  The implementation of multi-dimensional outcome assessment poses a significant 
challenge to TBI studies, particularly in acute care settings.  Thus, current data standardization 
initiatives are aiming to increase comparability of studies and validate and refine multi-
dimensional sets of outcome measures that can be used across the TBI spectrum (Hicks et al., 
2013; Tosetti et al., 2013; Wilde et al., 2010).  The heterogeneity of TBI makes the 
implementation of multi-dimensional outcome assessment particularly complex, because 
patients with different levels of injury severity and functional recovery represent different 
contexts of use (U.S. Food & Drug Administration, 2014; Walton et al., 2015) for outcome 
measures.  Certain outcome measures may not be suitable for use across the TBI spectrum.  
However, this has not always been properly acknowledged in TBI research.  Consideration 
should therefore be given to how appropriate particular assessments are for use with different 
sub-groups of patients.    
 
  There are a number of potential ways of approaching multi-dimensional outcome assessment 
in TBI, but currently no consensus about how it should be implemented.  Selection of the NINDS 
common data elements (CDE) outcome measures for TBI was based on expert opinion and took 
into consideration a range of factors, including the applicability of assessments across a range 
of injury severity and functional levels; how easy assessments are to administer; and their 
brevity (Hicks et al., 2013; Wilde et al., 2010).  The CDEs include recommendations for the use 
of outcome assessments in two populations (adult and paediatric) and four study types 
(epidemiology, acute hospital, moderate-to-severe TBI rehabilitation, mild TBI/concussion) 
(National Institute of Neurological Disorders and Stroke, 2018b).  Some advice is also provided 
concerning the applicability of specific tools; for example, administration of the WAIS 
processing speed index tests requires “a functional level in the severe disability or above on the 
GOS/GOSE” (National Institute of Neurological Disorders and Stroke, 2018a).  There are other 
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study types in addition to those included in the CDE recommendations, and in practice there 
will be study-specific reasons for choosing particular outcome measures.     
 
  As the CDE recommendations are not derived from systematic empirical work, research is 
required to assess the applicability of outcome measures in TBI studies.  CENTER-TBI and 
TRACK-TBI aim to validate the applicability of the CDEs in different contexts of use and both 
projects have among their objectives that of developing a “sliding” or “flexible” approach in 
which outcome assessments are tailored for different sub-groups of TBI patients (Maas et al., 
2015; Yue et al., 2018; Yue et al., 2013).  This type of tailored approach could be used when 
selecting outcome measures in prospective studies and could also guide retrospective analyses 
of data collected for large observational studies, such as CENTER-TBI and TRACK-TBI.  There are 
several possible ways in which a sliding approach could be implemented.  TRACK-TBI 
investigators have proposed a prospective flexible outcomes assessment framework in which 
patients are stratified into two tiers based on scores on the GOAT: the abbreviated outcomes 
battery is suitable for patients who lack orientation (i.e., GOAT scores < 75); whereas the 
comprehensive outcomes battery is suitable for patients with GOAT scores of 75 or above (Yue 
et al., 2018).  An alternative would be to use the GOSE to stratify patients into functional 
recovery sub-groups for tailored outcome assessment.  The use of functional status to guide the 
selection of assessments for individual patients is common in clinical practice, but there has 
been no formal evaluation of this approach in TBI research.     
 
  The CDE conception of multi-dimensional outcome assessment places the GOSE alongside 
other instruments as a specific assessment in the domain of functional outcome (Kean & Malec, 
2014; Maas et al., 2017; Wilde et al., 2010).  An alternative conception is to consider the GOSE 
as an overall description of outcome, albeit one that is lacking in detail (Nelson, Ranson, 
Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  The GOSE summarises 
daily functioning and social reintegration after TBI (Jennett et al., 1981; McMillan et al., 2016), 
but it does not fully capture specific problems patients may experience, particularly in the 
domains of emotional wellbeing, cognition, and life satisfaction (Alali et al., 2015; Maas et al., 
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2017; McMillan et al., 2016; Menon & Maas, 2015; Nelson, Ranson, Ferguson, Giacino, 
Okonkwo, Valadka, Manley, McCrea, et al., 2017; Nichol et al., 2011; Weir et al., 2012; Wilson 
et al., 2000).  As correlations between the GOSE and other outcome measures are often modest 
(Allanson et al., 2017; Kreitzer et al., 2018; Nelson, Ranson, Ferguson, Giacino, Okonkwo, 
Valadka, Manley, McCrea, et al., 2017), additional assessment tools are necessary to fully 
characterise outcome after TBI.  The construct of global functional outcome misses important 
aspects of the patient’s feeling and functioning (Walton et al., 2015).  Thus, it is important to 
incorporate other types of COA in TBI studies:  PROs capture the patient’s perspective and 
measure changes in how the patient feels, while PerfOs are objective and tap into specific 
aspects of the patient’s functioning (U.S. Food & Drug Administration, 2009; Walton et al., 
2015).  Figure 6.1 is a schematic diagram, modified from Nelson and colleagues (Nelson, 
Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017) depicting the 
outcome domains, individual outcome measures, and types of COA that were used in the 
CENTER-TBI study, and whether they assessed the patient’s functioning or feeling.   
 
  It would be informative to investigate how multi-dimensional outcome assessment could be 
tailored in relation to post-TBI functional level.  Patients assigned to different GOSE categories 
potentially have different assessment needs and therefore represent different contexts of use 
for outcome measures (Maas et al., 2017; Nelson, Ranson, Ferguson, Giacino, Okonkwo, 
Valadka, Manley, McCrea, et al., 2017).  Patients with severe disabilities may be unable to 
complete certain assessments such as questionnaires, cognitive tests, and tests of physical 
mobility, and may require assistance when completing the GOSE; whereas patients with good 
functional recovery may meet diagnostic criteria for psychological conditions or have clinically 
relevant TBI-related symptoms, which the GOSE is unable to fully capture (Maas et al., 2017; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  As the 
measurement properties of outcome assessments can be affected by the setting in which they 
are used (Walton et al., 2015), it is important to ensure that the instruments selected for 
specific TBI sub-groups are appropriate for their intended context of use (U.S. Food & Drug 
Administration, 2014; Walton et al., 2015).  Specifically, there is a need for advice on the use of 
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outcome assessments in studies of groups of patients, such as RCTs or CER, where issues such 
as completion rates and test sensitivity across the range of patients are of key importance.  
 
 Figure 6.1: Multi-dimensional assessment with the CENTER-TBI outcome measures (Modified 
from Nelson et al., 2017)  











































































  In previous longitudinal TBI studies, half or more participants have sometimes been lost to 
follow-up (Corrigan et al., 2003; Richter et al., 2019).  This is problematic because selective 
attrition of specific sub-groups of patients can result in systematic bias in study outcomes, 
limiting the generalisability of research findings (Corrigan et al., 2003; Krellman et al., 2014).  
Predictors of loss to follow-up in TBI studies include factors such as lower socio-economic 
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status, learning disability, living alone, homelessness, history of substance abuse, and violent 
injury aetiology (Corrigan et al., 2003; Krellman et al., 2014; Langley, Johnson, Slatyer, Skilbeck, 
& Thomas, 2010; Yue et al., 2013).  Follow-up thresholds of 60-80% have previously been 
proposed to be acceptable in cohort studies (Altman, 2000; Babbie, 1973; Kristman, Manno, & 
Cote, 2004).  However, outcome completion rates ranged from 46-60% for the TRACK-TBI Pilot 
study (Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, & McCrea, 2017), 
indicating that follow-ups may be especially difficult to obtain in large-scale multicentre TBI 
studies with multi-dimensional sets of outcome measures.  
  
6.2.1. Study aims 
  CENTER-TBI outcomes were collected, where possible, for patients at all post-TBI functional 
levels.  CENTER-TBI did not use a prospective sliding approach to outcome assessment.  
However, for patients in a vegetative state, outcomes were measured using the GOSE and JFK 
Coma Recovery Scale - Revised (Giacino, Kalmar, & Whyte, 2004).  The usability of multi-
dimensional outcome assessment across the spectrum of functional recovery has not been 
evaluated.  The CENTER-TBI data provide an opportunity to evaluate the quality and validity of 
different outcome measures in relation to GOSE assignment.  The current study therefore 
aimed to:  
 Examine the quality (i.e., completeness of outcomes) and measurement properties (i.e., 
floor/ceiling effects and internal consistency) of CENTER-TBI outcomes data in relation to 
post-TBI functional level 
 Provide guidance on contexts of use for particular outcome measures that can be used to 
provide a multi-dimensional description of outcomes for patients at different levels of 









  Potentially eligible patients were enrolled in the CENTER-TBI core study (see CENTER-TBI 
inclusion criteria in Chapter 3).  
Additional inclusion criteria for the current study were as follows: 
 Adults aged 16 years and over (no upper age limit) 
 All injury severities  
 GOSE composite score ≥2 (i.e., lower severe disability or better)  
 The GOSE must be completed at 6 months post-injury  
 
6.3.2.  Design 
  The study had a cross-sectional design and used CENTER-TBI outcomes data collected 6 
months after injury.  
 
6.3.3. Measures (all measures are described in detail in Chapter 3) 
Acute measures  
 Glasgow Coma Scale (GCS) (Teasdale & Jennett, 1974) 
 CT abnormality   
 Abbreviated Injury Scale (AIS) and Injury Severity Score (ISS) (Baker et al., 1974) 
 American Society of Anesthesiologists’ (ASA) classification of Physical Health (Dripps, 1963) 
 Clinical care pathway (i.e., ER, Admission, ICU) 
 
Outcome measures: Assessment of level of disability 
  The GOSE was used to assess level of disability in this study.  As the GOSE structured interview 
(Wilson et al., 1998) and GOSE questionnaire (Wilson et al., 2002) were found to be broadly 
comparable in Chapters 4 and 5, the GOSE composite score (described in Chapter 3), was used 
to measure level of disability (Wilson & Horton, 2018).  Possible GOSE scores ranged from 
‘lower severe disability’ to ‘upper good recovery.’  Patients assigned to the ‘vegetative state’ 
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category were excluded from the analysis because they were not able to complete the outcome 
measures under consideration.   
 
  Other outcome measures 
  Six-month follow-up data was used in this study because all outcome measures, including the 
GOSE, patient-reported questionnaires, cognitive assessments, and tests of physical 
functioning, were mandated for collection at this time point.  Data collection for CENTER-TBI 
was complex and challenging and an international collaborative effort was required to obtain 
follow-ups in the 65 participating study sites.  The outcome domains and scoring approaches 
for each of the CENTER-TBI outcome measures are detailed in Table 6.1 (further detail about 
the CENTER-TBI outcome measures is included in Chapter 3).    
 









The GOSE has 8 hierarchical outcome categories, including: 
death, vegetative state, severe disability (lower and upper), 
moderate disability (lower and upper), and good recovery 
(lower and upper). Composite GOSE scores were calculated 






The SF-36v2 comprises 8 health domains and two summary 
measures, i.e., physical component summary (PCS) score 
and mental component summary (MCS) score.  The 8 health 
domains and 2 summary component measures were scored 
using standardised T-scores (mean=50, SD=10), based on US 
general population norms in 2009 (normal range=45-55). 




The QOLIBRI comprises six domains, including four 
‘satisfaction’ scales (cognition, self, daily life and autonomy, 
social relationships), and two ‘bothered’ scales (emotions 
and physical problems), as well as a total score.  The 
QOLIBRI-OS consists of six overall ‘satisfaction’ questions.  
Scores range from 0-100.  QOLIBRI total scores <60 and 
QOLIBRI-OS scores <52 = impaired HRQoL (Wilson et al., 







Total symptom severity scores range from 0-80. PTSD can be 





Total scores range from 0-27.  Cut-offs: no depression=0-4; 
mild depression=5-9; moderate depression=10-14; 






Total scores range from 0-21.  Cut-offs: no anxiety=0-4; mild 






Post-concussion symptoms were judged to be present if at 
least 3 symptoms were rated as a moderate or severe 
problem (Sterr et al., 2006).   
RAVLT 
 
Cognition   Two summary scores were used, i.e., total score (sum of 
words recalled across 5 trials) and 20-minute delay (number 
of words recalled after 20-minute delay).  Norms range from 
53.9 (6.7) to 37.1 (7.5) for the total score, and from 11.7 
(2.2) to 7.0 (2.4) for the 20-minute delayed recall (scores 
decline with increasing age) (Strauss et al., 2006).  
TMT A & B 
 
Cognition  Scoring is based on the time taken to complete each part.  
For CENTER-TBI, Part A was discontinued after 100 seconds 
and Part B was discontinued after 300 seconds.   
CANTAB  
 
Cognition   The CANTAB sub-tests (RTI, PAL, AST, SWM, RVP, SOC) were 







Scoring was based on the time taken to complete the tests.  
Scores for the TUG can be interpreted as follows; <10 
seconds = normal; <20 seconds = good mobility, can go out 
alone, mobile without a gait aid; <30 seconds = problems 
with mobility, cannot go outside alone, requires a gait aid.   
 
 
6.3.4. Statistical analysis   
Demographic and clinical characteristics  
  The demographic and clinical characteristics for the study sample and for patients without a 6-
month GOSE were described using frequencies and percentages for categorical data, and 
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medians and interquartile ranges (IQR) for continuous data (i.e., age and total ISS score).  
Differences between the groups were tested using independent samples t-tests for continuous 
data and Chi-square (2) tests for categorical data.   
 
Scores on outcome measures  
  Means and standard deviations were calculated for scores on the outcome measures.  One-
way analysis of variance (ANOVA) was used to test for statistically significant differences 
between the GOSE categories.  As 28 ANOVAs were performed, Bonferroni adjusted p values 
were used (i.e., 0.0018) to minimise the risk of type 1 error.  The ANOVAs were conducted to 
provide a context for further analysis of the CENTER-TBI data.  No adjustments were made for 
potentially confounding covariates (e.g., age, education level, pre-injury mental health issues), 
and the ANOVAs should therefore be interpreted with caution.  Detailed analysis of differences 
between outcome groups is the focus of a separate CENTER-TBI study proposal.   
 
 Data quality and outcome measure validity in relation to post-TBI functional level  
  The distribution of GOSE scores was examined to determine the number and percentage of 
patients assigned to each level of disability.  Completeness of outcomes was then examined in 
relation to GOSE assignment.  A recent systematic review showed that at 6-months, follow-up 
rates tend to be above 90% in interventional studies, whereas follow-up rates typically range 
from 60% in observational TBI studies (Richter et al., 2019).  Completion rates below 60% were 
therefore considered particularly problematic.  The number and percentage of patients who 
completed each outcome measure was calculated for each GOSE category, and for the total 
study sample.  Some QOLIBRI-OS forms were completed by a proxy alone: these were excluded 
from the completion rate analyses because the QOLIBRI-OS is a patient-reported outcome and 
has unknown validity when completed by proxy respondents.  Reasons for non-completion of 
the RAVLT, TMT A & B, CANTAB, and 10-meter walk/TUG were examined and coded using the 
following categories: (1) Non-neurological or logistic reasons; (2) Cognitive/neurological 
deficits; (3) Invalid test; and (4) Reason not provided.  It was not possible to examine reasons 
for non-completion of PROs as this information was not collected as part of CENTER-TBI.   
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  Floor and ceiling effects were examined for the completed outcome measures to assess the 
sensitivity of each measure when used with patients with different levels of disability.  
Consistent with previous research (Hall et al., 1996), floor and ceiling ranges were generally 
defined as the top and bottom 10% of the range of possible scores for each outcome measure.  
Ceiling ranges are not applicable for tests involving latencies and were not calculated for the 
TMT, RTI, AST, and TUG.  The range for the CANTAB sub-tests was defined as the empirical or 
expected minimum and maximum scores, given the underlying distribution of scores.  Outliers 
are scores which lie outside this range, and present potential problems for analysis.  For the 
Trail Making Test, for example, this problem is dealt with by setting the maximum possible time 
for the test (i.e the floor).  There are no published floor and ceiling ranges for the CANTAB sub-
tests.  Thus, floor/ceiling ranges were calculated for these tests in the context of adult TBI, and 
the ranges defined are relative to the total study sample.  In CENTER-TBI, some of the CANTAB 
sub-test score distributions show substantial skew and kurtosis and may be non-normal.  
Empirical minimum and maximum scores were therefore defined for the CANTAB using Tukey’s 
rule (Tukey, 1977) to exclude outliers in the range.  Minimum and maximum scores were 
calculated as 1.5 times the interquartile range below the 25th percentile and above the 75th 
percentile.  For example, for the RTI sub-test, reaction times ranged from 218-1813 
milliseconds (25th percentile = 324; 75th percentile = 424; IQR = 100); thus the floor range was 
defined as 574-1813.  Scores considered at the “ceiling” and “floor” for each relevant outcome 
measure are defined in Table 6.2.  Outcome measures were considered to have good sensitivity 
if they had minimal floor/ceiling effects (defined in this study as ≤10% of participants).    
 
  The internal consistency of the PROs was assessed using Cronbach’s alpha (α) (Cronbach, 
1951).  In line with conventions, α >0.7 was interpreted as acceptable (Nunnally, 1978).  
 
  Statistical analyses were conducted using IBM SPSS Statistics 23.  The data were downloaded 





Table 6.2: Definition of floor and ceiling ranges for each outcome measure  
 
 
Measure Range Floor Ceiling 
SF-26v2  
(sub-scales) 
Total score  
(higher = better) 
0-100 0-9 91-100 
QOLIBRI Total score 
(higher = better) 




(higher = better) 
0-100 0-9 91-100 
PCL-5 Total score 
(higher = worse) 
0-80 73-80 0-7 
PHQ-9 Total score 
(higher = worse) 
0-27 25-27 0-2 
GAD-7 Total score 
(higher = worse) 
0-21 20-21 0-1 
RPQ Total moderate/severe symptoms 
(higher = worse) 
0-16 16 0 
RAVLT 
 
Principal list items recalled  
(higher = better) 
0-75 0-6 69-75 
TMT Part A Completion time in seconds 
(higher = worse) 
10-101 91-101 n/a 
TMT Part B Completion time in seconds 
(higher = worse) 
29-301 271-301 n/a 
CANTAB RTI Median five-choice reaction time 








Total errors (adjusted) 
(higher = worse) 
0-194 91-194 0-8 
CANTAB AST 
 
Median reaction latency 
(higher=worse)  




(higher = worse) 
0-151 99-151 0-9 
CANTAB RVP 
 








Problems solved in minimum 
moves (higher = better) 
0-12 0 12 
TUG Completion time in seconds 
(higher = worse) 








6.4.1. Demographics and clinical characteristics  
  The participant selection process for the current study is displayed in Figure 6.2.  Of the 3692 
adult patients eligible for follow-up at 6 months post-injury, 2600 were successfully followed-up 
using the GOSE, and the GOSE was not obtained for 1091 patients.  A total of 2573 survivors 
scored in the ‘lower severe disability’ category or better.  The current study sample therefore 
comprised 69.7% of all patients eligible for 6-month follow-up.    
 
Figure 6.3 displays the GOSE completion rates for the ‘eligible sample’ for each of the CENTER-
TBI study sites and shows that follow-up rates on the GOSE were variable in this multicentre 

















Figure 6.2: Participant selection process for the current study   
 
Total CENTER-TBI 




Total no. patients aged 
< 16 years (n=149) 
 
Total no. patients with 
date of death within 6 months  
of injury (n=471) 
 
Total no. patients 
withdrawn from study 





Eligible sample (n=3692) 
(surviving adult patients eligible for 




Total no. patients without 
 6-month GOSE (n=1091) 
Total no. patients who were assessed  





Total no. patients in  
‘vegetative state’ (n=27) 
Current study sample (n=2573) 
(total no. patients who scored ≥2  
and were assessed using the GOSE 







Figure 6.3: GOSE completion rates for the ‘eligible sample’ and number of GOSE assessments due for each study site 
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  Tables 6.3 and 6.4 summarise the demographic and clinical characteristics of the current study 
sample (n=2573), and for patients without a 6-month GOSE (n=1091).  Completion rates were 
100% for age, gender, clinical care pathway, and AIS score, and above 94% for ASA physical 
health classification, cause of injury, GCS score, and ISS.  Completion rates for education, 
previous employment, marital status, and CT abnormality ranged from 78-94%.     
 
Table 6.3: Demographic characteristics for the current study sample and GOSE unknown  







  16-25 
  26-35 
  36-45 
  46-55 
  56-65 
  66-75 
  76-86 




























  Male 












 Caucasian  












  Primary school or less 
  Secondary school/High school  
  Post-high school training  
















Previous employment    
  Working (full-time or part-time)  
  Not working  
  Retired 

















  Partnered 
  Previously partnered 













Data are n (%) 
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Table 6.4: Clinical characteristics for the study sample and GOSE unknown  






ASA Physical Health  
  Healthy patient    
  Mild systemic disease   
  Severe/life threatening  















Cause of injury  
  Road traffic accident 
  Incidental fall 
  Violence/assault 
















Clinical Care Pathway  
  Emergency Room 
  Admitted to hospital ward 














  13-15 
  9-12 














  Present  











 Head & neck injury1 
  No injury/minor injury  
  Moderate injury  
  Serious injury  
  Severe injury  
  Critical injury 




















Non-head & neck injury2 
  No injury/mild injury 











1Head & neck injury = combined AIS score for head, neck and cervical regions   
2Non-head & neck injury (severe injury= Total ISS >7) 
 
  Patients in the current study sample were significantly older than those without a 6-month 
GOSE: the median (IQR) age was 51 years (32-65) for the study sample and 45 years (28-62) for 
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patients without a 6-month GOSE (p<0.001).  The two groups were comparable for gender 
(most patients were male) and race (most patients were Caucasian).  However, the current 
study sample had a higher level of education, significantly more of them were previously 
employed or retired, and significantly more of them were partnered or previously partnered 
prior to injury.   
 
  Patients in the current study sample were comparable to those without a 6-month GOSE for 
ASA physical health classification (most patients were healthy or had mild systemic disease 
prior to injury); clinical care pathway (around 80% of the patients were admitted to the hospital 
ward or intensive care unit upon recruitment to the study); GCS score (most patients had GCS 
scores in the 13-15 range); and injuries to other body regions (around one-third of the patients 
sustained severe non-head and neck injuries).  However, the study sample had a higher 
proportion of patients with injuries caused by road traffic accidents, more patients with CT 
abnormalities, fewer patients with minor or moderate head and neck injuries, and more 
patients who met criteria for major trauma (i.e., total ISS >15).  Total ISS scores were 
comparable for the current study sample (median = 16, IQR=9-26) and for patients without a 6-
month GOSE (median=14, IQR=8-25) (p=0.03).    
 
6.4.2. Scores on outcome measures  
  Scores were distributed on the GOSE as follows:  patients assigned to the ‘severe disability’ 
categories comprised 14.8% of the total study sample (lower SD = 7.8%; upper SD = 7%); 
patients assigned to the ‘moderate disability’ categories comprised 23.9% of the sample (lower 
MD = 10.3%; upper MD = 13.6%); and patients assigned to the ‘good recovery’ categories 
comprised 61.4% of the sample (lower GR = 21.7%; upper GR = 39.7%).   
 
  Scores for the CENTER-TBI outcome measures are displayed in Tables 6.5 (PROs) and 6.6 
(PerfOs).  One-way ANOVAs showed that scores were significantly different between GOSE 
categories on all outcome measures.  Scores for the SF-36v2, QOLIBRI, and QOLIBRI-OS were 
generally better (higher) for patients with better functional recovery and worse (lower) for 
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patients with poorer outcomes on the GOSE.  Scores on the SF-36v2 sub-scales, QOLIBRI and 
QOLIBRI-OS were generally indicative of good quality of life in patients assigned to the 
‘moderate disability’ and ‘good recovery’ categories.  However, patients with ‘severe disability’ 
generally had lower than average quality of life (i.e., below 45 on the SF-36v2 sub-scales and 
below 60 on the QOLIBRI).  Scores on the SF-36v2 MCS and PCS were in the normal range for 
patients with ‘good recovery,’ but below average for patients in the ‘severe disability’ and 
‘moderate disability’ categories.  Scores on the PCL-5, PHQ-9, GAD-7, and RPQ were better 
(lower) for patients with better functional outcomes. The PHQ-9 score for the total study 
sample was indicative of mild depression.  Patients in the ‘lower severe disability’ group scored 
in the moderate depression range, patients in the ‘upper severe disability,’ ‘moderate 
disability’, and ‘lower good recovery’ groups scored in the mild depression range, and the 
‘upper good recovery’ group scored in the ‘no depression’ range.  GAD-7 scores were in the 
mild anxiety range for the ‘severe disability’ and ‘moderate disability’ groups, and in the ‘no 
anxiety’ range for patients in the ‘good recovery’ groups.  
 
  Scores on the RAVLT were better (higher) for patients with better functional recovery and 
worse (lower) for patients with poorer functional outcomes.  RAVLT mean scores were within 
the normal range for the ‘moderate disability’ and ‘good recovery’ groups, but below the 
normal range for the ‘severe disability’ categories.  Scores on the TMT were better (lower) for 
patients with better functional outcomes, and worse (higher) for patients with poorer 
outcomes, but in the normal range (i.e., <100 seconds for Part A; <300 seconds for Part B) for all 
GOSE categories.  Scores on the CANTAB RTI, PAL, AST, and SWM were better (lower) for 
patients with better functional recovery and worse (highest) for patients with poorer functional 
recovery.  Scores on the CANTAB AST and RVP were more uniform across GOSE categories, but 
generally better (higher) for patients with better functional recovery.  Scores on the 10-meter 
walk and TUG were better for patients with better functional recovery and worse for patient 
with poorer functional outcomes.  TUG mean times were indicative of good physical mobility 




6.4.3. Data quality and validity in relation to post-TBI functional level   
Data completeness 
  Table 6.7 displays the outcome measure completion rates.  PRO completion rates were above 
80% for all outcome measures for the total study sample.  The RAVLT and TMT were completed 
by 68% of the total study sample, while CANTAB completion rates ranged from 52-59% of the 
total study sample and tests of physical functioning were completed by 51% of the total study 
sample.  Completion rates for all outcome measures were lowest for patients assigned to the 
‘lower severe disability’ category and higher for the other GOSE categories.  Completion rates 
were below 60% for all outcome measures for patients in the ‘lower severe disability’ group. 
Furthermore, PerfO completion rates were below 60% for patients in the ‘upper severe 
disability’ group.  CANTAB RVP and 10-meter walk/TUG completion rates were below 60% for 
patients in the ‘lower moderate disability,’ and all CANTAB sub-tests had completion rates 
below 60% for patients in the ‘upper good recovery’ group.    
 
  Tables 6.8 and 6.9 display the reasons provided for non-completion of the RAVLT, TMT, 10-
meter walk/TUG, and CANTAB sub-tests.  Around one third of the total study sample did not 
complete the RAVLT (n=820) or TMT (n=806):  no reason was provided for the RAVLT for 50% of 
these patients, and no reason was provided for the TMT for 44% of these patients.  Where 
reasons for non-completion were provided, ‘non-neurological/logistic reasons’ was the most 
common reason given overall (RAVLT = 42% of the patients; TMT = 48% of the patients).  
‘Cognitive/neurological deficits’ accounted for 7% of uncompleted RAVLT and 8% of 
uncompleted TMT.  A total of 1122 patients (44% of the total study sample) did not complete 
the 10-meter walk/TUG: no reason was provided for 38% of these patients, and where reasons 
were provided, ‘non-neurological/logistic reasons’ accounted for 57% of the patients, and 
‘cognitive/neurological deficits’ accounted for 5% of the patients.  ‘Invalid test’ accounted for a 
minority of non-completed assessments (RAVLT = 3 patients; TMT = 4 patients; 10-meter 
walk/TUG = 4 patients).  More than one-half of patients in the study sample did not complete 
the CANTAB sub-tests, and for around two-thirds of these patients, investigators did not 
provide a reason for non-completion. Where reasons were provided, ‘non-neurological/logistic 
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reasons’ was the most common reason given overall (RTI & PAL = 24% of the patients; AST, 
SWM & SOC = 29% of the patients; RVP = 31% of the patients).  ‘Cognitive/neurological deficits’ 
accounted for 3-7% of the uncompleted CANTAB sub-tests and ‘invalid test’ accounted for less 
than 1% of the uncompleted tests.  
 
Floor and ceiling effects 
  The proportion of patients scoring in the floor and ceiling ranges for each of the completed 
PROs and PerfOs are displayed in Tables 6.10 and 6.11.  The percentages shown are based on 
the total number of completed outcome measures for each GOSE category and for the total 
study sample.  The PROs with the largest proportion of ceiling effects overall were the RPQ 
(52%), PCL-5 (49%), SF-36v2 ‘role-emotional’ sub-scale (46%), GAD-7 (44%), SF-36v2 ‘physical 
functioning’ sub-scale (44%), PHQ-9 (42%), SF-36v2 ‘social functioning’ sub-scale (38%), SF-36v2 
‘role-physical’ sub-scale (32%) and SF-36v2 ‘bodily pain’ sub-scale (29%).  Ceiling effects were 
more common for patients with better levels of functional recovery (e.g.,  56-69% of patients in 
the ‘upper good recovery’ category scored in the ceiling range on the SF-36v2 ‘physical 
functioning,’ ‘role-physical,’ ‘social functioning,’ and ‘role-emotional’ sub-scales, and 63-81% in 
the ‘upper good recovery’ category scored in the ceiling range on the PCL-5, PHQ-9, GAD-7, and 
RPQ).  Ceiling effects were found mainly for patients in the ‘upper moderate disability’ and 
‘good recovery’ categories on the SF-36v2 sub-scales, whereas they occurred in all GOSE 
categories, apart from ‘lower severe disability,’ on the PCL-5, PHQ-9, GAD-7, and RPQ.  Floor 
effects were found on the SF-36v2 ‘physical functioning,’ ‘role-physical’ and role-emotional’ 
sub-scales for patients in the ‘severe disability’ categories.     
 
  Floor and ceiling effects were absent on the RAVLT, CANTAB SOC, and CANTAB RVP.  Floor 
effects were minimal on the TMT and TUG, but present for patients with ‘severe disabilities.’  
Floor effects were found for most GOSE categories on the CANTAB PAL and were most notable 
for patients with poorer levels of functioning.  Ceiling effects were found for most GOSE 
categories on the CANTAB PAL and SWM and were most notable for patients with better levels 
of recovery.  
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Internal consistency  
  Cronbach’s alpha (α) for the completed PROs are displayed in Table 6.12.  For the total study 
sample, internal consistency was as follows: QOLIBRI-OS, PCL-5, GAD-7, and RPQ (α ≥ 0.90); 
QOLIBRI (α = 0.85); PHQ-9 (α = 0.88); SF-36v2 sub-scales (α ranged from 0.79 to 0.95).  For the 
individual GOSE categories, all PROs had α ≥ 0.80, apart from the SF-36v2 ‘general health,’ 
‘social functioning,’ and ‘energy and fatigue’ sub-scales.     
146 
 
Table 6.5: Descriptive statistics for PROs for each GOSE category and for the total study sample 







Severe Disability Moderate Disability Good Recovery 
Lower Upper  Lower  Upper  Lower  Upper  
SF-36v2  
Physical functioning  
Role – physical  
Bodily pain  
General health  
Social functioning  
Role – emotional  
Energy & fatigue  








































































































































RPQ 20.7 (13.1) 17.2 (14.6) 20.1 (13.6) 16.9 (13.2) 12.3 (11.0) 3.9 (7.0) F=154.8, p<0.001 11.1 (12.5) 




Table 6.6: Descriptive statistics for PerfOs for each GOSE category and for the total study sample 







Severe Disability Moderate Disability Good Recovery 
Lower Upper  Lower  Upper  Lower  Upper  
ARAVLT total score 
ARAVLT 20-min delay 
ATMT Part A time  







































534 (189)  
55 (51)  
710 (146)  
50 (35)  
0.8 (0.1)  
7.4 (2.0)  
527 (186) 
56 (50)  
731 (194) 
42 (22)  
0.8 (0.1)  
7.2 (2.2)  
493 (203)  
39 (42)  
675 (190)  
34 (22) 
0.9 (0.1)  
7.8 (1.9)  
435 (147)  
28 (35)  
628 (167)  
 28 (20) 
0.9 (0.1)  
8.3 (2.1)  
440 (128)  
33 (41)  
642 (176)  
30 (23)  
0.9 (0.1)  
8.0 (2.1)  
415 (133) 
26 (33)  
610 (168)  
28 (22)  
0.9 (0.1)  







442 (152)  
32 (39)  
637 (176)  
30 (23)  
0.9 (0.1)  
8.1 (2.1)  


















Data are mean (SD) (Arounded to one decimal place; Brounded to nearest whole number)   
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Table 6.7: Outcome measure completion rates for each GOSE category and for the total study sample  



























SF-36v2 91 (46%) 135 (75%) 231 (88%) 312 (89%) 489 (88%) 848 (83%) 2106 (82%) 
QOLIBRI 87 (44%) 130 (72%) 228 (86%) 316 (91%) 490 (88%) 846 (83%) 2097 (82%) 
QOLIBRI-OS 78 (39%) 129 (71%) 234 (89%) 317 (91%) 501 (90%) 873 (86%) 2132 (83%) 
PCL-5 86 (43%) 125 (69%) 226 (86%) 310 (89%) 494 (89%) 847 (83%) 2088 (81%) 
PHQ-9 92 (46%) 127 (70%) 231 (88%) 314 (90%) 490 (88%) 841 (82%) 2095 (81%) 
GAD-7 91 (46%) 128 (71%) 231 (88%) 312 (89%) 489 (88%) 843 (83%) 2094 (81%) 






RAVLT 48 (24%) 100 (55%) 190 (72%) 275 (79%) 436 (78%) 691 (68%) 1753 (68%) 
TMT A&B 44 (22%) 98 (54%) 194 (73%) 280 (80%) 436 (78%) 702 (69%) 1754 (68%) 
CANTAB RTI 27 (14%) 76 (42%) 178 (67%) 237 (68%) 382 (68%) 542 (53%) 1442 (56%) 
CANTAB PAL 28 (14%) 80 (44%) 184 (70%) 248 (71%) 395 (71%) 589 (58%) 1524 (59%) 
CANTAB AST 25 (13%) 76 (42%) 176 (67%) 236 (68%) 383 (69%) 570 (56%) 1466 (57%) 
CANTAB SWM 25 (13%) 69 (38%) 172 (65%) 240 (69%) 378 (68%) 579 (57%) 1463 (57%) 
CANTAB RVP 23 (12%) 54 (30%) 155 (59%) 227 (65%) 347 (62%) 543 (53%) 1349 (52%) 
CANTAB SOC 19 (10%) 64 (35%) 168 (64%) 236 (68%) 363 (65%) 570 (56%) 1420 (55%) 
10-m walk & TUG 29 (15%) 61 (34%) 140 (53%) 225 (64%) 368 (66%) 500 (49%) 1323 (51%) 
Data are number (%, rounded to nearest whole number) of completed outcome measures for each GOSE category and overall 




Table 6.8: Reasons for non-completion of RAVLT, TMT, and 10-meter walk/TUG for each GOSE category and for the total sample 
 GOSE Classification   
Totals Severe Disability Moderate Disability Good Recovery 







  Non-neurological    
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 




















































  Non-neurological  
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 




























































  Non-neurological    
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 


















































Data are number (%, rounded to nearest whole number) of non-completed outcome measures for each GOSE category and for the 
total number of non-completed assessments.  A Non-completed RAVLT comprises 32% of the total study sample.  B Non-completed 




Table 6.9: Reasons for non-completion of CANTAB sub-tests for each GOSE category and for the total sample 
 GOSE Classification   
Totals Severe Disability Moderate Disability Good Recovery 









  Non-neurological    
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 


























































  Non-neurological  
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 


























































  Non-neurological    
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 




















































Data are number (%, rounded to nearest whole number) of non-completed outcome measures for each GOSE category and for the 
total number of non-completed assessments. A Non-completed CANTAB RTI comprises 57% of the total study sample.  B Non-
completed CANTAB PAL comprises 57% of the total study sample.  C Non-completed CANTAB AST comprises 55% of the total study 
sample.  D Non-completed CANTAB SWM comprises 55% of the total study sample.  E Non-completed CANTAB RVP comprises 59% of 













  Non-neurological  
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 



























































  Non-neurological    
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 



























































  Non-neurological    
  or logistic reasons   
  Cognitive deficits 
  Invalid test 
  Reason not 
  provided 




















































Table 6.10: Floor/ceiling effects on the completed PROs for each GOSE category and for the total study sample  
 GOSE Classification   
Total study 
sample 
Severe Disability Moderate Disability Good Recovery 
Lower Upper  Lower  Upper Lower  Upper  






Physical function 20% 2% 13% 12% 2% 19% 1% 27% 0% 40% 0% 67% 2% 43% 
Role – physical 34% 2% 19% 6% 16% 6% 10% 9% 2% 27% 1% 56% 7% 31% 
Bodily pain 1% 13% 3% 15% 2% 17% 2% 21% 1% 20% 0% 43% 1% 29% 
General health 8% 0% 1% 1% 2% 6% 1% 9% 1% 13% 0% 26% 1% 16% 
Social functioning 14% 10% 2% 11% 6% 11% 0% 19% 1% 32% 0% 61% 1% 37% 
Role - emotional 14% 15% 10% 22% 7% 23% 3% 33% 1% 41% 0% 68% 3% 46% 
Energy & Fatigue 3% 1% 4% 1% 5% 2% 2% 1% 1% 4% 0% 9% 2% 5% 
Mental Health 1% 8% 1% 10% 0% 6% 0% 7% 0% 9% 0% 19% 0% 13% 
MCS Score 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
PCS Score   0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
         
        
        
        
        
QOLIBRI  3% 0% 1% 3% 1% 4% 0% 7% 0% 12% 0% 32% 0% 17% 
QOLIBRI-OS        5% 4% 4% 5% 3% 3% 1% 7% 1% 13% 0% 32% 1% 18% 
PCL-5         0% 24% 0% 30% 0% 23% 0% 33% 0% 42% 0% 72% 0% 49% 
PHQ-9        0% 8% 1% 21% 1% 18% 0% 24% 0% 37% 0% 65% 0% 42% 
GAD-7       0% 22% 1% 28% 2% 26% 1% 31% 0% 38% 0% 63% 1% 44% 
RPQ 0% 14% 0% 25% 0% 22% 0% 33% 0% 43% 0% 81% 0% 52% 
Data are % patients scoring in the floor/ceiling ranges for each outcome measure (rounded to nearest whole number) 
F = Floor effect; C = Ceiling effect; n = number of patients who completed each outcome measure in each category   
 
         ≤10% of patients scored in floor/ceiling range                             11-49% of patients scored in floor/ceiling range 
         ≥50% of patients scored in floor/ceiling range 






Table 6.11: Floor/ceiling effects on the completed PerfOs for each GOSE category and for the total study sample  
 GOSE Classification   
Total study 
sample  
Severe Disability Moderate Disability Good Recovery 
Lower Upper  Lower  Upper Lower  Upper  
F C F C F C F C F C F C F C 
RAVLT 4% 0% 1% 0% 1% 1% 0% 1% 0% 1% 0% 1% 0% 1% 
ATMT Part A 27% 11% 6% 1% 4% 3% 4% 
ATMT Part B 32% 9% 5% 1% 2% 2% 3% 
ACANTAB RTI 0% 0% 0% 0% 0% 0% 0% 
CANTAB PAL 25% 4% 29% 14% 16% 22% 10% 36% 13% 36% 7% 38% 11% 33% 
ACANTAB AST 4% 7% 5% 2% 3% 2% 3% 
CANTAB SWM 8% 16% 0% 12% 1% 13% 0% 23% 1% 20% 1% 23% 1% 20% 
CANTAB RVP 4% 0% 0% 2% 1% 2% 0% 5% 3% 5% 1% 8% 1% 5% 
CANTAB SOC 0% 0% 0% 0% 0% 2% 0% 5% 0% 3% 0% 6% 0% 4% 
ATUG  21% 10% 2% 1% 1% 1% 2% 
Data are % patients scoring in the floor/ceiling ranges for each outcome measure (rounded to nearest whole number).                         
F = Floor effect; C = Ceiling effect.  n = number of patients who completed each outcome measure in each category     
ATMT, CANTAB RTI, CANTAB AST, TUG = floor effects only as these tests are time-based        










Table 6.12: Cronbach’s alpha of the completed PROs for each GOSE category and for the total study sample  
 GOSE Classification   
Overall α  
for each PRO  
Severe Disability Moderate Disability Good Recovery 








General health   
SF-36v2 
Social functioning  
SF-36v2 
Role - emotional 
SF-36v2 



















































































































QOLIBRI  0.86 0.81 0.81 0.83 0.83 0.88  0.85 
QOLIBRI-OS 0.88 0.88 0.85 0.86 0.88 0.89 0.91 
PCL-5 0.93 0.93 0.93 0.93 0.92 0.91 0.93 
PHQ-9 0.84 0.83 0.86 0.86 0.85 0.82 0.88 
GAD-7  0.87 0.89 0.92 0.91 0.89 0.88 0.91 




6.5. Discussion  
  This chapter examined the usefulness of implementing multi-dimensional outcome 
assessment across the spectrum of TBI recovery.  Patients were stratified according to GOSE 
category and the quality and validity of the CENTER-TBI outcome measures were evaluated 
in relation to level of global functioning.  The findings and their implications are discussed 
below.   
 
6.5.1. Data quality and validity in relation to post-TBI functional level 
Data completeness 
  The completeness of the CENTER-TBI outcome measures provides information about the 
feasibility of collecting individual assessments in different contexts of use, according to post-
TBI functional level at 6 months.  In this study, patients with better levels of functional 
recovery were found to have higher outcome completion rates than those with poorer 
functional recovery.  Completion rates were also found to be better for PROs than for 
cognitive assessments and tests of physical functioning.  PRO completion rates were 
generally very good across the spectrum of recovery (i.e., >70%), but fell below 50% for 
patients assigned to the ‘lower severe disability’ category.  PerfOs have greater logistic 
demands than PROs and were completed less frequently than PROS: certain CANTAB sub-
tests and tests of physical functioning fell below 60% across all GOSE categories.  The COA 
completion rates indicate that multi-dimensional outcome assessment was particularly 
difficult to implement with patients with greater functional limitations.  Nevertheless, there 
was limited information available about the reasons for non-completion of the outcome 
measures, as CENTER-TBI investigators provided reasons for non-completion of the RAVLT, 
TMT, and 10-meter walk/TUG assessments, but not for the PROs, and explanations for 
missing PerfOs were not always provided.     
 
  Explanations were missing for up to half of the uncompleted RAVLT, TMT, and 10-meter 
walk/TUG assessments, and for more than half of the uncompleted CANTAB sub-tests.  
Thus, the test completion codes were not used particularly well by CENTER-TBI 
investigators.  Where explanations were provided, ‘non-neurological or logistic reasons’ was 




minority of the uncompleted assessments in the ‘upper severe disability,’ ‘moderate 
disability’ and ‘good recovery’ categories, this reason accounted for up to one-quarter of 
uncompleted assessments in the ‘lower severe disability’ category.  Previous research has 
shown that patients who are more severely affected by TBI are particularly at risk of loss to 
follow-up due to cognitive impairment, physical disability, or logistic problems such as 
inability to travel independently to appointments (Sherer et al., 2010).  The findings from 
the current study appear to fit with this.  However, it is important to note that there could 
also be site specific reasons for non-completion of follow-ups, which could not be examined.    
 
  More than half of participants may be lost to follow-up in longitudinal TBI studies (Corrigan 
et al., 2003; Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, & McCrea, 
2017; Richter et al., 2019).  Patients who are lost to follow-up often have systematically 
different characteristics to those who are retained in longitudinal TBI studies (Corrigan et 
al., 2003; Krellman et al., 2014; Langley et al., 2010; Yue et al., 2013).  Thus, in the current 
study, the demographic and clinical characteristics of patients who were followed up using 
the GOSE were compared with survivors that were not followed-up.  A total of 30% of the 
patients eligible for follow up did not have a 6-month GOSE.  Some differences were found 
between the study sample and patients without a 6-month GOSE. For example, patients 
included in the study were older and better educated than those not followed up.  More of 
them were previously employed or retired and more were partnered or previously 
partnered prior to injury.  In addition, more patients in the study sample were injured in 
road traffic accidents, and a greater proportion had CT abnormalities and greater injury 
severity.  These demographic and clinical differences suggest that the study findings may 
have limitations in their generalisability.  
 
Floor and ceiling effects and internal consistency of PROs 
  When tailoring outcome assessments for TBI studies, investigators should consider basic 
psychometric properties, such as the sensitivity of instruments and the internal consistency 
of PROs (Andresen, 2000; Frost, Reeeve, Liepa, Stauffer, & Hays, 2007).  In this study, PRO 
ceiling effects were particularly common in the GOSE ‘upper good recovery’ categories, 
indicating that patients who had returned to their previous level of functioning typically 




concussion symptoms.  PRO ceiling effects were less common for patients with greater 
levels of disability, but occurred across the recovery spectrum on the PCL-5 and GAD-7, and 
were also apparent on the RVP for patients in the ‘upper severe disability’ category and 
better.  Ceiling effects were least common on the QOLIBRI and QOLIBRI-OS, affecting around 
one-third of patients in the ‘upper good recovery’ category, and a minority of patients in the 
other GOSE categories.  PRO floor effects were found to be minimal.  However, at least 20% 
of patients in the ‘lower severe disability’ category scored in the floor ranges on the SF-36v2 
‘physical functioning,’ ‘role-physical’ and ‘role-emotional’ sub-scales, suggesting that the SF-
36v2 lacks sensitivity when used with patients with greater levels of functional limitation.    
 
  The findings indicate that most of the PROs, apart from the QOLIBRI/QOLIBI-OS, lacked 
precision when completed by patients with better levels of functional recovery.  While 
measures of emotional adjustment focus on negative outcomes (i.e., symptoms of distress), 
the QOLIBRI scales assess both negative and positive aspects (i.e., life satisfaction).  As a 
result, the QOLIBRI measures are less prone to ceiling effects than measures of emotional 
distress.  The ceiling effects on the RPQ are of particular concern because they indicate that 
the scale does not pick up symptoms that are relevant to patients with greater functional 
limitations.  The RPQ was originally developed for patients with concussion/mild TBI and 
focuses on cognitive, emotional and somatic post-concussion symptoms (King et al., 1995; 
Potter, Leigh, Wade, & Fleminger, 2006; Smith-Seemiller, Fow, Kant, & Franzen, 2003).  
Thus, it does not capture problems of relevance to patients with severe disabilities, such as 
reduced mobility and communication difficulties, and should not be used with these 
patients as the results can be misleading.  Despite the ceiling effects, all PROs were found to 
have excellent internal consistency across the GOSE categories (i.e., α generally >0.80) 
(Nunnally, 1978), indicating that the internal structure of the questionnaires was not 
affected by the context in which they were used.   
 
  Ceiling effects were found for most GOSE categories on the CANTAB PAL and SWM sub-
tests, but were minimal or absent on the other cognitive tests.    The ceiling and floor ranges 
defined for the CANTAB sub-tests may contain information about performance which was 
not explored in this study.  Floor effects were found for patients with ‘severe disabilities’ on 




PAL test arises from patients who did not complete the whole test and have adjusted 
scores.  The adjusted scoring procedure for the PAL produces a large number of values that 
are outliers in comparison to patients who completed the test, and these outliers 
consequently appear in the floor range.  The floor range defined for the PAL in this study 
may therefore be problematic.  Despite this, there may be useful discrimination among low 
PAL scores.  Floor effects were minimal on the RAVLT, CANTAB AST, CANTAB SWM, CANTAB 
RVP, and CANTAB SOC.  Taken together, these findings indicate that most cognitive tests 
had good sensitivity, apart from the CANTAB PAL and SWM, which showed some lack of 
sensitivity across GOSE categories, and the TMT and TUG which may not be suitable for 
patients with the most severe disabilities.  
 
6.5.2. Recommendations  
  The current study demonstrates that the completeness and validity of TBI outcome 
measures in CENTER-TBI was affected by the context in which they were used.  A “sliding” or 
“flexible” approach (CENTER-TBI, 2018; Yue et al., 2018; Yue et al., 2013) may therefore be 
useful in retrospective analyses of CENTER-TBI data to ensure that outcome assessments are 
tailored appropriately for different TBI sub-groups.  The “flexible battery approach” is 
popular in clinical practice (Strauss et al., 2006; Sweet, Moberg, & Suchy, 2000a; Sweet, 
Moberg, & Suchy, 2000b), but has not been used routinely in TBI research, perhaps because 
the use of different measures for sub-groups of patients reduces comparability between 
patients and potentially introduces bias.  The use of a sliding approach to outcome 
assessment is not straightforward, and selection of appropriate measures is complex given 
the heterogeneous nature of TBI.  Nevertheless, the current study provides information 
about which outcome measures may be advisable for patients with different post-TBI levels 
of functional recovery.  This information will be useful when selecting measures for use in 
future prospective studies and provides guidance for performing retrospective analyses of 
data collected for CENTER-TBI.  It may also provide guidance for other InTBIR studies, such 
as TRACK-TBI.  The findings from the study also have implications for further refinement of 
the CDEs (Hicks et al., 2013), as they highlight the importance of selecting appropriate 
measures for use with specific TBI sub-groups.  There are study-specific reasons for choosing 





  Multi-dimensional outcome assessment was found to be particularly challenging to 
implement for patients with severe functional limitations.  Moreover, patients assigned to 
the ‘lower severe disability’ category had relatively poorer HRQoL and psychological status 
than patients with better levels of functional recovery, their performance was relatively 
poor on cognitive tests, and floor effects were found on assessments of physical functioning, 
such as the SF-36v2 ‘physical functioning’ and ‘role-physical’ sub-scales and TUG.  An 
abbreviated set of outcome measures could be useful for patients assigned to the GOSE 
‘lower severe disability’ category.  The choice of particular assessments for this group will 
depend on the purposes of the research, and further work is needed to validate measures 
that may be suitable.  In particular, the Functional Independence Measure (FIM) (Linacre, 
Heinemann, Wright, Granger, & Hamilton, 1994), could be used with patients who cannot 
self-report and who are unable to complete cognitive assessments or tests of physical 
functioning.  The FIM can be completed via observational ratings and proxy reports, making 
it suitable for use with patients who are unable to self-report (Wilde et al., 2010).  
Furthermore, it measures problems that the RPQ does not capture, such as impaired 
mobility and communication difficulties, making it suitable for patients with severe 
functional limitations.  As the FIM is best suited for in-patients settings, the potential for 
ceiling effects (Hall et al., 1996) should be taken into consideration, especially if used with 
patients who have been discharged from hospital.    
 
  Although as a group, most patients in the GOSE ‘good recovery’ categories reported no 
psychiatric symptoms or post-concussion symptoms in this study, investigators should be 
aware that some patients with good levels of functioning may meet diagnostic criteria for 
psychological disorders, such as clinical depression, anxiety, or PTSD, or have clinically 
relevant TBI symptoms or impaired performance on cognitive tests (Maas et al., 2017; 
Nelson, Ranson, Ferguson, Giacino, Okonkwo, Valadka, Manley, McCrea, et al., 2017).  
Measures that capture emotional adjustment, TBI symptoms, and cognition are therefore 
useful to include when assessing outcomes in patients who might otherwise appear to have 
fully recovered.  These assessments may be particularly helpful in distinguishing between 
patients in the ‘lower’ and ‘upper good recovery’ categories, given that the boundary 





  The findings from this study indicate that multi-dimensional outcome assessment in TBI 
research could be guided by stratifying patients into groups according to their level of 
functional recovery on the GOSE.  However, it should be borne in mind that the GOSE is not 
the only measure suitable for this purpose.  The GOAT has been used to stratify patients 
into sub-groups for further tailored outcome assessment in TRACK-TBI (Yue et al., 2018; Yue 
et al., 2013).  In future TBI research, alternative screening measures could be chosen instead 
of the GOSE or GOAT: one possibility is the Disability Rating Scale (DRS), another CDE 
measure of global functioning that is applicable across different functional levels (Hicks et 
al., 2013).  Another possibility would be to stratify patients by injury severity.  However, as 
the relationship between injury severity and outcome is indirect, tailoring outcome 
assessment according to GCS or ISS scores may not be particularly useful.  
   
  Detailed outcome assessments can be difficult to obtain in large-scale multicentre studies, 
such as CENTER-TBI.  Thus, a pragmatic approach was used in CENTER-TBI to maximise 
follow-up rates and outcome assessments could be completed in person, via telephone, via 
post, or using information from clinical records.  Steps were also taken to mitigate failure to 
return for follow-ups, such as contacting participants early in the follow-up time window, 
obtaining contact details for relatives/caregivers, and organising and paying for participant 
transportation (Bodien et al., 2018; Maas, Menon, et al., 2015).  Completion of the full set of 
CENTER-TBI outcome measures was estimated to take around 3 hours per participant, and 
the final selection of assessments depended on whether the patient was cognitively able, 
and whether the assessments were logistically feasible (Maas, Menon, et al., 2015).   
 
  In this study, PerfO completion rates were relatively low in comparison to PRO completion 
rates.  Investigators should therefore be mindful of practical constraints when obtaining 
follow-ups.  The QOLIBRI and QOLIBRI-OS were found to have good completion rates and 
sensitivity across all GOSE categories.  As meta-analyses have shown that response rates in 
longitudinal studies are better for questionnaires that are shorter in length (Edwards, 
Roberts, Sandercock, & Frost, 2004; Rolstad, Adler, & Ryden, 2011), it is advisable to use a 
short multi-dimensional PRO, such as the QOLIBRI-OS, along with the GOSE, in situations 
where it is difficult to complete detailed follow-ups.  This will help to minimise the burden of 




in different contexts of use. In situations where face-to-face visits are feasible, PerfOs 
should be a priority, since they provide information not available from other outcome 
measures.    
 
6.5.3. Limitations  
  This study demonstrates how multi-dimensional outcome assessment could be tailored 
according to post-TBI functional level.  However, some key limitations should be considered.  
Firstly, the completion rates obtained in CENTER-TBI may not be generalizable to other 
studies.  Outcome completion rates were better for patients with better levels of functional 
recovery.  However, from the information available, it was not possible to fully examine 
reasons for missing outcomes.  Test completion codes have previously been used in the 
citicoline brain injury treatment (COBRIT) trial (Bagiella et al., 2010b; Zafonte et al., 2009), 
and are useful in RCTs and CER as a means of recording reasons for missing outcome 
measures.  GOSE follow-up rates were highly variable between study sites, indicating that 
there may have been site-specific reasons for non-completion of other outcome measures.  
Furthermore, reasons were missing for up to half of the non-completed PerfOs, suggesting 
that test completion codes may be difficult to implement in large-scale multicentre studies 
such has CENTER-TBI.  It is unclear why the completion codes were not adopted by CENTER-
TBI investigators for all follow-ups.  However, investigator training and monitoring may have 
helped to ensure that test completion codes were completed more fully.  Secondly, 
outcome completion rates were found to be lowest for patients assigned to the ‘lower 
severe disability’ category.  Nevertheless, CENTER-TBI did not use a prospective flexible 
assessment approach and therefore did not include a suitable measure specifically suitable 
for patients with severe disabilities, i.e., the FIM (Linacre et al., 1994).  Further research is 
therefore needed to assess which instruments are suitable for use with patients with the 
greater functional limitations, who may be unable to complete measures of feeling (i.e., 
PROs) and functioning (i.e., PerfOs).  Thirdly, most patients in this study were assigned to 
the GOSE ‘good recovery’ categories and the sample mainly comprised patients scoring in 
the GCS 13-15 range, which is conventionally categorised as ‘mild’ TBI (Teasdale & Jennet, 
1974).  As patients with more severe injuries and poorer outcomes were a relatively small 





6.5.4. Conclusion  
  Outcomes can be difficult to obtain in large-scale multicentre studies, particularly for 
patients with the greatest levels of disability.  In this study, most of the PROs and some 
CANTAB sub-tests were found to lack sensitivity when completed by patients with better 
levels of functional recovery.  Furthermore, floor effects were found on the TMT, CANTAB 
PAL, and TUG for patients assigned to the ‘lower severe disability’ category: measures such 
as the FIM may therefore be appropriate for use with this sub-group.  The findings from this 
study indicate that a sliding approach could be used in TBI research to tailor outcome 
assessment for different contexts of use.  In particular, the GOSE could be used to guide 
detailed assessment in specific outcome domains for patients at different post-TBI 
functional levels.  An abbreviated set of outcome measures could be used with patients with 
the greatest levels of post-TBI functional limitation.  Furthermore, in situations where it is 
difficult to obtain detailed outcome assessment, a short multi-dimensional HRQoL measure, 
such as the QOLIBRI, may be used in addition to the GOSE.  The findings from this study 
provide information for researchers undertaking further analyses of the CENTER-TBI data, 
for future prospective TBI studies, and for refinement of the CDEs.  The particular measures 
that are selected in future TBI studies will depend upon the purposes of the research, but 
investigators should ensure that they are validated for specific contexts of use and capture 



















Integrated discussion and conclusions 
 
  This final chapter draws together the main findings and recommendations from the thesis 




















7.1.  Integrated discussion  
  Traumatic brain injury (TBI) affects multiple aspects of health and daily functioning.  
However, in the acute care setting, researchers have often used single measures of global 
functional outcome, such as the Glasgow Outcome Scale (GOS), to characterize recovery, 
and have not routinely incorporated measures that capture the multi-dimensional impact of 
TBI.  Multi-dimensional outcome assessment is an increasingly widely used, but poorly 
defined, concept in TBI research.  Pragmatically, outcome assessments can be considered to 
be multi-dimensional if they measure two or more aspects of health and daily life.  
However, consensus is lacking on which particular domains are key.  This thesis investigated 
the measurement of global functional outcome in TBI research and considered the role of 
the GOSE in multi-dimensional outcome assessment.  The International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) framework for clinical outcome 
assessments (COAs) was used to examine the usability of clinician-reported outcomes 
(ClinROs), patient-reported outcomes (PROs), and performance outcomes (PROs) in adult 
TBI.  Chapter 2 examined the patterns of use and reporting quality of COAs, including 
measures of global functional outcome, in clinical trials in adult TBI.  Chapters 4 and 5 
evaluated the comparability of clinician ratings and respondent reports of global functional 
outcome: firstly, by exploring whether the GOSE structured interview provides added value 
over the GOSE questionnaire, and secondly, by examining how clinician ratings on the GOSE 
structured interview and patient reports on the GOSE questionnaire relate to prognostic 
factors and other outcome domains.  Chapter 6 considered how multi-dimensional outcome 
assessment in TBI studies could be tailored for patients with different levels of global 
functional outcome.    
 
  The author of this thesis was responsible for conducting follow-up assessments with 
patients in NHS Lothian.  CENTER-TBI follow-ups could be completed in person, via 
telephone, via post, or using information from clinical records.  The outcomes data 
collection process involved contacting TBI patients or their relatives/caregivers in advance 
of the scheduled follow-up date, and, upon contact with the patient (and/or their relative or 
carer), the most appropriate approach to completing the outcome measures was 




CENTER-TBI investigators were encouraged to complete both versions of the GOSE, where 
possible.  Thus, the data provided an opportunity to compare clinician ratings and patient 
reports of global functional outcome in the studies presented in Chapters 4 and 5.   
 
  Consistent with CENTER-TBI guidelines, the author of this thesis took steps to mitigate 
against participant drop-out, such as contacting patients early in the follow-up time 
window, obtaining contact details for relatives/caregivers, and organising and paying for 
participant transportation (Maas, Menon, et al., 2015).  Despite this, data collection for 
some of the NHS Lothian follow-ups was found to be challenging: this experience appeared 
to be common among CENTER-TBI outcome assessors.  The process of contacting patients 
and organising follow-ups could be laborious at times.  Furthermore, clinical judgement was 
required when determining which assessments were appropriate for completion with 
specific individuals.  Of particular relevance to this thesis, several of the NHS Lothian 
patients were assigned to the GOSE ‘lower severe disability’ category upon follow-up 
(particularly at 3 months after injury).  These patients were unable to complete the full set 
of CENTER-TBI outcome measures, highlighting the difficulties associated with implementing 
multi-dimensional outcome assessment across spectrum of recovery, and providing the 
motivation for the study presented in Chapter 6.     
 
7.1.1. Participant characteristics  
  The participants described in this thesis were selected from the CENTER-TBI core study 
(Maas, Menon, et al., 2015).  The patients included in the study samples were, on average, 
older than those enrolled in European studies in previous decades (Murray et al., 1999), and 
approximately one-quarter were 66 years or older and retired.  Around two-thirds of the 
patients were male, and almost all of them were Caucasian.  Incidental falls were the most 
common cause of injury overall, followed by road traffic accidents.  Consistent with previous 
studies (Leong et al., 2013; van Leeuwen et al., 2012), a considerable proportion of the 
participants in the study samples had co-morbid extracranial injuries (i.e., 34-40% had 
severe injuries to non-head and neck body regions).  Approximately two-thirds had scores in 
the GCS 13-15 range (Teasdale et al., 1979).  Furthermore, 44-51% of the participants in the 
study samples were admitted to ICU, around half had CT abnormalities, and total ISS scores 





  The demographic and clinical characteristics of the study samples are broadly comparable 
to the total CENTER-TBI core study sample and reflect the changing epidemiology of TBI in 
Europe: the average age of TBI is increasing, and falls are now the most common cause of 
injury in high-income countries, particularly in older adults (Brazinova et al., 2016; Maas et 
al., 2017; Peeters et al., 2017; Peeters et al., 2015).  The increased incidence of TBI in older 
adults has implications for the use of study outcome measures.  For example, as cognitive 
functioning declines with increasing age (Strauss et al., 2006), it may be necessary to adjust 
for the effect of age on performance on cognitive assessments in TBI studies.  Adjustments 
for potentially confounding covariates such as age and acute stage prognostic factors (e.g., 
injury severity) were not performed in this thesis, but the impact of these factors will be 
examined in further CENTER-TBI analyses.  
 
7.1.2. Approaches to measuring global functional outcome  
  The first main theme of this thesis was the comparison between clinician-ratings and 
patient-reports on the GOSE.  This comparison is important for two main reasons.  Firstly, 
despite the drive towards use of PROs in clinical research (U.S. Food & Drug Administration, 
2009; Walton et al., 2015), patients with TBI may be unable to provide an accurate self-
report on the GOSE questionnaire (Prigatano, 2005a, 2005b; Wilson et al., 2002).  Secondly, 
as investigators are often not masked in observational studies, such as CENTER-TBI, clinician 
ratings on the GOSE structured interview may be influenced by knowledge about prognostic 
factors, e.g., injury severity (Sherer et al., 2010), as well as knowledge about performance 
on other outcome measures, e.g., cognitive tests.  CENTER-TBI provided an opportunity to 
examine these issues as a pragmatic approach was taken to data collection, and the GOSE 
could be completed as a clinician-rated structured interview (Wilson et al., 1998) or as a 
self-completion questionnaire (Wilson et al., 2002).  
 
  The systematic review in Chapter 2 (Horton et al., 2018) demonstrated that the GOS/E is 
the most commonly used COA in previous clinical trials in adult TBI.  However, the review 
also showed that the GOS/GOSE was not used uniformly across the studies and insufficient 
information was provided about how it was used.  The scale was mainly used in RCTs in 




collected information via guided or structured interviews rather than using the GOSE 
questionnaire.  In terms of reporting quality, none of the articles provided information 
about whether extracranial injuries were included in GOS/GOSE ratings.  Most articles did 
not state whether patients with pre-existing severe disability were excluded, or who the 
respondent was.  Furthermore, around half of the articles did not state the primary method 
of contact for GOS/GOSE assessments.  As discussed previously, heterogeneity in 
implementing the GOS/E is potentially problematic because different modes of data 
collection may not be equivalent (Eremenco et al., 2014; Powers et al., 2017; Walton et al., 
2015).  Thus, the way in which the GOS/GOSE is used may influence study findings.  As 
noted in Chapter 2, this is an important issue when pooling data for secondary analyses.                
 
  The findings from Chapter 2 provided the motivation for the studies presented in Chapters 
4 and 5.  Chapter 4 demonstrated that GOSE structured interview and GOSE questionnaire 
scores were similar in different contexts of use, including with patients with pre-existing 
functional limitations, epilepsy, CT abnormalities, and moderate-to-severe TBI.  In addition, 
Chapter 5 showed that GOSE assignment was not affected by investigator bias or by the 
patient’s perspective.  Together, these findings indicate that clinician ratings and patient 
reports of global functional outcome are broadly comparable.  Nevertheless, the findings 
also revealed that there are certain circumstances in which it is advisable to supplement 
information obtained via the GOSE questionnaire with information from the GOSE 
structured interview.  Firstly, due to the subjective nature of TBI-related symptoms, the 
boundary between the ‘lower’ and ‘upper good recovery’ categories can be difficult to 
determine.  In Chapter 4, the impact of TBI symptoms on daily functioning was found to be 
under-reported on the GOSE questionnaire.  This issue can at least partly be overcome by 
collecting additional information about symptoms using the GOSE structured interview, or 
by re-scoring the symptoms section of the GOSE questionnaire.  Secondly, Chapter 4 
showed that inconsistencies can occur between clinician ratings and respondent reports 
when the GOSE is completed with patients with greater levels of disability and those with 
extracranial injuries, but only in the first few months after injury.  The GOSE structured 
interview is therefore useful at 3-month follow-up when assessing patients with greater 
levels of disability, and for gathering additional information about the reasons for functional 




  Previous TBI studies have provided limited information about the comparability of clinician 
ratings and patient reports of global functional outcome.  Thus, the studies presented in 
Chapters 4 and 5 are novel because they directly compared clinician ratings and patient 
reports of global functional outcome in large samples of TBI patients.  The large number of 
participants in CENTER-TBI made it possible to conduct a detailed investigation of 
agreement on individual GOSE sections; enabled exploration of the effect of factors such as 
extracranial injury on GOSE assignment; and allowed the effect of investigator bias and the 
patient’s perspective on GOSE scores to be examined, none of which have formally been 
investigated.  Nevertheless, as CENTER-TBI was an observational project, the studies 
presented in Chapters 4 and 5 did not have an experimental design.  The GOSE was not 
collected in a uniform way across the CENTER-TBI study sites.  Thus, systematic comparisons 
between different modes of data collection (i.e., face-to-face versus telephone interviews, 
and patient versus proxy reports on the GOSE questionnaire) were not possible. 
Additionally, as patient self-awareness was not measured directly as part of the CENTER-TBI 
follow-ups, the study presented in Chapter 5 lacked verification about the accuracy of 
patient’s self-reports.   
 
  In light of the limitations presented above, it would be useful to make systematic 
comparisons between different modes of GOSE data collection in a future prospective study 
in which investigators were masked.  Information could be obtained from independent 
investigators via face-to-face and telephone interviews, and then compared, to determine 
whether face-to-face contact with the investigator adds any added value when assessing 
functional recovery.  A direct comparison between patient reports and reports from other 
informants was not possible in this thesis due to the way that the CENTER-TBI outcomes 
were collected.  However, as lack of self-awareness may be problematic when measuring 
global functional outcome, particularly when assessing patients with greater injury severity 
(Prigatano, 2005a, 2005b), it would also be useful compare patient and proxy reports on the 
GOSE questionnaire and use the Patient Competency Rating Scale (Prigatano & Fordyce, 
1986) to verify the accuracy of patients’ self-reports.  These suggestions notwithstanding, it 
is important to note that systematic comparisons between GOSE approaches are difficult to 




difficult to achieve, especially if other outcome assessments are incorporated.  Conducting 
such a study may therefore be difficult and only practical in certain settings.   
 
  Taken together, the findings from Chapters 4 and 5 indicate that information collected via 
structured interviews makes little overall difference to GOSE assignment and suggest that 
mixed modes of GOSE collection can be used to facilitate participant retention in studies 
with pragmatic constraints.  CENTER-TBI investigators were encouraged to complete both 
versions of the GOSE, if possible, and the scale was not used uniformly across study sites 
(Maas, Menon, et al., 2015).  A composite GOSE score (Wilson & Horton, 2018), comprising 
clinician ratings and patient reports, was therefore created as part of the CENTER-TBI data 
curation process, to maximise outcome completion rates.  When creating the GOSE 
composite, information collected via the GOSE structured interview was prioritised, if 
available.  As the information obtained via the GOSE structured interview and GOSE 
questionnaire was found to be comparable in Chapters 4 and 5, the GOSE composite was 
used in Chapter 6 of this thesis.   
 
7.1.3 Tailoring outcome assessment in relation to level of global outcome  
  The second main theme in this thesis was consideration of the usefulness of tailoring multi-
dimensional outcome assessment for patients with different levels of functional recovery.  
CENTER-TBI and TRACK-TBI both have the goal of validating individual outcome measures in 
different contexts of use.  Furthermore, both projects are investigating approaches to 
tailoring outcome assessments for TBI sub-groups, for example, using the Galveston 
Orientation and Amnesia Test (GOAT) (Yue et al., 2018; Yue et al., 2013) or injury severity 
(CENTER-TBI, 2018) to stratify patients.  In clinical practice, neuropsychological assessments 
are tailored to the particular needs of the individual, and the choice of instruments often 
depends on the information available about the patient, as well as the specific reasons for 
referral (Strauss et al., 2006).  The “flexible battery approach,” which incorporates variable 
but routine sub-sets of tests for different patient types, has been favoured by clinical 
neuropsychologists for decades (Sweet et al., 2000a; Sweet et al., 2000b).  However, the 
concept of a “flexible” or “sliding” approach to outcome assessment is relatively novel in TBI 
research, and there is currently no consensus about how tailored outcome assessments 





  Patients assigned to different GOSE categories represent different contexts of use for 
outcome measures (Maas et al., 2017; Nelson, Ranson, Ferguson, Giacino, Okonkwo, 
Valadka, Manley, McCrea, et al., 2017; Walton et al., 2015).  Therefore, the study presented 
in Chapter 6 considered the quality and validity of the CENTER-TBI outcome measures when 
used with patients assigned to different GOSE categories.  The applicability of individual 
outcome measures has not been formally investigated in relation to the patient’s level of 
functional recovery.  However, it is presumably already taken into consideration by 
researchers when planning and designing TBI studies.  Chapter 6 showed that multi-
dimensional outcome assessment was more challenging to implement with patients with 
greater functional limitations.  Furthermore, ceiling effects were found to be present on 
several outcome measures, mainly for patients with better functional levels, whereas floor 
effects were minimal and only occurred in the ‘lower severe disability’ group.  These 
findings demonstrate that the applicability of outcome assessment in TBI research is 
strongly driven by level of global functional outcome.  Due to the heterogeneity of TBI, few 
outcome measures can be applied with all patients.  A one-size-fits-all approach to 
characterising outcomes in TBI studies is therefore insufficient, and consistent with CENTER-
TBI and TRACK-TBI objectives, a tailored approach is necessary to characterise recovery in 
different TBI sub-groups.  It should be noted, however, that use of a tailored approach may 
not be applicable in all TBI study types, as it reduces the comparability between patient sub-
groups and potentially introduces bias.      
 
  Detailed outcome assessments can be difficult to obtain in large-scale multicentre studies.  
This is potentially problematic because selective attrition of participants in longitudinal TBI 
studies can result in systematic bias is study findings (Corrigan et al., 2003; Krellman et al., 
2014; Langley et al., 2010).  Completion of the full set of CENTER-TBI outcome measures was 
estimated to take around 3 hours per patient and assessments were conducted if they were 
logistically feasible and patients were cognitively able (Maas, Menon, et al., 2015).  
Cognitive assessments and tests of physical functioning were found to have the lowest 
completion rates: these measures must be completed face-to-face, making them more 
difficult to obtain than outcomes that can be collected via telephone or post.  Furthermore, 




for patients with severe disabilities.  Due to the limited information available, it was not 
possible to make conclusions about the reasons for non-completion of these outcome 
measures in Chapter 6.  Failure to complete CENTER-TBI follow-ups was partly due to logistic 
constraints and patient-specific limitations, but it could also be due to site-specific issues 
that could not be addressed in this thesis.  There was variability in the follow-up completion 
rates between study-sites.  Thus, the outcome completion rates presented in this thesis may 
not be generalizable beyond CENTER-TBI.    
 
  The findings from Chapter 6 are relevant to other researchers as they provide guidance for 
selecting outcome measures in different contexts of use (Walton et al., 2015), i.e., according 
to post-TBI functional level.  The findings are of relevance to further CENTER-TBI analyses.  
Firstly, they will inform other CENTER-TBI outcomes analyses, which will examine the 
outcome measures in more detail with the overarching objective of developing a multi-
dimensional tool for classifying outcomes after TBI (CENTER-TBI, 2018).  The responsiveness, 
sensitivity, and parsimony of the outcome measures will be examined by other CENTER-TBI 
researchers, and structural equation modelling will be done to identify predictors, 
moderators and confounders in TBI outcome assessment.  The findings from Chapter 6 will 
also inform other strands of the CENTER-TBI project and may be useful for investigators with 
a background in acute TBI, who have limited knowledge about outcomes research.  The 
information obtained about outcome completion rates for different GOSE categories could 
be used to help guide the selection of outcome measures for comparative effectiveness 
research (CER).  CER aims to improve clinical decision-making by investigating differences in 
care and outcome in observational studies (Maas, Menon, et al., 2015).  It exploits the 
natural variability in clinical practice and allows investigators to identify which treatments 
work best in ordinary clinical settings (Maas et al., 2012).  Selection of sensitive outcome 
measures with good completion rates is important in CER because it reduces the likelihood 
of bias due to selective attrition of patients (i.e., patients with severe disabilities may have 
poor completion rates due to cognitive or physical impairment).   
 
  Chapter 6 also provides guidance for designing future prospective studies as it indicates 
that researchers should be aware of practical constraints when designing studies and 




challenging to obtain, a short TBI-specific PRO, such as the QOLIBRI or QOLIBRI-OS (von 
Steinbüchel, Wilson, Gibbons, Hawthorne, Hofer, Schmidt, Bullinger, Maas, Neugebauer, 
Powell, von Wild, Zitnay, Bakx, Christensen, Koskinen, Sarajuuri, et al., 2010; von 
Steinbüchel et al., 2012), could be used in addition to the GOSE to gather information about 
the multi-dimensional impact of TBI.  Where more detailed follow-ups are practical, the use 
of cognitive tests with good sensitivity across the spectrum of recovery is advisable.  
Measures of emotional adjustment should also be included, where practical, to capture 
problems such as depression and anxiety in patients who may otherwise appear to have 
fully recovered on the GOSE (Maas, Menon, et al., 2015; Nelson, Ranson, Ferguson, Giacino, 
Okonkwo, Valadka, Manley, McCrea, et al., 2017).   
 
  Multi-dimensional outcome assessment has not been implemented routinely in previous 
TBI clinical trials, particularly in acute study settings (Horton et al., 2018).  Thus, researchers 
designing future studies, particularly those comparing the effectiveness of acute treatments 
and interventions, should aim to select outcome measures that capture the multi-
dimensional impact of TBI, while also taking practical issues into consideration.  The findings 
from this thesis indicate that while completion rates for the GOSE are relatively good 
compared to other outcomes, it does not provide sufficient detail about specific aspects of 
the patient’s functioning and feeling which are relevant in TBI.  TBI researchers may 
therefore need to compromise between using a brief, but blunt measure, such as the GOSE, 
which is appropriate for use across the TBI spectrum; versus a more detailed set of outcome 
assessments, which capture the multi-dimensional impact of TBI, but which are time 
consuming and potentially difficult to obtain.   
 
  Chapter 6 provides information about the sensitivity and internal consistency of the 
CENTER-TBI outcome measures with patients with different levels of post-TBI functioning.  
However, further validation of TBI outcome measures is now required.  CENTER-TBI and 
TRACK-TBI researchers are currently working on this task.  The data from these studies will 
be used to validate outcome measures in different contexts of use (i.e., paediatric TBI, adult 
TBI, epidemiology, acute hospital, moderate-to-severe TBI rehabilitation, mild 
TBI/concussion), and this will inform further refinement of the NINDS CDEs (National 




Wilde et al., 2010) were introduced to reduce heterogeneity in the use of outcome 
measures in TBI studies.  Future refinement of the CDEs will allow researchers to pool data 
for secondary analyses.  Nevertheless, variability in the use of outcome measures is likely to 
remain an issue in TBI research, due to the complexity of TBI, heterogeneity in TBI studies, 
and wide range of outcome measures available.  
 
7.1. Conclusions 
  This thesis makes an original contribution to the field of TBI research: firstly, because it 
highlights the issues of heterogeneity, limited use of multi-dimensional outcomes, and 
incomplete reporting of outcome measures in clinical trials in TBI; secondly, because it  
directly compares clinician ratings and patient reports of global functional outcome in TBI 
using large numbers of patients;  and thirdly, because it considers the applicability of multi-
dimensional outcome assessment in TBI studies in relation to level of global functional 
outcome.  Chapters 4 and 5 demonstrate that clinician ratings and patient reports provide 
broadly comparable information about global functional outcome after TBI.  Furthermore, 
Chapter 6 suggests that TBI outcome measures could be tailored to capture the multi-
dimensional impact of TBI across the spectrum of functional recovery.  These findings 
indicate that mixed modes of GOSE data collection can be used to maximise follow-ups in 
studies with pragmatic constraints.  The findings also demonstrate that the applicability of 
individual outcome measures is strongly driven by level of global functional outcome.  This 
PhD project was part of the CENTER-TBI outcomes research strand (Maas, Menon, et al., 
2015).  The findings therefore have immediate implications for further CENTER-TBI analyses.  
The findings also have implications for selecting outcome measures in future prospective 
studies, for refining the CDE outcome measures in TBI (Hicks et al., 2013; Wilde et al., 2010), 
for conducting comparative effectiveness research (CER) (Maas et al., 2012), and for pooling 
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Appendix 2: General Study Characteristics and Risk of Selection Bias  
General Study Characteristics Risk of 
Selection Bias 
Acute drug studies (neuroprotection) 
Treatment/ 
Intervention 







(time point)  
Secondary outcome(s) or other 






(Chen et al., 2002) 
120 33.6 (18-60) severe acute 
single centre 
Glasgow Outcome Scale (GOS) 
(6 months) 
n/a not stated U U 
CRASH 
Corticosteroid 
Study (Edwards et 
al., 2005; Roberts 
et al., 2004) 




GOS (6 months) n/a 97% U L 
CRASH-2 
Tranexamic Acid  
(Perel et al., 2011) 
270 36.5 (adults) all acute 
multicentre 
modified Oxford Handicap Scale 
(mOHS) (6 months) 
n/a 100% L L 
Intensive Insulin 
Therapy (Cinotti et 
al., 2014)  




GOS (90 days after ICU 
admission) 
mortality, neurological outcome 
at different time points  
100% L L 
Mannitol  
(Cruz, Minoja, & 
Okuchi, 2001) 
178 29 (adults)  severe acute 
single centre 





(Cruz, Minoja, & 
Okuchi, 2002) 
141 30 (adults) severe acute 
single centre 













including Finger Tapping Test, 
Namewriting Test, Seashore 
Rhythm Test, Trail Making Test 
(TMT) Part A & B, Stroop Color 
Word Tests Parts 1 &2, 
Wechsler Memory Scale – 
Revised (WMS-R): Attention 
and Concentration Index, 
Logical Memory and Visual 
Reproduction, Selective 
Reminding Test  (SRT)(recall 
and delayed recall), Kimura 
Memory for Designs Test, 
Wechsler Adult Intelligence 
Scale (WAIS) Verbal Intelligence 
Quotient (VIQ) and 
Performance Intelligence 
Quotient (PIQ), Controlled Oral 
Word Association Test (COWAT)   
(1/6/12 months) 
n/a 1m = 87%                
6m = 53%              





Erythropoietin (Li et 
al., 2016)  
159 42.3 (15-71) severe acute 
single centre 
GOS (3 months after treatment. 
Patients treated within 6 hours 
of injury) 
n/a 92% U U 
Pharmos 
dexanabinol trial 
(Maas et al., 2006) 
861 32.5* (16-65) severe acute 
multicentre 
Glasgow Outcome Scale - 
Extended (GOSE) (6 months) 
Barthel Index, SF-36 98% L L 
Erythropoietin, 
EPO-TBI trial 
(Nichol et al., 2015) 




GOSE (6 months) n/a 98% L L 
Erythropoietin 
(Robertson et al., 
2014) 




GOS (GOSE) (6 months) Disability Rating Scale (DRS)  91% U L 




et al., 2009) 




Serious Adverse Events (15 days 
after injury) 
GCS, Disability Rating Scale 
(DRS), mOHS 
96% L L 
SYNAPSE Trial of 
progesterone 
(Skolnick et al., 
2014) 
1195 34.5*(16-70)  severe acute 
multicentre 
GOS (6 months) GOSE, SF-36 99% L L 
Magnesium 
(Temkin et al., 
2007) 






Composite comprising 39 
individual measures, including 
mortality, seizures, functional 
n/a 93% 
neuropsych. 





measures (i.e., functional status 
examination (FSE), GOSE, Sf-
36), and cognitive tests (i.e., 
Weschsler Abbreviated Scale of 
Intelligence (WASI) Full Scale 
IQ, WAIS III – Processing Speed 
Index, SRT, Paced Auditory 
Serial Additional test (PASAT), 
TMT A&B, Finger Tapping Test, 
Grooved Pegboard Test, 
COWAT, Stroop Test (1&2), 
Kimura Memory for Designs 
Test, Galveston Orientation and 
Amnesia Test (GOAT) 
(6 months)  
Progesterone, 
PROTECT III trial 
(Wright et al., 
2014) 




GOSE (6 months) DRS 94% L L 
Intensive insulin 
therapy (Yang et 
al., 2009) 
240 45.5 (adults)  severe acute 
single centre 
Mortality (6 months) GOS 97% U L 
Traxoprodil 
(Yurkewicz, 
404 31.3 (16-70)  severe acute 
multicentre 
GOS (6 months) DRS, Cognitive Abilities 
Screening Instrument (CASI), 









et al., 2013) 






Intracranial haemorrhage  
(at hospital discharge) 
GOS 100% L L 
Citicoline, COBRIT 
trial (Zafonte et al., 
2012) 






TBI clinical trials network 
battery (i.e., TMT A&B, GOSE, 
COWAT, California Verbal 
Learning Test (CVLT), WAIS III 
Processing Speed Index, and 
Digit Span, Stroop test (1&2)) 
(90 days) 
n/a 82% L L 
Hypothermia trials 






Primary outcome  








(Andrews et al., 
2015) 







GOSE (6 months) modified 
Oxford Handicap Scale (mOHS) 
97% L L 
Hypothermia 
(Clifton et al., 2001) 
392 31.5 (16-65) severe acute 
multicentre 
GOS (6 months) Neurobehavioural Rating Scale-
Revised, DRS, GOAT, SRT, Rey-
Osterrieth Complex Figure Test, 
Symbol Digit Modalities Test, 




TMT Part B, COWAT, Grooved 
Pegboard Test 
Hypothermia 
(Clifton et al., 2011) 
232 28.5 (16 - 45) severe acute 
multicentre 
GOS (6 months) DRS 92% L L 
Hypothermia (Jiang 
et al., 2006) 
215 32.9 (18-45) severe acute 
multicentre 





Hayashi, & Ohashi, 
2015) 
148 39 (15-69) severe acute 
multicentre 
GOS (6 months) n/a 99% L L 
Physiology of 
hypothermia (Yan, 
Tang, Deng, Zhong, 
& Yang, 2010) 
148 27.3 (18-64)  severe acute 
single centre 
Physiology & GOS (1-7 years) GOS unclear U U 
Hypothermia (Zhi, 
Zhang, & Lin, 2003) 
396 42.5 (15-65) severe acute 
single centre 
GOS (6 months) n/a 
 
100% U U 
Surgical trials 






Primary outcome  








(DECRA) (Cooper et 
155 24.2* (15-59) severe acute 
multicentre 





STICH Surgical trial 
(Gregson et al., 
2015; Mendelow et 
al., 2015) 
170 48 (16-83) all acute 
multicentre 
Postal GOSE (6 months) Rankin Scale, EuroQol (EQ-5D) 99% L H 
Decompressive 
Craniectomy 
(Hutchinson et al., 
2017) 
408 33.6 (10-65) severe acute 
multicentre 
GOSE (6 months) GOSE, SF-36 98% L L 
Standard vs limited 
Craniectomy  
(Jiang et al., 2005) 
486 44.5 (14-70)  severe acute 
multicentre 
GOS (6 months) n/a 100% L L 
Surgical trial of 
Decompression  
(Li et al., 2012)  
182 36.8 (14-72) severe acute 
single centre 
GOS (5-60  months) n/a 91% U U 
Surgical trial of 
Craniectomy (Lü et 
al., 2003) 




GOS (6 months) n/a 100% U U 
Other acute studies (pre-hospital intubation, osmotic therapy, technology/monitoring, bed rest) 






Primary outcome  








et al., 2010) 











(Bulger et al., 2010) 









(Cooper et al., 
2004) 




GOSE (6 months)  Functional Independence 
Measure (FIM), Rancho Los 
Amigos Scale  




(Chesnut et al., 
2012) 




Composite with 21 components 
including survival, GOAT, GOSE, 
DRS, Mini Mental Status Exam 
(MMSE), Spanish Verbal 
Learning Test, Brief VisuoSpatial 
Memory Test, WAIS III Digit 
Symbol and Symbol Search, 
Grooved Pegboard Test, TMT 
Part A, Color Trails 1&2, 
COWAT, Category Fluency - 
Animals and Actions, PASAT   
(6 months) 
n/a 92% L L 
Technology/monito
ring - CPP display 









Cain, Newell, & 
Mitchell, 2006) 
Bed rest for mTBI  
(de Kruijk, Leffers, 
Meerhoff, Rutten, 
& Twijnstra, 2002) 




16 post-traumatic complaints 
including cognitive, vegetative, 
dysthymic, and physical 
symptoms, SF-36  
(2 weeks/3 months/6 months) 
n/a 74% L U 
Post-acute drug studies 






Primary outcome  







(Giacino et al., 
2012) 
184 36.4 (16-65)  severe post-acute 
multicentre 
DRS (4 weeks after treatment. 
Patients recruited within 4-16 
weeks of injury) 
Coma Recovery Scale-Revised 
(CRS-R) 
98% L L 
Amantadine 
(Hammond et al., 
2015) 





(NPI-I) most problematic item  
(28 days after treatment. 
Patients recruited at least 6 
months after injury) 
NPI most aberrant item, NPI 
distress score, Clinical Global 
Impressions (CGI) 
94% L L 
Armodafanil 
(Menn, Yang, & 
Lankford, 2014) 




multiple sleep latency test 
(MSLT), Clinical Global 
Impressions of Change (CGI-C)  
(2, 4, 8, 12 weeks. Patients 
Epworth Sleepiness Scale (ESS), 
MSLT, Clinical Global 
Impression of Severity of Illness 
(CGI-S), Clinical Global 




recruited 1-10 years post-
injury) 
Impression of change (CGI-C) 
Rivastigmine (Silver 
et al., 2006) 
157 37.1 (18-50)  all post-acute 
multicentre 
Cambridge Neuropsychological 
Test Automated Battery 
(CANTAB) Rapid Visual 
Information Processing (RVP), 
Hopkins Verbal Learning Test 
(HVLT) (12 weeks. Patients 
recruited at least 1 year after 
injury) 
CANTAB (RVP, Spatial Working 
Memory (SWM), Paired 
Associates Learning (PAL) & 
Reaction Time (RT)), HVLT, 
COWAT, WAIS-III Digit Span & 
Letter-Number Sequencing, 
TMT A&B, Neurobehavioural 
Functioning Inventory (NFI), 
Beck Depression Inventory II 
(BDI-II), Deiner Satisfaction with 
Life scale, CGI-C 
85% L L 
Rivastigmine 
(Tenovuo, Alin, & 
Helenius, 2009) 




Symptom Checklist 90 (SCL-90), 
Deiner Satisfaction with Life 
Scale, Cognispeed tests (i.e., 
simple reaction time, ten-
choice reaction time, 
subtraction and vigilance tests). 
(Baseline, end of period 1, after 
wash-out, after 2nd period. 
Patients recruited at least 1 
year after injury) 
 




Post-acute rehabilitation/counselling studies 
Study  n Mean/ 
median* age, 
(range) 
TBI Severity Study 
Setting 
Primary outcome  








(Bedard et al., 
2014) 




Beck Depression Inventory-II 
(Post 10-week intervention. 
Time since TBI not reported) 
PHQ-9, SCL-90-R, Philadelphia 
Mindfulness Scale (PHLMS), 
Toronto Mindfulness Scale 
(TMS) 
72%   
Telephone 
counselling (Bell et 
al., 2005) 




Composite including FIM, DRS, 
Community Integration 
Questionnaire (CIQ), NFI, FSE, 
GOSE, SF-36, Brief Symptom 
Inventory (BSI), EuroQol EQ-5D, 
Modified Perceived Quality of 
Life (PQOL) (1 year) 
Individual measures and 
composites of measures in a 
common outcome domain 
92% L L 
Telephone 
counselling (Bell et 
al., 2008) 




Two composites for post-
traumatic symptoms (Head 
Injury Symptom Checklist and 
12 functional areas) and 
general health (SF-12, PQOL, 
PHQ, major role, and 
community integration) (6 
months) 





counselling (Bell et 
al., 2011) 






Composite including FIM, DRS,  
Participation with Recombined 
Tools - Objective (PART-O), 
GOSE, EuroQol EQ-5D, PQOL, 
Sf-12, BSI-18 (1 year) 
functional composite (FIM, DRS, 
GOSE, PART-O, EuroQol EQ-5D), 
community participation, 
wellbeing, and vocational 
measures 
1 year: 82% 




(Brown et al., 2015) 






Advocacy Behaviour Rating 
Scale (ABRS) (at least 1 year 
since injury)  
n/a 84% U U 
Early intervention 






395 33 (16-60) mild post-acute 
single centre 
Post-Concussion Symptoms 
Questionnaire (PCSQ), Life 
Satisfaction Questionnaire 
(LiSat-11), CIQ, SF-36 (1 year) 
Interest Checklist, Role 
Checklist, Job Satisfaction 
Checklist 
90% L L 
CBT for depression  
(Fann et al., 2015)  







Hamilton Depression Rating 
Scale (HAMD-17) & patient-
reported Symptom Checklist-20 
(SCL-20) (16 weeks after 
recruitment to study. Patients 
recruited within 10 years of 
injury) 
PHQ-9, MINI International 
Neuropsychiatric Interview, 
Environmental Reward 
Observation Scale (EROS), 
Automatic Thoughts 
Questionnaire (ATQ), 
Dysfunctional Attitudes Scale 
(DAS), Patient Global 
Impression (PGI), Satisfaction 




with Depression Care, Working 
Alliance Inventory - Short Form, 
SF-36, Head Injury Symptom 
Checklist 
Multidisciplinary 










Questionnaire (RFQ), General 
Health Questionnaire (GHQ), 
neurocognitive battery (Stroop 
Test, Symbol-Digit Modalities 
Test, Paced Visual Serial 
Addition Task, Simple Reaction 
Time, Choice Reaction Time, 
HVLT, WAIS III Vocabulary, 
WAIS III Letter-Number 
Sequencing, WAIS III Matrix-
Reasoning (6 months) 
n/a 89% U U 




Ulfarsson, & de 
Boussard, 2013) 
173 39.4 (15-70) mild post-acute 
multicentre 
RPQ, Hospital Anxiety and 
Depression Scale (HADS), (3 
months) 








110 34.5 (16-65) severe post-acute 
single centre 
Barthel Index, Brain Injury 
Community Rehabilitation 
Outcome-39 (BICRO-39) 
(18-40 months after allocation. 
No limit on duration since 
injury) 
FIM, Functional Assessment 
Measure (FAM), HADS  
85% L L 
Cognitive rehab 
(Salazar et al., 
2000) 
120 25.5 (range 





Return to work and fitness for 
duty  
(12 months after treatment. 
Patients recruited within 3 
months of injury) 
MMSE, SRT, Trahan Continuous 
Visual Memory Test 
(TCVMT),PASAT, Wisconsin 
Card Sorting Test (WCST),WMS-
R General Memory, Auditory 
Consonant Trigrams, Halsted-
Reitan Neuropsychological 
Impairment Index, Katz 
Adjustment Scale  
100% L L 
Brief alcohol 
intervention 
(Sander et al., 
2012) 







Questionnaire III, Readiness to 
Change Questionnaire (3 
months following treatment) 
 59% U L 
Comparison of two 
rehab approaches 
(Vanderploeg et al., 
2008) 







return to work or school (1 year 
post-treatment. Patients 
recruited within 6 months of 
injury) 
CVLT, WMS-R, Semantic 
Fluency, Lexical Fluency, TMT 
Part B, WCST, FIM, DRS, Present 
State Exam, Apathy Evaluation 
Scale, Neurobehavioural Rating 







treatment for mTBI 
(Vikane et al., 2017) 
151 32* (16-55) mild post-acute 
multicentre 
Number of days to sustainable 
RTW (1 year) 
RPQ, GOSE, Patient Global 
Impression (PGI, HADS 







et al., 2016) 
365 29.3 (20-54) mild post-acute 
multicentre 
Pittsburgh Sleep Quality Index 
(PSQI) 
(6 and 12 months post-
intervention. Patients recruited 
within 24 months of return 
from service) 
RPQ, BSI-18, PTSD Checklist - 
Military Version (PCL-M), 
EuroQoL (pain question), 11-
point numerical rating scale 
(NRS-11) for pain, PHQ-9, SF-12, 
Sheehan Disability Scale, 
Alcohol use Disorders 
Identification Test (AUDIT-C) 
6 months = 
76% 
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Appendix 3: COAs by type, study setting, and frequency of use 
  







1 Glasgow Outcome Scale (GOS) clinRO X  21 
2 *Disability Rating Scale (DRS) clinRO X X 12 
3 *GOS - Extended (GOSE) structured interview  clinRO X X 11 
4 GOSE - questionnaire clinRO X  10 
5 *SF-36 PRO X X 8 
6 *Trail Making Test (TMT) Part B perfO X X 7 
7 *Trail Making Test (TMT) Part A perfO X X 6 
8 *Controlled Oral Word Association Test (COWAT) perfO X X 6 
9 *Functional Independence Measure (FIM) clinRO X X 5 
10 *Selective Reminding Test (SRT) perfO X X 4 
11 *Galveston Orientation and Amnesia Test (GOAT) perfO X X 4 
12 Rivermead Post-concussion Questionnaire (RPQ) PRO  X 4 
13 *EuroQol (EQ5D) PRO X X 3 
14 Clinical Global Impressions Scale  clinRO  X 3 
15 *Functional Status Examination (FSE) PRO X X 3 
16 Grooved Pegboard Test perfO X  3 
17 Hopkins Verbal Learning Test (HVLT) perfO  X 3 
18 Modified Oxford Handicap Scale (MOHS) clinRO X  3 
19 Modified Perceived Quality of Life  (PQOL) PRO  X 3 
20 *Paced Auditory Serial Addition Test (PASAT) perfO X X 3 
21 *Stroop Colour Word Test (Parts 1&2) perfO X X 3 
22 WAIS III Digit Span  perfO X  3 
23 Beck Depression Inventory (BDI) II PRO  X 2 
24 Brief Symptom Inventory - 18 (BSI-18) PRO  X 2 
25 Community Integration Questionnaire (CIQ) PRO  X 2 
26 California Verbal Learning Test (CVLT) PerfO X  2 
27 Diener Satisfaction with Life Scale PRO  X 2 
28 Finger Tapping Test perfO X  2 
29 Head Injury Symptom Checklist  PRO  X 2 
30 Kimura Memory for Designs Test perfO X  2 
31 *Mini Mental State Exam (MMSE) perfO X X 2 
32 *Neurobehavioural Rating Scale  clinRO X X 2 
33 Patient Health Questionnaire (PHQ) depression PRO  X 2 
34 *Rancho Los Amigos Scale clinRO X X 2 
35 Return to Work (RTW) clinRO  X 2 
36 Rivermead Follow-up Questionnaire (RFQ) PRO  X 2 
37 SF-12 PRO  X 2 
38 *Symbol Digit Modalities Test  perfO X X 2 
39 WAIS III Processing Speed Index perfO X  2 
40 WAIS III Letter-Number Sequencing perfO  X 2 
41 Wisconsin Card Sorting Test (WCST) perfO  X 2 




43 Advocacy Behaviour Rating Scale (ABRS) clinRO  X 1 
44 Alcohol Expectancy Questionnaire III PRO  X 1 
45 Alcohol Use Disorders Identification Test (AUDIT-C) PRO  X 1 
46 Apathy Evaluation Scale  PRO  X 1 
47 Auditory Consonant Trigrams  perfO  X 1 
48 Automatic Thoughts Questionnaire (ATQ) PRO  X 1 
49 Barthel Index clinRO  X 1 
50 Brief Symptom Inventory (BSI) PRO  X 1 
51 Brain Injury Community Rehabilitation Outcome-39 
(BICRO-39) 
PRO  X 1 
52 Brief Visuospatial Memory Test perfO X  1 
53 Cambridge Neuropsychological Test Automated 
Battery (CANTAB) Paired Associates Learning (PAL)  
perfO  X 1 
54 CANTAB Rapid Visual Information Processing (RVP) perfO  X 1 
55 CANTAB Reaction Time (RT) perfO  X 1 
56 CANTAB Spatial Working Memory (SWM) perfO  X 1 
57 Category Fluency - Actions perfO X  1 
58 Category Fluency - Animals perfO X  1 
59 Choice Reaction Time perfO  X 1 
60 Cognispeed Simple Reaction Time perfO  X 1 
61 Cognispeed Subtraction Test perfO  X 1 
62 Cognispeed Ten-Choice Reaction Time perfO  X 1 
63 Cognispeed Vigilance Test perfO  X 1 
64 Cognitive Abilities Screening Instrument (CASI) clinRO X  1 
65 Color Trails 1 perfO X  1 
66 Color Trails 2 perfO X  1 
67 Coma Recovery Scale-Revised (CRS-R) clinRO  X 1 
68 Dysfunctional Attitudes Scale (DAS) PRO  X 1 
69 Environmental Reward Observation Scale (EROS) PRO  X 1 
70 Epworth Sleepiness Scale (ESS) PRO  X 1 
71 Finnish Traumatic Brain Injury Questionnaire (FITBIQ) PRO  X 1 
72 Functional Assessment Measure (FAM) clinRO  X 1 
73 Functional independence clinRO  X 1 
74 General Health Questionnaire (GHQ) PRO  X 1 
75 Halsted-Reitan Neuropsychological Impairment Index perfO  X 1 
76 Hamilton Depression Rating Scale (HAMD-17) PRO  X 1 
77 Hospital Anxiety and Depression Scale (HADS) PRO  X 1 
78 Interest Checklist PRO  X 1 
79 Job Satisfaction Checklist  PRO  X 1 
80 Katz Adjustment Scale  PRO  X 1 
81 Lexical Fluency perfO  X 1 
82 Life satisfaction questionnaire (LiSat-11) PRO  X 1 
82 Medical Outcomes Study 6-item Cognitive Functioning 
Scale 
PRO  X 1 
83 MINI  International Neuropsychiatric Interview clinRO  X 1 




85 Namewriting Test  perfO X  1 
86 Neuropsychiatric Inventory (NPI-I) observer-rated ObsRO  X 1 
87 Neuropsychiatric Inventory (NPI-I) participant-rated PRO  X 1 
88 Occupational Gaps Questionnaire (OGQ) PRO  X 1 
89 Paced Visual Serial Addition Task perfO  X 1 
90 Participation with Recombined Tools - Objective 
(PART-O) 
PRO  X 1 
91 Patient Global Impression (PGI) PRO  X 1 
92 Patient Health Questionnaire (PHQ) panic/anxiety PRO  X 1 
93 Patient Health Questionnaire-9 (PHQ-9) PRO  X 1 
94 Philadelphia Mindfulness Scale (PHLMS) PRO  X 1 
95 Pittsburgh Sleep Quality Index (PSQI) PRO  X 1 
96 Post-Concussion Symptoms Questionnaire (PCSQ) PRO  X 1 
97 Post-traumatic Checklist - Military Version (PCL-M) PRO  X 1 
98 Present State Exam clinRO  X 1 
99 Rankin Scale  clinRO X  1 
100 Readiness to Change Questionnaire PRO  X 1 
101 Rey-Osterrieth Complex Figure Test perfO X  1 
102 Role Checklist PRO  X 1 
103 Satisfaction with Depression Care  PRO  X 1 
104 Seashore Rhythm Test perfO X  1 
105 Semantic Fluency perfO  X 1 
106 Sheehan Disability Scale PRO  X 1 
107 Simple Reaction Time perfO  X 1 
108 Spanish Verbal Learning Test perfO X  1 
109 Symptom Checklist (SCL-20) PRO  X 1 
110 Symptom Checklist (SCL-90) PRO  X 1 
111 TBI Work Instability Scale  PRO  X 1 
112 Toronto Mindfulness Scale (TMS) PRO  X 1 
113 Trahan Continuous Visual Memory Test perfO  X 1 
114 WAIS III Digit Symbol perfO X  1 
115 WAIS III Information and Vocabulary perfO  X 1 
116 WAIS III Vocabulary  perfO  X 1 
117 WAIS Matrix-Reasoning  perfO  X 1 
118 WAIS performance intelligence quotient (PIQ) perfO X  1 
119 WAIS Verbal Intelligence Quotient (VIQ) perfO X  1 
120 WAISIII Symbol Search perfO X  1 
121 Weschsler Abbreviated Scale of Intelligence (WASI) 
Full Scale IQ 
perfO X  1 
122 WMS-R - General Memory perfO  X 1 
123 WMS-R - Visual Reproduction perfO  X 1 
124 WMS-R - Attention and Concentration Index perfO X  1 
125 WMS-R - Logical Memory and Visual Reproduction  perfO X  1 
126 Working Alliance Inventory-Short Form PRO  X 1 
*COAs used in both acute and post-acute studies are marked with an asterisk         
 
